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Chair: Ariella Shikanov 
 
RhoC-GTPase, a member of the Ras-superfamily of small guanosine triphosphatases (GTPases), 
is over-expressed in advanced breast cancer and has been implicated in highly motile and invasive 
cancer phenotypes. The overexpression of RhoC mRNA in advanced breast cancers suggests that 
it plays a role as a transformative oncogene for human mammary epithelial cells and as a potential 
xx 
 
marker to screen breast cancer patients with highly aggressive tumors and provide therapeutic 
interventions prior to the development of metastases. Short interfering RNA (siRNA) inhibits 
RhoC protein expression resulting in the suppression of breast cancer metastasis by inhibiting 
cancer cell invasion and migration. Transforming anti-RhoC siRNA into a clinically-viable 
therapy requires the development of biocompatible delivery systems that incorporate a large dose 
of siRNA and shuttle the therapeutic payload into the cytoplasm of aggressive breast cancer cells. 
This dissertation describes the development of peptide targeted, degradable, pH-sensitive, 
membrane-destabilizing β-cyclodextrin (β-CD) polymers that proved effective in condensing anti-
RhoC siRNA to form “smart” nanoparticles. The peptide targeted “smart” nanoparticles facilitated 
selective homing into target breast cancer cells through receptor-mediated endocytosis and 
achieved functional delivery of anti-RhoC siRNA past the endosome into the cytoplasm of breast 
cancer cells resulting in the efficient knockdown of RhoC mRNA and protein levels.  Specifically, 
we utilized the varying reactivity of the primary and secondary hydroxyl groups of the β-CD core 
to develop asymmetric “smart” polymers. The secondary hydroxyl groups were modified with 
amphiphilic copolymers comprising of pH-sensitive dimethyl aminoethyl methacrylate 
(DMAEMA) and hydrophobic hexyl methacrylate (HMA) monomers incorporated at a 50/50 
molar feed ratio and grafted via acid-labile hydrazone linkages to form β-CD-P(HMA-co-
DMAEMA) polymers. The β-CD-P(HMA-co-DMAEMA) polymers were stable at physiological 
pH, but rapidly degraded into membrane-active fragments at the acidic pH of the endosome. The 
siRNA molecules were complexed to the P(HMA-co-DMAEMA) grafts following the partial 
conversion of DMAEMA monomers into cationic TMAEMA monomers. The β-CD-P(HMA-co-
DMAEMA-co-TMAEMA) polymers delivered anti-RhoC siRNA into the cytoplasm of SUM149 
and MDA-MB-231 cells resulting in a 80-90% and 90-100% reduction in RhoC mRNA and 
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protein levels, respectively. The incorporation of peptide targeted moieties to the free ends of 
polyethylene glycol (PEG) brushes on the primary face of the β-CD core resulted in selective 
accumulation of “smart” nanoparticles in breast cancer cells overexpressing underglycosylated 
Mucin 1 (uMUC1) surface receptors both in vitro and in vivo. Further, combining the peptide 
ligands and anti-RhoC siRNA molecules on the same asymmetric nanoparticle demonstrated a 
synergistic reduction in breast cancer cell invasion and migration in vitro. These results 
collectively confirm the successful development of a targeted, degradable “smart” nanoparticles 
that can enhance the functional delivery of anti-RhoC siRNA into the cytoplasm of aggressive 










1.1 Breast cancer: incidence, epidemiology and risk factors 
Breast cancer is a major global public health problem in women. It is the most common 
cancer among women with an estimated 1.15 million incident cases diagnosed in 2002, 
constituting nearly one fifth of the estimated 5.0 million cancer cases diagnosed each year in the 
world. Among the reported incident cases and deaths from the disease - developed countries 
account for 641,600 cases and 190,900 deaths while less developed countries account for 509,700 
cases and 219,600 deaths1, 2. If the current trends in incidence rates hold constant, there will be 
approximately 2.7 million new cases in the world in 2030, with more than 60% of the cases (1.72 
million) occurring in less developed regions of the world. Thereby, suggesting a steady growth in 
the incidence and mortality rates of the disease with considerable variation by world region 
(Figure 1.1 and 1.2). For instance, the estimated age-standardized rates varied from 18.7 per 
100,000 women in China to 99.4 per 100,000 women in North America (Figure 1.1 and 1.2)3. In 
general, the incidence is high (greater than 80 per 100,000) in developed regions of the world and 
low (less than 30 per 100,000) in developing regions; the range of mortality rates is much less 
(approximately 6 – 23 per 100,000) because of the more favorable survival of breast cancer in 
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(high-incidence) developed regions. The highest incidence rates of breast cancer are observed in 
northern and western Europe, North America, Australia, New Zealand, and in southern countries 
of South America, notably Uruguay and Argentina1 (Figure 1.1). In general, the high rates of 
breast cancer in developed countries are the consequence of a higher prevalence of the known risk 
factors for the disease. The risk factors include early age at menarche, nulliparity, late age at first 
birth, late age at any birth, low parity, exposure to exogenous hormones (e.g., oral contraceptives 
and menopausal hormone therapy), obesity, and late menopause – relate to the hormonal (largely 
estrogen) milieu to which the breast is exposed from menarche to the cessation of ovulation at 
menopause. The depletion of circulating estrogen after menopause attributes to the age-specific 
incidence of breast cancer - a rapid increase in incidence rate before menopause (up to age 50 
years) while the rate of incidence decreases thereafter. While incidence rates are less than 40 per 
100,000 women in most less developed countries, breast cancer is still the most common cancer 
among women in the majority of less developed countries. This increase is widely attributed to the 
‘‘westernization’’ of lifestyles, an ill-defined surrogate for changes in factors such as childbearing, 
















1.2 Trends in North America 
An observed increase in the incidence rate of the disease appeared in the US between 1980 
and 1987 due to the widespread increase in mammographic screening during that period. The 
overall rate of increase has slowed to 0.6% per year since the late 1980s. According to the US 
SEER cancer registries, the period between 2002 and 2003 showed a statistically significant 
decline in female breast cancer incidence rates4. On further analyses by tumor size and stage, the 
study suggested that the incidence rates decreased for small tumors (2 cm) by 4.1% per year from 
2000 through 2003 and for localized disease by 3.1% per year from 1999 through 20034. No 
decrease in incidence was observed for larger tumors or advanced-stage disease during the same 
periods. The decreasing rate of mortality in many high-risk countries can be attributed to a 
combination of the introduction of mammographic screening, and improved awareness and 
intensified early clinical diagnosis resulting in the diagnosis of more small, early stage tumors; and 
advances in both primary and adjuvant treatments for breast cancer2. 
 
1.3 Breast cancer: staging and treatment 
Until fairly recently, breast cancer was viewed as a single deadly disease that warranted 
the use of extreme treatment measures5. For instance, records dating back to 1600 B.C. indicate 
the use of cauterization techniques by Egyptian physicians to treat breast cancer, while extensive 
surgeries involving removal of the breast and all the surrounding muscle and bone were adopted 
during the Renaissance period6. Halsted adapted a less extreme but still extensive surgery that 
became the standard of care in the late 19th century6. 
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By the first half of the 20th century, clinicians began to subscribe to the “one-size doesn’t 
fit all” concept implying that not all breast cancers shared the same prognosis or required the same 
treatment. Therefore, attempts were made to define characteristics that could reliably delineate 
between tumors that required aggressive treatment from those that did not. In 1987, the 
International Union against Cancer (UICC) and the American Joint Committee on Cancer (AJCC) 
adapted the tumor-node-metastasis (TNM) staging convention as the international standard for 
reliable diagnosis and treatment of the disease6. The TNM system originally developed by Pierre 
Denoix (1942) represented an attempt to classify cancer based on the major morphological 
attributes of malignant tumors that were thought to influence disease prognosis: size of the primary 
tumor (T), presence and extent of regional lymph node involvement (N), and presence of distant 
metastases (M).  
Breast cancer staging is useful because of its ability to estimate prognosis. Figure 1.3 
shows the relationship between cancer stage and 10-year relative survival in breast cancer patients 
(adapted from a report by Bland and colleagues that used data from 1.3 million cases (1985 to 
1996) in the National Cancer Data Base (NCDB))5. The data suggests that there are significant 
differences among stages: only 5% to 12% of Stage I/II patients die in the first 10 years after 
diagnosis, compared with over 60% of Stage III patients and over 90% of Stage IV patients. Breast 
cancer staging also provides valuable information about appropriate treatment options for each 
cancer stage. For instance, AJCC/UICC staging is commonly used to select patients and to report 
outcomes in clinical trials; therefore, clinicians can make a reasoned judgment about whether 




The objective of treating patients diagnosed with early-stage breast cancer is to cure them 
of the disease – local surgical interventions supplemented with adjuvant therapies are frequently 
explored to eradicate microscopic tumor cells that may have spread systemically at the time of 
diagnosis using chemotherapy, endocrine therapy, and biological therapy3. However, in metastatic 
breast cancer (stage IV), cure is very uncommon and the goals are symptom palliation and 
prolongation of survival. Therefore, maximizing quality of life (Qol) during therapy assumes the 
greatest importance. The median survival of metastatic breast cancer (MBC) is 2–4 years; this 
estimate has been relatively stable over decades. The median survival of MBC patients, however, 
varies based on prognostic characteristics exhibited by the patient: those with ER-positive or PR-
positive disease presenting with metastases only to the bones have a longer median survival, 
whereas patients with ER-negative/ PR-negative disease involving liver, lung, or brain have a 
shorter median survival7.  
 
 
Figure 1.3: Ten-year Relative Survival Associated with AJCC/UICC (TNM) Breast Cancer Stage 
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The current standard of treatment for metastatic breast cancer involves palliative 
interventions like chemotherapy or endocrine therapy. Chemotherapy is the initial therapy for ER-
negative/PR-negative metastatic breast cancer, of metastatic breast cancer with widespread, 
symptomatic visceral disease, and for ER-positive or PR-positive breast cancer that is endocrine 
therapy-refractory7. Multiple chemotherapy agents have activity in metastatic breast cancer, with 
higher response rates in first (30–60%) than in subsequent (10–40%) lines of treatment. Given the 
palliative nature of chemotherapy for metastatic disease, a favorable side effect profile is desirable. 
However, drug-related toxicities such as low blood counts and fatigue often occur with prolonged 
chemotherapy duration, prompting consideration of a hiatus in treatment according to patient 
tolerance. The use of Trastuzumab, a monoclonal antibody (mAb) against HER-2/neu, in 
combination with taxane-based chemotherapy for metastatic disease is the current standard of 
treatment for HER-2/neu-positive metastatic breast cancer due to improved patient survival8. Other 
mAb-based treatments like Bevacizumab (a mAb directed against vascular endothelial growth 
factor) is believed to work by inhibiting new blood vessel formation in tumors9. Bevacizumab 
delays the time to disease progression when combined with paclitaxel in first-line metastatic 
therapy, but without a significant impact on survival or time to progression. For women with 
metastatic breast cancer involving bone, bisphosphonates are an additional component of their 
systemic therapy. The bisphosphonates inhibit osteoclast function, thus inhibiting bone loss at sites 
of metastasis and reducing the risks of pathologic fracture, pain, and functional impairment. A side 
effect of bisphosphonates is osteonecrosis of the jaw, a failure of bone healing sometimes 
associated with dental work which may cause recurrent infections and pain. In summary, it is 
evident that alternative treatment options that can tackle the metastatic spread at the source, while 
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improving patient Qol, overall survival rate, and tumor-targeted delivery of therapeutic agents to 
overcome systemic treatment associated toxicities, are needed. 
 
1.4 Metastatic breast cancer  
Metastasis is of great significance to the clinical management of breast cancer since cancer 
associated mortality stems primarily from the disseminated disease rather than the primary tumor. 
Recent evidence suggests that the onset of metastasis can be an early event and potentially 60% -
70% of patients have initiated the metastatic process at the time of diagnosis10.  Metastasis is the 
process, whereby cancer cells spread throughout the body, establishing new colonies in organs at 
a distance from the one where the primary tumor originated. To successfully colonize a secondary 
site - a cancer cell must complete a sequential series of steps before it becomes a clinically 
detectable lesion. These steps typically include separation from the primary tumor, invasion 
through surrounding tissues and basement membranes, entry and survival in circulation, 
lymphatics or peritoneal space, and colonization of a distant target organ10. These are usually, but 
not always, followed by extravasation into the surrounding tissue, survival in the foreign 
microenvironment, proliferation, and induction of angiogenesis, all the while evading apoptotic 
death. To successfully complete the sequence of metastatic events, the cells of the primary tumor  
must have the ability to a) interact with the local microenvironment, b) migrate, c) invade the 
surrounding tissue, d) resist apoptosis, and e) induce angiogenesis11. The onset of these metastatic 
phenotypes observed in primary cancer cells have been shown to be due to the overexpression of 
RHO-family GTPase proteins that regulate and control cell morphology and motility in metastatic 
cancer (Figure 1.4)12. The aggressive migratory and metastatic phenotypes expressed by these 
transformed cells are a result of combined, but distinct, effect of Rho-regulated kinases, ROCK1 
Figure 1. Principal steps in metastasis. 
Transformation of normal epithelial cells 
leads to carcinoma in situ, which, as a result 
of loss of adherens junctions, evolves toward 
the invasive carcinoma stage. Following 
basement membrane degradation, tumor 
cells invade the surrounding stroma, migrate 
and intravasate into blood or lymph vessels, 
and become transported until they arrest in 
the capillaries of a distant organ. 
 
Figure 2. (A) The Rho GTPase cycle. Rho GTPases cycle between 
an inactive GDP-bound form and an active GTP-bound form. (B) 
Rho-GTPase-regulated pathways affect actin filament organization. 
Rho promotes contractile actin:myosin filament assembly through 
two effectors, mDia and p160ROCK. 
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and ROCK213. Modulation of RHO-protein activity has shown to modulate the metastasis of tumor 
cells by disrupting epithelial-sheet organization, increasing cell motility, and promoting the 
degradation of the ECM13. These studies have led to further investigation of the role and 
mechanism of action of Rho-family proteins in regulating cytoskeletal dynamics that affect 
multiple cellular functions including cell motility and invasiveness observed during metastasis. 
 
1.5 Role of RhoC-GTPase proteins in breast cancer metastasis 
RhoC, a member of the Ras superfamily of low molecular weight guanine nucleotide 
(GTP)-binding proteins14, have been implicated in the signal transduction process of integrins and 
 
Figure 1.4: Involvement of RHO proteins at different stages of tumor progression. A) 
Maintenance of normal epithelial polarity. B) Benign tumors: loss of polarity and multilayering. C) 
Locally invasive tumors: loss of tissue boundaries and increased motility. RHOA and RAC1 regulate 
proteases that facilitate motility by degrading the BM. D) Metastasis to a distant site: intravasation and 
extravasation. RHOC promotes expression of angiogenic factors, leading to an increase in 




growth factor receptors to the cytoplasm through a tightly regulated and highly complex signaling 
pathway15. By cycling between an inactive GDP-bound and active GTP-bound state, RhoC acts as 
a molecular on/off switch16 that is involved in all aspects of cellular motility and invasion including 
maintaining cell polarity, cytoskeletal organization, and external signal transduction17, 18, 19. The 
Rho-GTPase cycle is tightly regulated by three groups of proteins (Figure 1.5)15. Guanine 
nucleotide exchange factors (GEF’s) facilitate the exchange of inactive GDP for active GTP 
molecules, GTPase-activating proteins (GAP’s) negatively regulate the switch by enhancing its 
intrinsic GTPase activity20, and guanine nucleotide dissociation inhibitors (GDI’s) are thought to 
block the GTPase cycle by sequestering and solubilizing the GDP-bound form of the protein. 
RhoC-GTPase activity in migrating cells is associated with focal adhesion assembly formation and 
cell contractility. An important downstream Rho target involved in facilitating actin:myosin 
filament assembly and subsequent contractility is the Ser/Thr kinase p160ROCK13. In its active 
state, p160ROCK, phosphorylates and activates LIMK, which in turn phosphorylates and 
inactivates cofilin leading to stabilization of actin filaments within the actin:myosin filament 
bundle. p160ROCK interacts with and phosphorylates the myosin binding subunit (MBS) of 
myosin light chain (MLC) phosphatase and thereby inactivates it. This leads to increased levels of 
myosin phosphorylation, which then results in their cross-linking with actin filaments and 
generates contractile forces. This promotes movement of the cell body and facilitates detachment 
of the rear end of the cells13 (Figure 1.5). 
Another important Rho-downstream target is mDia, the mammalian ortholog of Drosophila 
Diaphanous (Figure 1.5). mDia belongs to the formin-homology containing family of proteins, 
which have been linked to actin filament assembly in both Drosophila and yeast13. The binding of 
Rho-GTP to mDia opens up and activates this scaffold protein. This activated complex in 
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combination with p160ROCK facilitates the assembly of actin:myosin filaments. Therefore, the 
involvement of activated RhoC proteins in cell migration and invasion of metastasizing cancer 
cells led to the evaluation of their possible use as a therapeutic target for the treatment of metastatic 
cancer.  
 
1.6 RhoC: a therapeutic target for suppressing breast cancer metastases 
Our collaborator, Professor Merajver, and others have previously shown that the 
overexpression of RhoC in breast cancer cells is strongly associated with aggressive cancer 
 
Figure 1.5: Model of RHO-protein regulation. RHO proteins can bind either GTP or GDP. When 
bound to GDP, they can be sequestered in the cytoplasm by RHO–GDP dissociation inhibitors (RHO–
GDIs). The exchange of GDP for GTP is promoted by RHO guanine nucleotide exchange factors 
(RHO–GEFs), and is often associated with translocation of RHO proteins to cell membranes. GTP-
bound RHO proteins interact with a range of effector proteins and modulate their ability to regulate 
cell behaviour. Most RHO proteins have an intrinsic ability to hydrolyse GTP to GDP and inorganic 




phenotypes with poor clinical outcomes16, 17, 21, 22. Further, Merajver et. al. showed that RhoC-
transfected human mammary epithelial (HME) cells grew under anchorage-independent 
conditions became motile and invasive through enhanced formation of actin stress fibers and focal 
adhesion contacts, produced angiogenic factors, and were tumorigenic and metastatic when 
orthotopically implanted in nude mice23, 22, 24. These findings clearly indicate that RhoC protein 
plays a critical role in promoting the proliferation, migration, and invasion of cancer cells and 
warrants its consideration as a therapeutic target for suppressing breast cancer metastases. Earlier 
research showed that the use of anti-RhoC silencing RNA (siRNA) (5’- 
GACCUGCCUCCUCAUCGUCTT-3’) to knock down RhoC expression at the mRNA level and 
subsequent protein levels – inhibited breast cancer cell proliferation, migration, and invasion in 
vitro25 and tumor growth and angiogenesis in vivo19. The goal of our study was to transform this 
promising anti-RhoC siRNA into an effective and clinically-viable therapy to suppress the 
metastatic spread of breast cancer cells.  
1.7 Introduction to small interfering RNA therapy 
Gene therapy involving the use of plasmid DNA (pDNA), antisense oligonucleotide 
(ASODN), and small interfering RNA (siRNA) to regulate specific gene expression has been 
harnessed for the treatment of diseases ranging from viral infections26, 27, hereditary disorders, and 
cancers28, 29. Specifically, siRNA molecules have been extensively studied following Fire and 
Mello’s work that demonstrated the use of double-stranded RNA (dsRNA) via the endogenous 
RNA interference (RNAi) pathway to suppress gene expression in Caenorhabditis elegans30. Since 
the discovery of RNAi in 1998, several proof-of-principle experiments pertaining to the 
therapeutic potential of siRNA have been demonstrated both in vitro and in vivo31, 32. In recent 
years, RNAi has gained momentum in gene silencing and drug development because of its ability 
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to silence the expression of virtually any gene with high efficiency and specificity, including 
targets traditionally considered to be 'undruggable'. Owing to its great potential in biological 
research and drug development, large amounts of effort and capital have been invested in bringing 
siRNA therapeutics to the market. At least 22 RNAi-based drugs have entered clinical trials, which 
include treatments for age-related macular degeneration (AMD), respiratory syncytial virus 
infection, and solid tumors. Among these clinical trials, most siRNAs are administered by local 
delivery, typically via the intravitreal or intranasal routes. However, local delivery may not be 
appropriate for all diseases. Under some circumstances, systemic drug administration by 
intravenous (i.v.) injection is needed. Therefore, numerous studies have focused on the design and 
development of carriers that can encapsulate siRNA molecules into stable particles to achieve 
efficient targeted delivery of the siRNA payload in vivo.  
 
1.8 Basic concept and mechanism of small interfering RNA (siRNA) 
RNAi is natural endogenous pathway specific to eukaryotic cells by which sequence-
specific dsRNA is able to target and cleave complementary mRNA31. RNAi is triggered by the 
presence of long pieces of dsRNA (> 30 bp) in the cell cytoplasm, which are cleaved into the 
fragments known as siRNA (21–23 bp) by the enzyme Dicer33. In practice, siRNA can be 
synthetically produced and then directly introduced into the cell, thus circumventing Dicer 
mechanics (Figure 1.6). The siRNA, is then incorporated into a protein complex called the RNA-
induced silencing complex (RISC)34. Argonaute 2 (AGO2), a multifunctional protein contained 
within RISC, unwinds the double-stranded siRNA, after which the sense strand (or passenger 
strand) of the siRNA is cleaved35. The activated RISC, which contains the antisense strand (or 
guide strand) of the siRNA, selectively seeks out and degrades mRNA that is complementary to 
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the antisense strand36 (Figure 1.6). The degradation of target mRNA molecules results in the 
subsequent suppression of the associated protein expression. The activated RISC complex can then 
move on to destroy additional mRNA targets, which further propagates gene silencing37. This extra 
potency ensures a therapeutic effect for 3–7 days in rapidly dividing cells, and for several weeks 
in non-dividing cells38. Eventually, siRNAs are diluted below a certain therapeutic threshold or 
degraded within the cell, and so repeated administration is necessary to achieve a persistent effect. 
There are three strategies for RNAi: short hairpin RNA (shRNA), endogenous microRNA 
(miRNA) and small interfering RNA (siRNA). Among them, siRNA is more suitable for drug use 
















Figure 1.6: RNAi mechanism. Briefly, the long dsRNA is cleaved into siRNA in the 
cytoplasm by Dicer enzymes. The double-stranded siRNA molecules are then unwound into 
passenger and guide strands in the RISC-AGO2 complex. The activated RISC-siRNA 
complex seek out, bind and degrade complimentary mRNA molecules. The degradation of 
target mRNA molecules results in the suppression of target proteins. 
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1.9 Barriers to systemic siRNA delivery in vivo 
The clinical use of siRNA-based drugs in cancer therapy is limited by the ability to 
efficiently deliver naked siRNA molecules to the cytoplasm of target cells. The siRNA molecules 
face several physiological barriers upon administration into the bloodstream, owing to their low 
stability, non-specific tissue penetration, and poor cellular uptake.  
 
1.9.1 Serum nuclease instability 
Naked siRNA molecules are extremely susceptible to serum nuclease degradation and can 
stimulate the innate immune system through the Toll-like receptor 7 (TLR7) pathway39, 40, 41.  The 
reported half-life for unprotected siRNA in serum ranges from several minutes to 1 h39. A common 
strategy to address both these challenges entails the chemical modification of the siRNA backbone. 
The incorporation of 2'-O-methyl modifications into the sugar structure of selected nucleotides 
within both the sense and antisense strands has been shown to evade the immune response (Figure 
1.7). 2'-O-methyl modifications have also been shown to confer resistance to endonuclease 
activity and to abrogate off-target effects when incorporated into the seed region, on the antisense 
strand. Other common modification approaches include the introduction of phosphorothioate 
backbone linkages at the 3'-end of the RNA strands to reduce susceptibility to exonucleases. It is 
also possible to incorporate alternative 2' sugar modifications (for example, a fluorine substitution) 
to increase resistance to endonucleases. However, an increase in siRNA stability did not 
necessarily translate into enhanced gene silencing activity in mice. In addition, the degradation of 






1.9.2 Non-specific tissue distribution 
In addition to nuclease degradation and renal clearance – other major barriers to in vivo 
delivery of siRNA includes their non-specific uptake by the reticuloendothelial system (RES). The 
RES comprises of phagocytic cells, including circulating monocytes and tissue macrophages, the 
physiological function of which is to clear the system of foreign pathogens, cellular debris, and 
apoptotic cells42. Organs like the liver and spleen that are highly perfused and exhibit a fenestrated 
vasculature harbor an abundance of tissue macrophages. Therefore, these organs accumulate high 
concentrations of siRNA following systemic administration. siRNA uptake after standard i.v. tail 
vein injection or intraperitoneal (i.p.) injection has been noted in the liver, spleen, kidney and bone 
marrow at 4 h, but the overall signal was weak43. The non-specific tissue distribution results in a 
significantly reduced therapeutic effect at the target site.  
 
1.9.3 Poor cellular uptake and internalization 
The hydrophilicity and negative charge of naked siRNA molecules prevents them from 
readily crossing biological membrane into the cytoplasm of target cells and induce effective gene 
inhibition44. Previous studies showed that siRNAs can access the cytoplasm by hydrodynamic 
 
Figure 1.7: Chemical modifications of siRNA molecules 
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injection, where large amount of siRNA molecules were rapidly injected into the body that resulted 
in the transient damage of cell membranes in highly vascularized organs32. However, this method 
is highly dangerous and not applicable for human use. Thus far, there is no evidence showing the 
efficient internalization of siRNA molecules into cells after conventional IV injections. 
 
1.10 Synthetic materials for siRNA delivery 
In order to develop siRNA-based molecules for cancer therapy, we need to develop 
effective delivery systems that can overcome the in vivo barriers encountered by naked siRNA. 
Therefore, the delivery systems must be engineered to (i) provide serum stability, (ii) allow 
immune evasion, (iii) mitigate interactions with serum proteins and non-cancer cells, (iv) resist 
non-specific accumulation in the RES, (v) preferentially extravasate and accumulate at the target 
site, (vi) permit cell entry and endosomal escape to avail the RNAi machinery in the cytoplasm of 
the target cells45, and (vii) have low toxicity46. The design rational for siRNA delivery systems 
stems from viral vectors that were previously used to deliver therapeutic payload into target cells. 
Viral vectors, such as retrovirus47 and adenovirus48, have displayed high efficiency in transferring 
nucleic acid into various mammalian cells. However, their safety profile, immunogenicity, and 
high cost limit their clinical application49, 50. This led to the need for non-viral delivery vehicles 
that can facilitate both uptake into the target tissue of interest and protect siRNA payloads and 
inhibit nonspecific delivery. 
 
1.10.1 Lipid-based vectors 
Prior to their use with siRNA, liposomes were used as delivery vectors for DNA-based 
drugs, owing to their ability to protect oligonucleotides from nuclease degradation and renal 
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clearance, and to promote cellular uptake and endosomal escape51. Several lipid nanoparticles have 
emerged over time to effectively deliver siRNA drugs. Cationic lipids like N-[1-(2,3-
dioleyloxy)propyl]-N,N,N-trimethlylammonium chloride (DOTMA) (Figure 1.8) to deliver both 
DNA and RNA into mouse, rat, and human cell lines are commonly used transfection reagents52. 
Cationic lipids have a cationic hydrophilic head group which is attached to a lipid hydrophobic 
moiety through a linker. The transfection mechanism of liposomes involves electrostatic 
interactions between negatively charged nucleic acids and positively charged lipids. When mixed 
together, they spontaneously form lipoplexes. Cationic lipids like dioleoyl-phosphatidylethanol-
amine and 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) (Figure 1.8) have been shown 
to exhibit efficient delivery of siTNF-α and low toxicity profiles in mouse models – making them 
the most widely used lipid vectors53. Cationic lipoplexes composed of DOTAP and cholesterol 
have exhibited enhanced transfection efficiency and reduced degradation compared to 
conventional lipoplexes54. In addition, the use of liver-targeted DOTAP/cholesterol to deliver 
siRNA against hepatitis B virus (HBV) through i.v. administration proved to show specific 
accumulation in the liver and functional suppression in viral protein expression in vivo54. To 
improve the pharmacokinetic profile of cationic lipids - liposomes were coated with lipid-anchored 
PEG. But using PEG has been shown to have some limitations, as the steric and charge effect of 
the PEG molecule blocks the interaction between the liposome and the endosomal membrane and 
subsequent endosomal escape. Moreover, although liposomes are among the most popular nucleic 
acid delivery agents, some concerns regarding their safety for therapeutic use remain. Toxicity of 
certain cationic lipid particles has been reported both in vitro and in vivo55,  and certain synthetic 
agents have been found to induce a gene signature of their own that might increase the off-target 




1.10.2 Polymer-based vectors 
Cationic linear and branched polymers make efficient transfection agents because of their 
ability to condense large nucleic acids into stabilized nanoparticles58, 59. The positively charged 
polymers, through electrostatic interactions, form polyplexes with the negatively charged 
phosphates of DNA, siRNA, and other oligonucleotides. These polyplexes have also shown to 
stimulate nonspecific endocytosis as well as endosomal escape56.  The proposed escape mechanism 
is the 'proton-sponge' effect58, whereby buffering of the endosome leads to an accumulation of ions 
within this compartment and an osmotic pressure that eventually bursts the endosome60 .  
PEI is a broadly investigated delivery carrier for the administration of a wide range of 
nucleotide-based therapies, including DNA, siRNA and oligonucleotides (Figure 1.9)61, 62 . The 
 
Figure 1.8: Chemical structure of common liposome reagents  
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intraperitoneal administration of complexed siRNA led to the delivery of the intact siRNA into the 
tumors and a marked reduction of tumor growth through siRNA-mediated downregulation of 
human epidermal growth factor 2 (HER2; also known as ERBB2)63.There has been significant 
concern regarding the toxicity of PEI at higher molecular masses and high doses64, 65 . Poly (L-
lysine) (PLL) (Figure 1.9) is a cationic biodegradable polymer that has been used as a non-viral 
gene delivery system for many years due to their excellent condensing ability with anionic agents66, 
67. A variety of PLL derivatives have been synthesized to improve stability, decrease toxicity, and 
increase half-life in vivo66, 67, 68. For example, previous studies proved that grafting hydrophilic 
PEG molecules to PLL significantly increase the circulation time of the encapsulated siRNA 
molecules and the accumulation in tumor tissues68. However, PLL-based polyplexes were limited 
in their ability to escape the endosomal/lysosomal trafficking pathway69 and subsequently release 
siRNA release into the cytoplasm of target cells, resulting in low transfection efficiency and 










Figure 1.9: Chemical structure of commonly used cationic polymers 
21 
 
Polymer–siRNA conjugates have also shown potential for applications in systemic siRNA 
delivery. Specifically, a polymer-conjugated delivery system called Dynamic PolyConjugates 
(DPC) have demonstrated efficient delivery of siRNA to hepatocytes (Figure 1.10)71. Key features 
of the DPC technology include a membrane-active cationic polymer, the ability to reversibly mask 
the activity of this polymer until it reaches the acidic environment of the endosome, and the ability 
to target this modified polymer and its siRNA cargo specifically to hepatocytes after intravenous 
injection. DPCs were capable of inducing knockdown of two mouse liver genes. Analyses of serum 
liver enzyme and cytokine levels in treated mice indicated that siRNA complexes formed with this 
















Figure 1.10: DPC materials are designed to respond to the acidic environment of the 
endosome and the reducing environment of the cytoplasm. In circulation, the 
membrane-disrupting PBAVE polymer (black) is shielded by PEG. After cell 
uptake, the PEG chains are shed as the pH of the endosome lowers, exposing the 
polymer and causing endosomal release. In the cytoplasm, the disulphide bond 
linking the siRNA to the polymer is reduced, freeing siRNA to trigger RNAi. 




1.11 Challenges and proposed solutions for systemic administration 
 
1.11.1 siRNA packaging 
Among the numerous requirements to be addressed in the development of safe and 
effective siRNA delivery systems, the first criteria involves the stable packaging of siRNA 
molecules. The system should have the ability to (i) prevent charge repulsion between negatively 
charged siRNA duplexes and cell membrane, (ii) shield the siRNA molecules from serum and 
nuclease degradation, and (iii) condense the siRNA molecules into nano-sized particles and 
facilitate their internalization into target cells72. Due to the anionic nature of siRNA molecules, 
cationic lipids and polymers can easily complex siRNAs into stable particles through electrostatic 
interactions. These particles usually carry a positive surface charge, which allows them to be taken 
up by cells through absorptive endocytosis. This complexation also limits the access of nuclease 
enzymes to siRNA and prevents degradation73. 
 
1.11.2 Stability of siRNA carriers 
Although the cationic surface charge of siRNA-based carriers improve cellular uptake, it 
suffers from poor pharmacokinetic properties when administered systemically. For instance, the 
positively charged particles can non-specifically interact with blood components to form large 
aggregates, which activate the complement system and eventually lead to rapid removal of 
particles from circulation through the RES system70, 72, 74. The incorporation of hydrophilic 
polymers like PEG in non-viral carriers have been shown to mask the cationic surface charge, 
reduce their non-specific binding with serum proteins, and therefore prolong their circulation 
time75. The modifications of carriers with PEG, however, affect their complexation with siRNA 
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molecules, internalization into cells, and the transfection efficiency76. To improve the transfection 
efficiency of PEGylated nanoparticles, including rationally designed PEG length and density or 
incorporation of pH-sensitive bonds linkers between the PEG molecule and the carriers. Therefore, 
the molecular weight and density of PEG molecules incorporated into siRNA-based carrier 
systems must be carefully selected77.  
 
1.11.3 Diffusion across the endothelial barrier 
The non-viral carriers encapsulating the desired dose of therapeutic siRNA molecules need 
to extravasate through the vascular endothelium to reach the target tissue. One of the unique 
features of tumor microvessels is their leakiness due to endothelial discontinuity. The pore size of 
tumor microvessels ranges from 100 to 780 nm in diameter. In comparison, microvessels in most 
normal tissues are less leaky; the tight junctions between endothelial cells are usually <2 nm and 
the pore size in post-capillary venules is <6 nm, whereas fenestrated endothelium of the renal 
glomeruli and the sinusoidal endothelium of the liver and spleen show larger pore sizes of 40–60 
and 150 nm, respectively78. Due to vessel leakiness, the major pathway of drug transport across 
tumor microvascular wall is by extravasation via diffusion and/or convection through the 
discontinuous endothelial junctions, while transcytosis plays a relatively minor role. Using the 
leakiness of tumor vessels, siRNA carriers (up to 500nm in size) can accumulate in the interstitial 
tumor space via the enhanced retention and permeability (EPR) effect (Figure 1.11)79, . This 
unique feature of the tumor vasculature facilitates successful delivery of non-viral complexes to 

























1.11.4 Cellular entry 
On reaching the interstitial space of the tumor tissue, the non-viral siRNA carriers must 
traverse the cellular membrane of the target cell. The cellular membrane is composed of a lipid 
 
Figure 1.11: Schematic drawing showing the accumulation of nanoparticles (NP) by the 
EPR effect. Differences between normal (A) and tumor (B) vessels are depicted. The large 
fenestrations between the endothelial cells in the tumor vessels allows NP’s to reach the 
matrix of the tumor cells by the EPR effect. Conversely, normal tissue contains tightly 
joined endothelial cells that prevents the diffusion of NP’s outside the blood vessels.  
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bilayer with embedded proteins that is selectively permeable to ions and small hydrophobic 
molecules through passive diffusion81. However, for large, charged particles, such as lipoplexes 
and polyplexes, previous studies have shown that most of them pass the cell membrane through 
endocytic pathways, including clathrin-mediated endocytosis (absorptive or receptor mediated)82, 
lipid-raft mediated endocytosis (calveolae mediated or not)83, phagocytosis (occurs in specialized 
cells), and macropinocytosis84, 85.   
 
1.11.5 Non-specific uptake 
The most common route of entry for cationic lipoplexes and polyplexes into cells is through 
non-specific absorptive endocytosis by the clathrin-coated pit mechanism. This is due to the 
electrostatic interaction between positively charged particles and the cellular membrane, 
containing negatively charged glycoprotein, proteoglycans, and glycerophosphates86. The uptake 
of these cationic molecules into cells can be enhanced by increasing their surface charge, which 
results in a higher affinity to the plasm membrane87, but this strategy is not practical since it also 
increases particle-associated toxicity and renal clearance. Previous work by Rejman et. al. showed 
that DOTAP/DNA lipoplexes were taken up into cells only through clathrin-mediated endocytosis, 
while PEI/DNA polyplexes were internalized by both clathrin and caveolae-mediated endocytosis 
mechanisms88. However, the exact route of cationic particles to be taken up by cells varies largely 
between different cell types and vectors used. The contribution of each pathway in the cellular 
uptake of siRNA complexing nanoparticles is still poorly understood89. 
 
1.11.6 Targeted uptake   
In order to selectively deliver therapeutic siRNA molecules to target cells, the non-viral 
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siRNA carriers can be coated with targeted ligands and specific antibodies, which are recognized 
by specific cell surface receptors90, 91. For example, asialoglycoprotein receptors that specifically 
bind asialoglycoproteins is abundantly expressed in hepatocytes92. Incorporation of sugar moieties 
like asialoglycoprotein or galactose into the vector proved to effectively target liver cancer cells 
both in vitro and in vivo93. Transferrin and folic acid are commonly use targeting ligands – as they 
can be easily conjugated to the surface of non-viral vectors and the receptors that bind specifically 
to these ligands are overexpressed in tumor cells94, 95. The use of exogenous ligands has also been 
examined as a means of targeting distribution and improving efficacy in vivo. Exogenous ligands 
are generally attached to the distal end of PEG groups anchored to the delivery system. 
 
1.11.7 Endo-lysosomal escape mechanism 
After internalization into cells via endocytosis, the non-viral vectors are entrapped in the 
endosome, where the pH drops from physiological (7.4) to around 5-6 due to the ATPase proton 
pumps96. The endocytic vesicles sequentially fuse with early endosomes which mature into late 
endosomes before fusing with lysosomes (Figure 1.12). The fate of the internalized molecules 
inside the vesicle depends on the specific type of receptors and includes the following: recycled to 
the cell surface, degraded inside lysosomes, or released to other intracellular compartments 
including the cytosol97. The endosomal entrapment and lysosomal degradation of siRNA–carrier 
contributes to the low transfection efficiency and is a major impediment for non-viral carriers. In 
order to escape from enzymatic degradation, the non-viral siRNA vectors should be able to release 
siRNA molecules to the cytoplasm at an early stage of the endo-lysosomal trafficking to preserve 
their therapeutic functions. Various approaches have been proposed to improve endosomal escape 
of non-viral siRNA based vectors based on two main hypotheses, “proton sponge” effect and 
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membrane destabilizing effect. Detail mechanisms will be explained in Chapter 2. 
 
1.11.8 Nucleic acid/vector dissociation 
On escaping the endosomal compartment, the non-viral siRNA vectors need to rapidly 
decomplex siRNA molecules and release them into the cytoplasm. Poor decomplexation of the 
loaded DNA/RNA molecules have been reported to result in low transfection efficiency98. The 
disassembly of the nucleic acids from the vectors can be regulated by the use of carriers exhibiting 
lower cationic charge or the use of degradable vectors. For example, ester and hydrazone bonds 
are incorporated as linkers between cationic grafts and the polymer backbone – resulting in vector 
fragmentation and cargo dissociation upon hydrolysis of the linkers99. It is, therefore, important to 
develop a vector which forms stable, compact particles with siRNA molecules, but rapidly release 
 
Figure 1.12: pH/redox dual-sensitive unimolecular NPs with excellent endosomal/lysosomal 
escape capabilities for efficient targeted delivery of siRNA. A schematic diagram of the cellular 




the therapeutic cargo into the cytoplasm upon endosomal escape. 
 
1.11.9 Effective RNA interference (RNAi) 
Unlike plasmid DNA, which can be replicated or incorporated into the host chromosome, 
siRNA molecules elicit only a transient suppression in gene expression (i.e., 3 – 7 days in fast 
dividing cells, and up to a month in slow dividing cells) in proliferating cells78. The persistence of 
silencing in different cell types depends on factors such as proliferation rate and transcriptional 
activity100. In addition, siRNA-induced gene silencing usually only suppress target gene 
expression, but does not completely inhibit their translation. The RNAi mechanism is deemed 
effective when the target protein expression is suppressed under a specific threshold to induce the 
desired change in biological effect. And this requires the efficacious cytoplasmic delivery of the 
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2.1 Rational and Design of EPPT1-Peptide Targeted, pH-Sensitive, Membrane-
Destabilizing Nanoparticles for Selective and Enhanced Functional Delivery of siRNA 
into the Cytoplasm of Aggressive Breast Cancer Cells 
 
2.1.1 “The inability of siRNA-based NP’s to escape the endosomal/lysosomal trafficking 
pathway could result in poor transfection efficiency” 
Endosomal entrapment is one of the major barriers, which limits the practical application 
of siRNA-based cancer therapy. In order to achieve effective gene silencing, several strategies 
have been developed to enhance the escape of nucleic acids from the endosomal/lysosomal 
trafficking pathway. Two mechanisms, namely “proton sponge” and membrane-destabilizing 
effect, have been extensively investigated to identify non-viral vector compositions that can escape 
the endosomal compartment1. 
 




2.1.1.1.1 “Proton sponge” effect 
The “proton sponge” effect was discovered in certain cationic polymers that comprise of a 
large number of ionizable groups (i.e, secondary and tertiary amine groups) with pKa values close 
to the endosomal/lysosomal pH (i.e., pH ranging from 5 to 7)2. Ionizable groups possess a charge 
that is dependent on the pH of the surrounding environment. In the endosome, these ionizable 
groups (i.e., pKa values between 5.4 and 7.6) present in siRNA-based polymers become 
protonated. In response to the protonation of amine groups, the ATPase proton pumps on the 
endosomal membrane facilitates an influx of protons from the cytosol into the endosome to 
maintain the acidic milieu. The influx of protons is accompanied by the inward movement of 
chloride counter ions and water molecules. The resultant endosmosis causes osmotic swelling and 

















2.1.1.1.2 “Proton sponge” effect-based carriers  
 
2.1.1.1.2.1  Polyethylenimine (PEI) 
PEI is the most well-known cationic polymer which has been proved to be highly effective 
in gene delivery both in vitro and in vivo3. This can be attributed to the strong buffering capacity 
of PEI comprising of a high density of protonable amine groups resulting in rapid endosomal 
escape5. PEI vectors have been synthesized to exhibit different molecular weights and structural 
configurations (e.g., linear and branched) to be used as transfection agents6 (Figure 2.2). The 
 
Figure 2.1: The ‘proton sponge’ hypotheses. (A) Polyplexes enter cell via 
endocytosis and are trapped in endosomes. (B) The membrane bound ATPase proton 
pumps actively translocate protons into endosomes. Polymers become protonated and 
resist the acidification of endosomes. More protons will be pumped into the 
endosomes continuously to lower the pH. (C) The proton pumping action is followed 
by passive chloride ions entry, increasing ionic concentration and hence water influx. 
High osmotic pressure causes the swelling and rupture of endosomes, releasing their 
contents to cytosol. 
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clinical application of PEI is limited by its substantial toxicity. Earlier research showed that both 
the transfection efficiency and cytotoxicity of PEI-based vectors increase with increasing 
molecular weight (600 Da – 700 kDa)7. The observed toxicity is due to the aggregation of PEI 
complexes on the cell membrane resulting in significant necrosis8. In addition, higher-branched 
PEI showed stronger complexation with nucleic acids and better transfection efficiency than the 
lower branched polymers9. However, the resultant toxicity profile also increased with the degree 
of branching. Modified versions of PEI, such as low molecular weight PEI (LMW-PEI)10 and low 
branching degree PEI, have been investigated to reduce the toxicity of the polymers without 
compromising their pH buffering capacity. In addition, the synthesis of various degradable PEI 
derivatives have resulted in lower toxicity profiles. For example, low MW PEI (2 kDa) cross-
linked with reducible disulfide linkage and conjugated to hyaluronic acid (HA) to form (PEI-SS)-
b-HA block copolymers encapsulated anti-vascular endothelial growth factor (VEGF) siRNA into 
serum-stable particles with negligible toxicity. These particles proved to efficiently suppress 
VEGF expression both in vitro and in vivo, as well as successfully suppress tumor growth 
following intratumoral injections11. The incorporation of negatively-charged succinic acid groups 
to the branched PEI (25 kDa) backbone also resulted in effective siRNA carriers with low 
toxicity12. Furthermore, the addition of PEG comprising Arg-Gly-Asp (RGD) peptide ligands to 











2.1.1.1.2.2 Poly (amidoamine) PAMAM dendrimers 
PAMAM dendrimers are a family of water-soluble polymers that is characterized by a 
unique tree-like branching architecture with a large number of primary, secondary, and tertiary 
amine groups (Figure 2.3)14, 15. The high density of protonable amine groups enables rapid 
endosomal escape of PAMAM-based dendriplexes due to the “proton sponge” mechanism16, but 
also leads to non-specific cytotoxicity. The toxicity of PAMAM dendrimers can be reduced by 
conjugation of hydrophilic polymers17, 18 or by partial neutralization of the cationic amine groups19. 
However, their gene silencing capacity was also reduced due to the poor pH buffering capacity 
and subsequent endosomal escape19.  The biocompatibility of dendrimers is related to their 
structure, molecular size, and surface charge20. Cytotoxicity and immunogenicity of dendrimers 
are related to its surface charge. Cationic polyamidoamine (PAMAM, amino-terminated surface) 
is more cytotoxic than anionic PAMAM (carboxylate-terminated surface) in Caco-2 cells. Similar 
















2.1.1.1.3 Membrane destabilization effect 
Several viruses such as the influenza virus have evolved pH-responsive fusogenic proteins, 
hemagglutinin, that is responsible for the virus binding to the cell that is being 
infected.  Hemagglutinin (HA) binds to monosaccharide sialic acid which is present on the surface 
of its target host cells (Figure 2.4)22. The cell membrane then engulfs the virus through endocytosis 
and forms endosome. When the pH within the endosome drops to 6.0, the HA molecule partially 
unfolds, releasing a very hydrophobic portion of its peptide chain that was previously hidden 
within the protein. This so-called "fusion peptide" acts like a molecular grappling hook by inserting 
itself into the endosomal membrane and locking on. Then, the rest of the HA molecule refolds into 
a new structure and pulls the endosomal membrane right up next to the virus particle's own 
membrane, causing the two to fuse together (Figure 2.4)22. Once this has happened, the viral RNA 
genome enters into the cell's cytoplasm. Several synthetic analogs of the pH responsive, 
membrane-destabilizing HA peptides have been developed to enhance cytoplasmic gene delivery. 
However, the clinical application of synthetic fusogenic peptides are limited by their potential 








    
 
Figure 2.4: Model of the sequence of events in influenza hemagglutin-mediated fusion. A 
representative schematic cross-section is shown (an actual contact zone will include 100 or more 
trimers). Stochastic release of a sufficient minimum number of fusion peptides is rate limiting. 
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2.1.1.1.4 Amphiphilic membrane destabilizing carriers 
To mimic the membrane-disruptive properties of viral fusogenic peptides, a family of pH-
sensitive poly (alkylacrylic acid) polymers (Figure 2.5) has been synthesized to enhance the 







The carboxyl groups on the amphiphilic polymers depicted in Figure 2.5 possess the ability to 
sense a change in environmental pH and become protonated at acidic pH. These polymers bear 
pendant carboxylic acid groups and destabilize membrane bilayers by pH-triggered 
conformational changes25. They collapse from an expanded hydrophilic coil at physiological pH 
to a hydrophobic globule in an acidic environment26, 27(Figure 2.6). Thus far, poly PEAA is the 
most extensively studied anionic carboxylated polymer for its membrane-destabilizing properties. 
PEAA is currently being investigated in liposomal delivery systems to induce pH-triggered release 
of liposome content28–31. It is also being evaluated as an endosomolytic agent32,33. At acidic pH 
and low concentrations, it can permeabilize cell membranes, whereas high polymer concentrations 
completely solubilize phospholipid bilayers34. Prior research illustrates that pH-responsive 
membrane destabilizing activity can be modulated by changing the number of alkyl groups in the 
polymer composition23,24. In addition, PPAA exhibited a pH-dependent membrane destabilization 
that is one order of magnitude higher than PEAA25 and proved to enhance the transfection 
 
Figure 2.5: Chemical structure of pH-senstive amphiphilic polymers. 
(A) Poly (ethyl acrylic acid) (PEAA), (B) Poly (propyl acrylic acid), and 





efficiency of cationic lipid/pDNA complexes both in vitro25 and in vivo35. The modification of pH-
responsive membrane-destabilizing polymer backbones to exhibit functionalized monomers like 
pyridyl disulphide acrylate (PDSA) via glutathione-sensitive disulphide linkages enabled coupling 












2.1.2 “Non-specific biodistribution of in vivo, systemic siRNA-based vectors can result in 
poor transfection efficiency” 
The systemic administration of synthetic siRNA-based vectors often results in 
accumulation in the organs of the RES system, namely the liver, spleen, kidneys, and lungs. It is 
no coincidence that much of the successful siRNA delivery seen in the recent years has targeted 
diseases within these organs36. One major challenge in nanomedicine development is how to 
selectively deliver nanoparticles to diseased tissues. Nanoparticle delivery systems require 
targeting for specific delivery to pathogenic sites when enhanced permeability and retention effect 
 
Figure 2.6: (A) Protonation of the pH-responsive carboxyl groups of PEAA at acidic 
pH induces (B) the hydrophobic alkyl groups to interact with the endosomal 
membrane, which results in the rupture of the membrane.   
A
  A 
B
  A 
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(EPR) is not suitable or is ineffective - this minimizes or avoids off-target effects of the active 
therapeutic agents on healthy tissues2. The conjugated targeting ligands are often specific to cell 
surface components that are unique, or upregulated in pathological tissues. The targeting ligands 
fall into several general classes: small molecules, polypeptide-based peptides, protein domains, 
antibodies, and nucleic acid-based aptamers37. At times, ligands from multiple classes (chimeras), 
or multiple ligands within the same class but with different targets (multi-valency and multi-
specificity) have been implemented to enhance nanoparticle targeting. The coupling of ligands to 
nanoparticles requires precise chemistry that ensures ligand-directed coupling with correct 
orientation and desired surface density37.  
 
2.1.2.1 Advantages and disadvantages of general targeting strategies 
 
2.1.2.1.1 Targeting with small molecules 
This is the most prolific targeting strategy. The advantage of using small molecule as a 
targeting ligand is its stability, ease of conjugation with nanoparticles, and the potential low cost38. 
However, there is no systematic approach to develop such ligands, and most small molecule 
targeting ligands do not bind cell surface receptors with high specificity and affinity. Biotin, also 
known as vitamin H, has been widely used for facile conjugation with nanoparticles coated with 
(strept)avidin for in vitro applications38. This conjugation method exploits the extremely high 
affinity (10−14−10−15 M) between biotin and (strept)avidin. Clinical applications of this 





2.1.2.1.2 Targeting with polypeptide-based homing peptide, protein domain, and antibody 
ligands 
Polypetide-based targeting ligands, include homing peptides, protein domains, and 
antibodies, have advantages over other classes of targeting ligands in that they can be systemically 
developed and generated by using various biological selection and expression systems, 
respectively. Some major issues of these targeting ligands include immunogenicity, stability, and 
difficulty for site-specific conjugation with nanoparticles38. 
 
2.1.2.1.3 Targeting with aptamers 
Since their introduction in 1990, aptamers have existed as a separate class of binding 
molecules39. Aptamers are short single-stranded nucleic acids (RNA or DNA) capable of 
displaying diverse structures with the potential of binding many biochemical targets, from small 
molecules to large proteins40. Aptamers are uniquely suited to nanoparticle targeting. Aptamers 
exhibit significant advantages relative to protein therapeutics in terms of size, synthetic 
accessibility and modification by medicinal chemistry. They are typically non-immunogenic41, 
non-toxic42, and modifiable for stability in circulation42.  Despite these properties, aptamers have 
been slow to reach the marketplace, with only one aptamer-based drug receiving approval so far. 
As aptamers are subject to biological degradation by nucleases that poses a major barrier to in 
vivo aptamer-targeted nanoparticle applications.  
 
2.1.3 Limitations of current siRNA carriers 
Although both “proton sponge” and membrane destabilization effect proved efficient in 
enhancing cytoplasmic delivery of therapeutic nucleic acids – they have a number of limitations. 
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Cationic polymers with strong pH buffering capacity, such as PEI, usually deliver the desired dose 
of nucleic acid cargo into the cytoplasm of cells when a large amount of polymer is used. The use 
of a large amount of polymer results in non-specific cytotoxicity due to the excess positive charge 
destabilizing cell membranes. On the other hand, the membrane destabilizing activity of pH-
sensitive amphiphilic polymers is based on a delicate balance between the hydrophilic and 
hydrophobic monomers. Excess positive charge abolishes their membrane destabilizing activity, 
while excess amount of hydrophobic groups reduces their solubility in aqueous solutions, thereby 
rendering them ineffective. In addition, PEI and the cohort of pH-responsive poly (alkylacrylic 
acid) polymers are non-biodegradable.  
An ideal non-viral vector must be biodegradable, biocompatible, and non-immunogenic. 
In other words, the vector system should be hydrolyzed and degraded into small fragments (i.e., < 
50 kDa) upon delivery of their therapeutic cargo. This ensures renal excretion of the vector 
fragments (the kidney typically excretes molecules less than 50 kDa in size) and eliminates 
accumulation and vector-associated toxicity. Moreover, the addition of targeting ligands to the 
afore-mentioned cationic polymers to improve target tissue accumulation of the non-viral vectors 
is not trivial and often affects the pH-buffering effect and the hydrophobic/hydrophilic balance. 
Finally, combination therapy – involving the co-delivery of therapeutic siRNA and small molecule 
anticancer drugs (e.g., chemotherapeutic agents) have shown to improve cancer treatment 
outcomes. Therefore, the development of polymeric carriers that can co-deliver both therapeutic 
DNA/RNA and anticancer drugs to the target cells has become the need of the hour. 
     
2.1.4 Structural requirements of an “ideal” polymeric carrier for in vivo siRNA delivery 
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The design rational of an “ideal” polymeric carrier to overcome the limitations of existing 
polymeric-based siRNA carriers should include the following characteristic: (i) degradable, (ii) 
high drug loading, (iii) low toxicity, (iv) cell-specific, and (v) able to co-deliver other therapeutic 
drugs. To meet the requirements of an ideal carrier, we developed a library of degradable, pH-
sensitive, membrane-destabilizing, star-shaped polymers as a platform technology that proved 
effective in complexing large doses of siRNA and functionally delivering therapeutic siRNA 
molecules into the cytoplasm of cancer cells in vitro. The carriers have a β-cyclodextrin (β-CD) 
core comprising of 7 glucose units linked by α-1,4-glycosidic bonds to form a cone-shaped 
structure. The β-CD core exhibits 7 hydroxyl (OH) groups on the primary face and 14 OH groups 
on the secondary face. The difference in the distribution of OH groups results in a difference in 
reactivity between the primary and secondary face, which facilitates the asymmetric conjugation 
of pH-sensitive/hydrophobic/cationic grafts on the secondary face and hydrophilic PEG grafts 
displaying targeting motifs on the primary face. The copolymer of pH-sensitive dimethyl 
aminoethyl methacrylate (DMAEMA), hydrophobic hexyl methacrylate (HMA) and cationic 
trimethyl aminoethyl methacrylate (TMAEMA) was grafted from the secondary face via acid-
labile linkages (Figure 2.7 B). Hydrazone linkages have been previously used to conjugate small 
molecular weight anticancer drugs (e.g., doxorubicin) to water-soluble hydroxypropyl 
methacrylate (HPMA) polymers and proved to hydrolyze and release the attached drug upon 
internalization into acidic intracellular vesicles43. Incorporation of the hydrazone linkages in these 
star-shaped polymers allows grafts with a large number of pH-sensitive/hydrophobic/cationic 
copolymers to achieve a high positive charge density that will allow the condensation of a large 
number of DNA/RNA molecules into the pH-sensitive particles with high therapeutic loading44. 
In addition, the acid-labile hydrazone linkages will be hydrolyzed in the endosome, which will 
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result in the fragmentation of the carriers into multiple grafts that can be easily eliminated from 
the body without inducing significant toxicity. Besides the unique reactivity profile of β-CD 
molecules – they are water-soluble comprising of a hydrophobic cavity that facilitates the 
encapsulation of hydrophobic anticancer drugs inside and complexation of hydrophilic therapeutic 
DNA/RNA molecules outside45. The incorporation of PEG polymers on the primary face as a 
passive targeting moiety can help reduce the adhesive interactions associated with the peritoneal 
mucus membrane and facilitate an increased uptake into the blood circulation upon IP 
administration of the polymers. PEG has been shown to be safe for use with biological 
systems46; several PEGylated drugs have been approved by the FDA and others are being tested 
in clinical trials47. PEGylation presents an important tool for prolonging the blood circulation 
times48–51 and by reducing the mononuclear phagocytic system (MPS) or reticuloendothelial 
system (RES) clearance as a result of minimizing the protein binding to the particle52. Finally, 
to address the non-specific distribution of siRNA-based delivery systems, we proposed the 
coupling of EPPT1-peptide as an active targeting moiety to the free ends of primary PEG 
brushes to facilitate target site accumulation of polymers. The synthetic peptide, designated 
EPPT1 (YCAREPPTRTFAYWG), is derived from the CDR3 Vh region of a monoclonal antibody 
(ASM2) raised against human epithelial cancer cells53. The EPPT1 synthetic peptide has 
significant affinity (Kd = 20 μM) for the uMUC-1-derived peptide, PDTRP, region. In a previous 
study, the EPPT1 peptide, labeled with 99mTc, was used to image breast carcinomas in vivo54 .We 
chose a peptide-based targeting strategy as peptides are much smaller than antibodies but larger 
than small molecules. The design of a small molecule that fits into a usually shallow and 
hydrophobic binding pocket can be challenging. As a compromise between small molecules and 
large antibodies, short peptides fit in the pocket and have high specificity and affinity. Overall, 
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these asymmetric, degradable, pH-sensitive, membrane destabilizing polymers possess are the 
features of an ideal non-viral vector for intracellular delivery of therapeutic macromolecule.  
 
2.1.5 Objective and Hypothesis 
The objective of this dissertation is to develop targeted “smart” particles to achieve 
enhanced cell specific cytoplasmic delivery of therapeutic anti-RhoC siRNA molecules to suppress 





Figure 2.7: (A) Chemical representation of the proposed ideal polymeric star-shaped β-CD-P(HMA-
co- DMAEMA-co-TMAEMA)n polymers. (B) Schematic drawing of the ideal β-CD-based polymers 
for cytoplasmic delivery of siRNA to the target site.   
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RhoC-associated cell invasion and migration in vitro and to determine our nanoparticle’s 
biodistribution and therapeutic behavior in vivo. The pH-sensitive polymers can condense anti-
RhoC siRNA molecules into “smart” particles that will be taken up by aggressive breast cancer 
cells via endocytosis. In the endosome, the particles will “sense” the drop in endosomal pH, which 
will trigger the degradation of the polymeric carrier into small membrane destabilizing fragments 
to destabilize the endosomal membrane and release the siRNA molecules into the cytoplasm in 
vitro. The addition of EPPT1-peptide ligands to the “smart” polymers can facilitate cell specific 
accumulation by binding to MUC1 receptors known to be overexpressed on aggressive breast 
cancer cells while minimizing uptake by healthy cells. The asymmetric, targeted “smart” 
nanoparticles were designed to maneuver through the systemic circulation without being 
recognized by blood components and to target the specific tumor tissue following extravasation 
out through the ‘leaky’ vasculature of the tumor in vivo.  
We hypothesize that the EPPT1-peptide targeted “smart” nanoparticles complexing anti-
RhoC siRNA molecules will demonstrate specificity and selectivity for uMUC1-receptor 
expressing breast cancer cells in vitro and in vivo. We hypothesize that the primary PEG grafts 
will shield the encapsulated siRNA from serum proteins and will reduce hemolysis of RBC’s. The 
asymmetric targeted polymer can condense anti-RhoC siRNA into stable particles that will be 
internalized in cancer cells via receptor-mediated endocytosis. In the endosome, the particles will 
destabilize the endosomal membrane through both hydrophobic disruption and endosomal 
swelling mechanism, releasing siRNA cargo into the cytoplasm of breast cancer cells to suppress 
RhoC expression. We hypothesize the incorporation of EPPT1-peptide ligands and anti-RhoC 
siRNA on the same polymer system can synergistically reduce cell invasion and migration of 




2.1.6 Specific aims 
The specific aims of this dissertation are:  
 
1. Investigate the feasibility of our “smart” nanoparticles’ amphiphilic copolymer graft 
composition to complex the desired dose of anti-RhoC siRNA molecules and to functionally 
deliver the therapeutic cargo past the endosome into the cytoplasm of aggressive breast cancer 
cells. Evaluate the effect of RhoC protein suppression on associated changes in cell invasion 
and migration in the aforementioned cell lines in vitro. 
 
2. Design and synthesize EPPT1-peptide targeted, PEGylated “smart” polymers with improved 
biocompatibility against blood components and enhanced target cell specificity in vitro. We 
engineered asymmetric polymers with varying PEG graft lengths to evaluate the effect of PEG 
molecular weight on hemocompatibility and serum stability. Determine if the incorporation of 
EPPT1-peptides results in target cell specificity and enhanced functional delivery of 
therapeutic anti-RhoC siRNA into the cytoplasm of these cells. 
 
3. Confirm the in vivo feasibility of our asymmetric “smart” nanoparticles. Evaluate the 
biodistribution of EPPT1-peptide targeted nanoparticles in SUM149 tumor-bearing mice 
compared to their non-targeted counterparts. Determine the dosing regimen of anti-RhoC 
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“Smart” Nanoparticles Enhance the Cytoplasmic Delivery of Anti-RhoC 




The American Cancer Society estimated that 232,670 women were diagnosed 
with invasive breast cancer in the U.S. in 20141. Approximately, 20-30% of breast cancer patients 
develop distant metastases to the bone, brain, liver, and lungs, which results in 40,000 deaths from 
breast cancer1, 2. Metastasis of aggressive breast cancer cells is a complex process that involves 
cell detachment from the primary lesion, migration through the extracellular matrix, invasion 
through the basement membrane, entrance into lymphatic and blood vessels, evasion from the 
immune system in the lymphatic and systemic circulations, extravasation into the interstitial space 
of distant organs, colonization in secondary sites, and initiation of new tumor lesions3, 4, 5. 
Overexpression of the Ras homology (Rho) family of low molecular weight (21-25 kDa) 
guanosine-5'-triphosphate (GTP)-binding proteins has been strongly implicated in the migration 
and invasion of aggressive breast cancer cells6. Specifically, the C-terminus of Rho proteins 
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undergoes post-translational modification where isoprenoid lipids (e.g. farnesyl or geranylgeranyl 
lipids) are covalently attached to allow Rho proteins to anchor to the cell membrane7. This 
isoprenylation of Rho-GDPases is initiated by the transduction of extracellular signals through 
integrins and growth factor receptors to the cytoplasm in tightly regulated signaling pathways6. 
Upon insertion into the cell membrane, the GTPase domain of Rho proteins, which binds to 
guanosine-5'-diphosphate (GDP)8 and GTP molecules, acts as a molecular on/off switch by 
cycling between inactive GDP-bound and active GTP-bound states9. The activated Rho-GTPase 
proteins are involved in all aspects of cellular motility and invasion including cell polarization, 
signal transduction, cytoskeletal reorganization, and formation of invasive cell membrane 
protrusions10-12. For example, RhoA and RhoC proteins play key roles in regulating the 
contractility of acto-myosin rings and cell motility13. In addition, the Rac1 protein stimulates the 
formation of lamellipodia (membrane ruffles)13, 14 while the Cdc42 protein dictates the direction 
of cell migration by coordinating actin polymerization at the leading side of the cell15. 
Overexpression of RhoC GTPases has been linked to the metastasis of inflammatory breast 
cancer (IBC)16, 17 and triple-negative breast cancer cells18, 19 as well as low patient survival rates. 
The role of RhoC in promoting cell migration and invasion has been confirmed by multiple in vitro 
and in vivo studies16, 19, 20. In one such study, transfecting human mammary epithelial (HME) cells 
with the gene encoding for RhoC allowed the cells to grow in an anchorage-independent manner 
and become highly motile and invasive due to enhanced formation of actin and focal adhesion 
points in vitro21. Further, the RhoC-expressing HME cells were tumorigenic and produced 
angiogenic factors when orthotopically implanted into the mammary fat pads of athymic nude 
mice21. Another report described the role of RhoC GTPases in breast cancer metastasis by 
assessing the number of cancer lesions in the lungs of RhoC+ and RhoC- tumor-bearing mice19. 
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The detection of 37 ± 12 lesions in RhoC+ mice (n = 12) compared to 5 ± 2 cancer lesions in RhoC- 
mice (n = 16) confirmed the role of RhoC in promoting breast cancer metastasis19. Cytofectin-
mediated transfection of anti-RhoC silencing RNA (siRNA) molecules into the cytoplasm of 
MDA-MB-231 cells has been shown to reduce RhoC expression at the mRNA and protein levels 
and result in 70% inhibition of cancer cell invasion in vitro20. In addition, direct injection of anti-
RhoC siRNA into tumors formed by implanting MDA-MB-231 breast cancer cells in the flanks of 
nu/nu mice caused a 53% reduction in tumor growth22. These results collectively show the 
therapeutic benefit of suppressing the activity of RhoC proteins to inhibit the metastatic spread of 
aggressive breast cancer cells. However, using anti-RhoC siRNA as a therapeutic agent in a 
defined dosing regimen remains a significant challenge due to the lack of a biocompatible carrier 
that can efficiently protect and selectively deliver the RNA cargo into the cytoplasm of breast 
cancer cells in order to silence cancer cell migration, invasion, and metastasis without exhibiting 
non-specific toxicity to healthy cells23 
We previously reported the synthesis of star-shaped, pH-sensitive, and membrane-
destabilizing polymers that enhance the cytoplasmic delivery of siRNA molecules into epithelial 
cancer cells24. We utilized β-cyclodextrin (β-CD) as the core carrier to graft copolymers with equal 
molar ratios of the hydrophobic hexyl methacrylate (HMA) and the pH-sensitive 2-
(dimethylamino)ethyl methacrylate (DMAEMA) monomers from the secondary face via acid-
labile hydrazone linkages (Figure 3.1)25. Finally, 50% of the DMAEMA monomers in each graft 
copolymer were quarternized into cationic N, N, N-trimethylaminoethyl methacrylate (TMAEMA) 
monomers to facilitate efficient condensation of siRNA molecules via electrostatic interactions 
between the cationic amine (N) groups of the polymer and anionic phosphate (P) groups of the 
siRNA forming “smart” pH-sensitive and membrane-destabilizing particles (Figure 3.2). 
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In this report, we investigate the ability of biodegradable, pH-sensitive, star-
shaped polymers to complex anti-RhoC siRNA molecules at low N/P ratios forming “smart” 
nanoparticles and whether they achieve functional delivery of the loaded cargo into aggressive 
breast cancer cells. We hypothesize that “smart” anti-RhoC particles will be taken up by breast 
cancer cells via adsorptive endocytosis followed by fragmentation and release of the membrane-
active P(HMA-co-DMAEMA-co-TMAEMA) grafts in response to acidic endosomal pH 
gradients, which will destabilize the endosomal membrane and release the loaded siRNA cargo 
into the cytoplasm (Figure 3.2). In the cytoplasm, anti-RhoC siRNA molecules will selectively 
bind to the RhoC mRNA resulting in mRNA degradation and blocking the expression of RhoC 
protein. We investigated the effect of functional delivery of anti-RhoC siRNA into the cytoplasm 
of triple negative MDA-MB-231 and inflammatory SUM149 breast cancer cells on RhoC 
















3.2 Materials and methods 
 
3.2.1 Materials 
Figure 3.2: A schematic drawing showing condensation of anti-RhoC siRNA molecules by star-
shaped pH-sensitive polymers forming “smart” particles, which are internalized by endocytosis. In the 
endosome, acid-labile hydrazone linkages are hydrolyzed by the acidic pH, which release the P(HMA-
co-DMAEMA-co-TMAEMA) grafts that rupture the endosomal membrane and release the loaded 
siRNA cargo into the cytoplasm. In the cytoplasm, anti-RhoC siRNA binds to RhoC mRNA triggering 
its degradation while particle’s debris are eliminated by exocytosis. 
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Ham’s F12 medium, OPTI-MEM reduced serum medium, Rosewell Park Memorial 
Institute-1640 (RPMI) medium, fetal bovine serum (FBS), 0.05% trypsin/0.20% 
ethylenediaminetetraacetic acid (EDTA) solution, and phosphate buffered saline (PBS) solution 
were purchased from Invitrogen Corporation (Carlsbad, CA). The anti-RhoC (5'-
GACCUGCCUCCUCAUCGUCTT-3') and scrambled (5'- CAGUCAGGAGGAUCCAAAGTG-
3’) siRNA sequences were synthesized by Dharmacon Scientific (Lafayette, CO). The human anti-
GAPDH siRNA, FAM-labeled GAPDH siRNA, scrambled siRNA, and siPORT-Amine 
transfection reagent were purchased from Ambion Inc. (Austin, TX). The RNeasy Mini kit and 
Omniscript reverse transcriptase kit were purchased from Qiagen (Valencia, CA). The SYBR 
green power master mix, forward and reverse RhoC, RhoA, and RPL19 primers were purchased 
from Applied Biosystems (Foster, CA). Anti-RhoC rabbit monoclonal antibody was purchased 
from Cell Signaling Technologies (Danvers, MA). The anti-RhoA mouse monoclonal antibody, 
anti-β-actin rabbit antibody, and goat anti-rabbit IgG-HRP antibodies were procured from Santa 
Cruz Biotechnology Inc. (Santa Cruz, CA). BD matrigel invasion assay and the motility assay kits 
were obtained from BD Biosciences (San Jose, CA) and Cellomics (Pittsburgh, PA), respectively. 
The Collagen I coated plates used in the motility assay were obtained from Life Technologies 
(Carlsbad, CA). 
 
3.2.2 Formulation and characterization of “smart” particles 
We synthesized our star-shaped β-CD-g-P(HMA79-co-DMAEMA33-co-TMAEMA48)4.8 
polymers following established protocols25. The star-shaped particles were prepared by dissolving 
β-CD-g-P(HMA79-co-DMAEMA33-co-TMAEMA48)4.8 polymers in RNase-free water prior to the 
addition of 0.7μg of scrambled siRNA at varying nitrogen (N)/phosphate (P) (+/-) ratios. Each 
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“smart” polymer-siRNA mixture was vortexed, centrifuged, and allowed to form particle 
complexes for 20min at room temperature. The lowest N/P ratio at which the β-CD-g-P(HMA79-
co-DMAEMA33-co-TMAEMA48)4.8 polymer and scrambled siRNA molecules formed stable 
complexes was determined by loading each mixture onto a 1% w/v agarose gel containing 
ethidium bromide (EtBr). Prior to loading the samples into the individual wells, the agarose gel 
was soaked in Tris-acetate-EDTA (TAE) buffer, followed by running it at 120V for 30 min. The 
free and bound siRNA molecules were visualized on the gel under UV light. The size and 
electrophoretic mobility of our “smart” particles complexing 1.4µg of scrambled siRNA prepared 
at different N/P ratios were measured using 90Plus particle size analyzer with ZetaPALS capability 
(Brookhaven Instruments Corporation, Holtsville, NY). All experiments were performed in double 
distilled water at 25°C. The zeta potential was calculated from the electrophoretic mobility using 
the Smoluchowski equation. The results are expressed as mean values of five samples.  
 
3.2.3 Cell culture 
SUM149 and MDA-MB-231 breast cancer cells were generously provided by Dr. Sofia D. 
Merajver (University of Michigan, School of Medicine) and cultured following established 
protocols27. Briefly, SUM149 cells were cultured in Ham’s F12 medium supplemented with 5% 
fetal bovine serum (HyClone Laboratories, South Logan, UT), insulin, and hydrocortisone (Sigma-
Aldrich, St. Louis, Mo). SUM149 cells were maintained at 37°C and 10% CO2. MDA-MB-231 
cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum, and 
incubated at 37°C and 5% CO2.  
 
3.2.4 Cellular uptake of “smart” particles 
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“Smart” β-CD particles were prepared at varying N/P (+/-) ratios (i.e., 1.5/1, 2.5/1, 4/1, 
8/1, and 12/1) by dissolving our β-CD-g-P(HMA79-co-DMAEMA33-co-TMAEMA48)4.8 polymer 
in OPTI-MEM solution prior to the addition of 0.57μg FAM-labeled anti-GAPDH siRNA. 
Similarly, the siPORT Amine polymer was mixed with 0.57μg FAM-labeled anti-GAPDH siRNA 
following manufacturer’s instructions. All complexes were vortexed, centrifuged and allowed to 
stand at room temperature for 20 min. The “smart” particle complexes were incubated with 
SUM149 and MDA-MB-231 cancer cells seeded at a density of 40,000 cells per well in 24-well 
plates for 6h at 37°C. Cells were then harvested by washing them with PBS to remove unbound 
particle complexes, followed by detaching them with 0.05% Trypsin/EDTA for 5 min, and 
centrifuging them to form cell pellets and remove the supernatant with free particles. Cell pellets 
were collected, suspended in their respective culture medium, and analyzed using Biosciences 
FACSCalibur Flow Cytometer (Becton Dickinson, Franklin Lakes, NJ) to determine the % of live 
cells that are fluorescently labeled due to “smart” particle internalization. The results are expressed 
as mean average values + the standard error of the mean of four samples.  
We visualized the uptake of β-CD-g-P(HMA79-co-DMAEMA33-co-TMAEMA48)4.8 
polymers complexed with FITC-labeled siRNA into SUM149 and MDA-MB-231 breast cancer 
cells using a Nikon A1 confocal microscope (Nikon Instruments Inc., Melville, NY) equipped with 
diode-based lasers. Briefly, SUM149 and MDA-MB-231 cells were seeded in 4-well Lab-Tek II 
Chambered Glass Slides (Thermo Scientific, Waltham, MA) at a seeding density of 7,000 
cells/well and allowed to adhere overnight. Both cell lines were incubated with free FITC-labeled 
siRNA and “smart” -CD particles prepared by complexing β-CD-g-P(HMA79-co-DMAEMA33-
co-TMAEMA48)4.8 polymers with FITC-labeled siRNA at a N/P ratio of 2.5/1 for 6 hours. The 
treated SUM149 and MDA-MB-231 cells were washed with PBS twice to remove the free “smart” 
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particles in solution, and fixed with 4% paraformaldehyde for 30 min. The fixed cells were washed 
again with PBS prior to staining the cell cytoskeleton with Rhodamine Phalloidin for 15 min, and 
washed one more time with PBS before microscopic examination. We used (ex) of 488 nm and 
(em) of 530 nm to image FITC-labeled siRNA while using (ex) of 512 nm and (em) of 600 nm 
to image the Rhodamine-stained cytoskeleton. We used a Nikon Apo 10 /1.25na lens to capture 
planar images of the cells followed by image processing using Nikon NIS Confocal Software. 
 
3.2.5 In vitro effect of “smart” anti-RhoC particles 
The β-CD-g-P(HMA79-co-DMAEMA33-co-TMAEMA48)4.8 polymer dissolved in OPTI-
MEM solution was allowed to complex with 0.57µg of anti-RhoC (+) or scrambled (-) siRNA at 
a N/P(+/-) ratio of 2.5/1 to prepare “smart” anti-RhoC (+) and scrambled (-) particles, respectively. 
SiPORT-Amine complexes loaded with 0.57µg of anti-RhoC (+) or scrambled (-) siRNA were 
prepared following manufacturer’s instructions. SUM149 and MDA-MB-231 cells were seeded at 
50,000 cells per well in 24-well plates and allowed to adhere for 18h before their incubation with 
different particles following established protocols25. The effect of different particles on RhoC 
expression in both cancer cell lines was quantified based on mRNA and protein levels. For the 
quantification of RhoC mRNA levels, the total RNA from each sample treatment condition of 
SUM149 and MDA-MB-231 cells was obtained using the RNeasy Mini Kit (Qiagen Inc., 
Valencia, CA) and quantified using Thermo Scientific NanoDropTM 1000 Spectrophotometer. 
Equal amounts of total RNA (0.25μg) from each treatment condition were reverse transcribed 
using Omniscript reverse transcriptase kit (Qiagen Inc., Valencia, CA) following manufacturer’s 
protocols. Quantitative PCR was performed with an Applied Biosystems PCR System at a final 
volume of 20μl, containing1.25μL of cDNA (corresponding to 250ng of total RNA for RhoA, 
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RhoC and RPL19 rRNA amplification), 0.1μL of each forward and reverse primer (corresponding 
to 0.01μg/μL of RhoA, RhoC and RPL19 primer sets), and 10μL of SYBR green qPCR Master 
Mix. The sequences of the forward and reverse primers for RhoC are 5’-
CATCCTGGTGGGGAATAAGA-3’ and 5’-GCACTCAAGGTAGCCAAAGG-3’, respectively. 
The sequences of the forward and reverse primers for RhoA are 5’-
ACCCGCCTTCGTCTCCGAGT-3’ and 5’-TGTGGGCACACACCTCTGGG-3’, respectively. 
The sequences of the forward and reverse primers for RPL19 are 5’-
GCTGCTCAGAAGATACCGTCA-3’ and 5’-TTGTCTGCCTTCAGCTTGTG-3’, respectively 
(Applied Biosystems, Foster, CA). The RPL19 primer was used as an internal control. The mean 
fold difference (2-ΔΔCT) in RhoA and RhoC mRNA expression in response to different particles 
was calculated following published protocols and normalized to untreated cells used as a negative 
control28. 
The change in the amount of RhoA and RhoC protein expression in treated SUM149 and 
MDA-MB-231 cells was quantified using western blotting techniques following established 
protocols29. Briefly, after the 48 h transfection cycle, the cells were washed in cold PBS and 
incubated with RIPA lysis buffer on ice for 5 min. The lysed cells were centrifuged at 14,000 rpm 
for 15 min to isolate the supernatant containing the protein fraction. The total protein concentration 
was measured using the bicinchoninic acid assay (Pierce Biotechnology, Rockford, IL) following 
manufacturer’s protocol. Equal amounts of protein extracts (10 μg) obtained from different particle 
treatments were resolved by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) before transferring to a polyvinylidene fluoride (PVDF) membrane using a semidry 
apparatus (Bio-Rad, Hercules, CA). Membranes were probed overnight at 4 °C with anti-β-actin 
rabbit antibody (Santa Cruz, CA) at a 1:1000 dilution and primary anti-RhoC rabbit monoclonal 
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antibody (Cell Signaling Technologies, MA) or anti-RhoA mouse antibody (Santa Cruz, CA) at a 
1:500 dilution. Bound primary antibodies were visualized using enhanced chemiluminescence 
(Pierce, Rockford, IL) after incubating with secondary horseradish peroxidase-coupled anti-rabbit 
or anti-mouse antibody (Santa Cruz, CA) at a 1:1000 dilution for 1 h at room temperature. The 
knockdown of RhoA and RhoC proteins in response to different particles was quantified using the 
ImageJ software (NIH, Bethesda, MD) and normalized to the endogenous β-actin control and 
untreated SUM149 and MDA-MB-231 cells. Five replicates were used for each condition in each 
experiment and the results show the average + the standard error of the mean (SEM). 
 
3.2.6 Boyden chamber invasion assay 
We used BD matrigel invasion assay chambers (BD Biosciences, Bedford, MA) to quantify 
cell invasion in both SUM149 and MDA-MB-231 cells as per manufacturer’s instructions. Briefly, 
SUM149 and MDA-MB-231 cell lines were plated in 6-well plates at a seeding density of 300,000 
cells per well and allowed to adhere for 18 h. The adhered cells were then treated with “smart” 
anti-RhoC (+) and scrambled (-) particles prepared by complexing β-CD-g-P(HMA79-co-
DMAEMA33-co-TMAEMA48)4.8 polymer with 2.28µg of anti-RhoC (+) and scrambled (-) siRNA 
molecules at a N/P ratio of 2.5/1 for 6 h in serum-free OPTI-MEM, followed by the addition of 
1mL of fresh culture medium to each well. After a total of 12 h, the culture medium was aspirated, 
replaced with serum-free OPTI-MEM containing the same particle mixtures for a second 
transfection cycle. After a total of 24 h, cells were washed with PBS, trypsinized using 0.05% 
Trypin/EDTA, and centrifuged to collect the cell pellets before suspending them in serum-free 
culture medium at a density of 50,000 cells per mL. The matrigel-coated inserts were rehydrated 
in serum-free media before adding 0.5 mL of the cell suspension to each insert. Wells in the culture 
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dish were filled with 0.75 mL serum-containing medium before placing the inserts with the seeded 
cells in each well and incubating for 24 h at 37°C. Adherent cells in the upper chamber that did 
not invade through the matrigel layer were gently removed using cotton swabs, while the adherent 
cells on the lower surface of each insert were stained with 1% crystal violent in 20% methanol for 
1 h followed by rinsing with water to remove excess dye. The stained cells were dissolved in 10% 
acetic acid and their absorbance was measured at 560 nm. Results were normalized to the untreated 
SUM149 and MDA-MB-231 cells and reported as the average of three independent experiments 
+ SEM.  
  
3.2.7 Random motility assay 
Random cell motility was determined by using a motility assay kit following 
manufacturer’s specifications (Cellomics, Pittsburg, PA). The β-CD-g-P(HMA79-co-
DMAEMA33-co-TMAEMA48)4.8 polymer was mixed with 2.28 µg of anti-RhoC (+) or scrambled 
(-) siRNA at a N/P ratio of 2.5/1 to prepare “smart” anti-RhoC (+) and scrambled (-) particles, 
respectively. SUM149 and MDA-MB-231 cells were transfected with “smart” anti-RhoC siRNA 
(+) and scrambled siRNA (-) particles, respectively, following the same protocol used in the 
Boyden chamber invasion assay. The treated cells were harvested in regular culture medium, and 
plated at a seeding density of 1,000 cells per well on the top of microscopic fluorescent beads 
evenly distributed in 96-well plates coated with collagen I (Life technologies, Carlsbad, CA). After 
incubation for 24 h at 37°C, the cells were fixed in formaldehyde and were stained with rhodamine-
conjugated phalloidin. Track and cell areas were quantified using the ImageJ software (NIH, 
Bethesda, MD). Cell motility for each treatment condition was calculated by dividing the track 
area by the cell area. The average track area per cell for particle-treated cells was normalized to 
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the average track area observed with untreated cells. Results are the average + SEM of five 
independent replicates. 
 
3.2.8 Scratch assay 
We evaluated the effect of “smart” anti-RhoC (+) particles prepared at N/P ratio of 2.5/1 
on the migratory activity of SUM149 and MDA-MB-231 cells compared to scrambled (-) particles 
using the wound healing assay. SUM149 and MDA-MB-231 cells were plated in 24-well plates at 
a seeding density of 50,000 cells/ well and allowed to grow under normal culture conditions to 
95% confluence. The cell monolayer was scratched with a sterile 200µL pipette tip to create a 
“wound” across the center of each well. Each well was washed with PBS to remove the detached 
cells, and the wound was imaged (t = 0 h) at a 10X magnification using a Nikon Eclipse Ti inverted 
microscope equipped with a camera to capture phase contrast images of the wound. Subsequently, 
the SUM149 and MDA-MB-231 cell monolayers were treated with “smart” anti-RhoC (+) or 
scrambled (-) particles prepared at an N/P ratio of 2.5/1 following the same protocol used in the 
Boyden chamber invasion assay. After 36 h, the wounds were imaged at a 10X magnification using 
the same microscope setup. The acquired images were processed using Green’s theorem to 
calculate the wound area at t = 0 h and 36 h. The wound area after 36 h was normalized to the 
initial area (t = 0 h) to quantify the change in cell migration in response to different particles. 
 
3.2.9 Statistical analysis 
Results are presented as the mean  standard error of the mean (SEM). Comparisons of 
various “smart” particle parameters (i.e., size, zeta potential, and cell uptake) at varying N/P ratios 
were done using one-way ANOVA with Tukey’s post hoc analysis. Statistical difference between 
68 
 
group population means (i.e., varying N/P ratios) was significant at the 0.05 level.  Statistical 
difference between particles encapsulating anti-RhoC (+) and scrambled (-) siRNA sequence was 
evaluated using paired t test where the population means were statistically significant at p ≤ 0.05. 
Similarly, the difference between particles encapsulating scrambled (-) siRNA sequence and 
untreated controls in both cell lines was evaluated using paired t test where the population means 
were statistically significant at p ≤ 0.05. 
 
3.3 Results and Discussion 
 
3.3.1 Formulation and characterization of “smart” particles 
We successfully utilized the asymmetric distribution of seven primary (C-6) and fourteen 
secondary (C-2 and C-3) hydroxyl (OH) groups on opposite sides of the β-CD core to graft the 
amphiphilic P(HMA79-co-DMAEMA81) polymers from the secondary face via acid-labile linkers 
technique following our published methods25. We grafted ~ five 25kDa polymer chains with an 
average 50/50 molar ratio of hydrophobic HMA and pH-sensitive DMAEMA monomers followed 
by 50% quaternization of DMAEMA monomers into TMAEMA to prepare star-shaped β-CD-g-
P(HMA79-co-DMAEMA33-co-TMAEMA48)4.8 polymers. The polymer composition used in our 
study previously showed fragmentation in response to the acidic pH of the endosome (pH 5.8) 
within 6 h25. The membrane active P(HMA79-co-DMAEMA33-co-TMAEMA48) grafts released 
from the β-CD core were successful in destabilizing the endosomal membrane and proved most 




We evaluated the ability of our “smart” β-CD-g-P(HMA79-co-DMAEMA33-co-
TMAEMA48)4.8 particles complexing scrambled siRNA at different N/P (+/-) ratios using the 
standard gel retardation assay. The results show complete condensation of our β-CD-g-P(HMA79-
co-DMAEMA33-co-TMAEMA48)4.8 polymers with the loaded siRNA molecules to form stable 
particles that were retained in the loading wells at N/P ratios as low as 1.5/1 (Figure 3.3 A). This 
complexation ratio (i.e., 1.5/1) is relevant as it much lower than the N/P ratios > 10/131, 32 of 
commonly used transfection reagents like polyethylenimine (PEI) and cationic PAMAM 
dendrimers. Therefore, resulting in a significant improvement over existing carriers as it warrants 
the use of small amounts of β-CD polymer for the condensation and delivery of a high dose of 
siRNA molecules, thereby, reducing the associated side effects33. 
Results show that β-CD particles prepared at a N/P ratio of 1.5/1 had an average size of 
154 ± 1.4 nm, which dropped to 112 ± 1.9 nm and 104 ± 2.0 nm upon increasing the N/P ratio to 
2.5/1 and 4/1, respectively (Figure 3.3 B). This is not surprising given that the increase in N/P 
ratio increases the number of cationic TMAEMA monomers available to complex the anionic 
phosphate groups, which results in better condensation and tighter packing of the siRNA cargo 
indicated by the smaller particle size. The drop in the particle size at different N/P ratios was 
compared using one-way ANOVA (Tukey’s post hoc) analysis and showed no statistical 
difference. Increasing the N/P ratio to 8/1 and 12/1 increased particle’s size to 180 ± 1.7 nm and 
151 ± 1.3 nm, which may be a result of the loose association of excess polymer with the particle’s 
surface. However, as the molecular size cut off for tumor vasculature is between 400 and 600 nm34, 
35, “smart” particles prepared at all N/P ratios are suited for delivery of therapeutic siRNA cargo 
into solid tumors34. Results show that particles’ zeta potential increased from 37 ± 1.21 mV for the 
those prepared at a N/P ratio of 1.5/1 to 50 ± 1.18 mV for the particles prepared at N/P ratio of 
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12/1 (Figure 3.3 B). The observed increase in zeta potential as a function of increasing N/P ratios 
was not significantly different. The positive zeta potential confirms the cationic nature of “smart” 
particles’ surface, which will mediate their efficient internalization by epithelial cancer cells via 














Figure 3.3: (A) Image of 1% w/v agarose gel containing ethidium bromide showing the 
electrophoretic mobility of free siRNA and “smart” particles prepared by the complexation 
of β-CD-g-P(HMA79-co-DMAEMA33-co-TMAEMA48)4.8 polymer with anti-GAPDH 
siRNA (0.71 µg) at different N/P (+/-) ratios. (B) Size (white bars) and zeta potential (solid 
squares) of “smart” particles prepared by complexation of β-CD-g-P(HMA79-co-
DMAEMA33-co-TMAEMA48)4.8 polymer with anti-GAPDH siRNA (1.4 µg) at different 








3.3.2 Cellular uptake of “smart” particles 
We prepared fluorescently-labeled particles by complexating β-CD-g-P(HMA79-co-
DMAEMA33-co-TMAEMA48)4.8 polymers with FAM-labeled anti-GAPDH siRNA at different 
N/P ratios and evaluated their uptake into both cell lines compared to free siRNA and siPORT 
amine-based complexes using flow cytometry. Results show insignificant uptake of free siRNA 
indicated by the low fraction of fluorescently-labeled SUM149 (0.4 ± 0.1%) and MDA-MB-231 
(15.2 ± 1.8%) cells (Figure 3.4, Panel A). “Smart” particles prepared at 1.5/1, 2.5/1, and 4/1 N/P 
ratios exhibited similar and efficient uptake by SUM149 and MDA-MB-231 cells indicated by 
fluorescence labeling of 98% - 100% of the treated cells. Incubating the cells with “smart” particles 
prepared an 8/1 and 12/1 N/P ratios reduced the fraction of fluorescently-labeled SUM149 and 
MDA-MB-231 cells to 90% and 83%-85%, respectively (Figure 3.4, Panel A). Uptake of “smart” 
particles prepared at all N/P ratios was statistically higher than free siRNA (p  0.005) but there 
was no statistical difference between all particles. The drop in the number of fluorescent cells can 
be attributed to higher positive surface charge density on particles’ surface due to the excess of 
cationic β-CD-based polymer used for siRNA complexation, which may result in cell death similar 
to other cationic particles38, 39. Therefore, we limited our studies to “smart” particles prepared at a 
N/P ratio of 2.5/1 and investigated their ability to deliver anti-RhoC siRNA into the cytoplasm of 
SUM149 and MDA-MB-231 breast cancer cells by quantifying the knockdown in RhoC 
expression at the mRNA and protein levels. 
We also visualized the uptake of “smart” -CD particles encapsulating FITC-labeled 
siRNA (P + siRNA) and free FITC-labeled siRNA (free siRNA) in SUM149 and MDA-MB-231 
cells using confocal laser scanning microscopy. Confocal microscopy images of SUM149 (Figure 
3.4, Panel B) and MDA-MB-231 (Figure 3.4, Panel C) cells incubated with “smart” -CD 
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particles loaded with FITC-labeled siRNA show a strong and uniform distribution of green 
fluorescence in the cytoplasm indicating efficient particle internalization by endocytosis. In 
comparison, images of the cell treated with free FITC-labeled siRNA shows no green fluorescence 
of the cytoplasm indicating poor RNA internalization (Figure 3, Panel B and C). Confocal 




Figure 3.4 (A): Percentage of fluorescently-labeled SUM149 and MDA-MB-231 breast 
cancer cells after incubating for 6 h in a serum-free culture medium with free siRNA, siPORT 
amine-based complexes, and “smart” particles prepared by complexation of β-CD-g-
P(HMA79-co-DMAEMA33-co-TMAEMA48)4.8 polymer with FAM–labeled anti-GAPDH 




















Figure 3.4: Fluorescence images of SUM149 (B) and MDA-MB-231 (C) cells after incubating 
with free FITC-labeled siRNA and “smart” βCD particles encapsulating FITC-labeled siRNA 
at an N/P ratio of 2.5/1 for 6 hours. Cell cytoskeleton was stained with Rhodamine-Phalloidin 
dye (λex = 540 nm; λem = 565 nm) while the intracellular distribution of FITC-labeled siRNA 
was visualized at λex of 494 nm and λem of 520 nm. 
 
   C 
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3.3.3 Silencing RhoC expression in SUM149 and MDA-MB-231 cells 
We investigated the ability of “smart” particles prepared at an N/P ratio of 2.5/1 to 
functionally deliver anti-RhoC siRNA molecules into the cytoplasm of SUM149 and MDA-MB-
231 cells by evaluating their ability to selectively knockdown RhoC gene expression at both the 
mRNA and protein levels compared to scrambled siRNA particles. Results show that our “smart” 
anti-RhoC siRNA particles (+) knockdown RhoC mRNA expression by 87 ± 1.1% in SUM149 
cells compared to scrambled siRNA particles (-) (p≤0.001) (Figure 3.5 A). Similarly, “smart” anti-
RhoC particles (+) knockdown RhoC mRNA level by 70 ± 11.4% in MDA-MB-231 cells 
compared to their scrambled counterparts (-) (p≤0.01) (Figure 3.5 A). 
Anti-RhoC particles (+) prepared using siPORT-Amine transfection agent reduced RhoC 
mRNA level by 86 ± 1.9% (p≤0.001) and 80% ± 11.7% (p≤0.05) compared to scrambled siRNA 
particles (-) in SUM149 and MDA-MB-231 cell lines, respectively. “Smart” particles 
encapsulating the scrambled siRNA sequence (-) caused no statistical difference in RhoC mRNA 
levels compared to that observed in untreated SUM149 and MDA-MB-231 cells, which indicates 
the biocompatibility of the β-CD-g-P(HMA79-co-DMAEMA33-co-TMAEMA48)4.8 carrier (Figure 
3.5 A). 
We quantified the change in RhoC protein expression in SUM149 and MDA-MB-231 
when transfected with “smart” anti-RhoC particles (+) prepared at N/P ratio of 2.5/1 and loaded 
with 100nM of the RNA cargo compared to particles loaded with the scrambled siRNA sequence 
(-). Results show 100% reduction in RhoC protein level in SUM149 cells treated with the anti-
RhoC (+) particles compared to those treated with scrambled one (-) (Figure 3.5 B). Similarly, 
“smart” anti-RhoC (+) particles reduced RhoC protein expression by 90% in MDA-MB-231 cells 
compared to particles loaded with the scrambled siRNA sequence (-) (Figure 3.5 C). In 
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comparison, anti-RhoC particles prepared using the commercial siPORT-Amine carrier reduced 
RhoC protein expression by only 34% and 28% in SUM149 and MDA-MB-231 cells, respectively. 
The limited effect of anti-RhoC siPORT-Amine particles on RhoC protein levels in SUM149 
(Figure 3.5 B) and MDA-MB-231 cells (Figure 3.5 C) compared to their more pronounced effect 
on RhoC mRNA levels (Figure 3.5 A) can be attributed to several factors including slow and 
incomplete dissociation of the siRNA from the cationic carrier observed with PEI-based 
complexes40 and higher degradation of the released siRNA molecules41. These results clearly show 
the ability of the β-CD-g-P(HMA79-co-DMAEMA33-co-TMAEMA48)4.8 polymer to condense the 
desired dose (100nM) of anti-RhoC siRNA at a low N/P ratio forming “smart” particles that 
successfully delivered their cargo into the cytoplasm of SUM149 and MDA-MB-231 knocking 




Given that the protein sequences of RhoA and RhoC are approximately 90% homologous27, 
we investigated the change in RhoA mRNA and protein levels in SUM149 cells upon treatment 
with “smart” anti-RhoC particles. ANOVA tests show no statistical significance in RhoA mRNA 
(Figure 3.6 A) and protein (Figure 3.6 B) expression levels between SUM149 cells treated with 
 
Figure 3.5: Effect of siPORT amine-based complexes and “smart” particles prepared by complexing 
β-CD-g-P(HMA79-co-DMAEMA33-co-TMAEMA48)4.8 polymer with 1.14μg of anti-RhoC (+) or 
scrambled (-) siRNA at N/P ratio of 2.5/1 on (A) RhoC mRNA and protein levels in (B) SUM149 
and (C) MDA-MB-231 cells. Results are the average + the standard error of the mean of five 
replicates. Statistical difference between particles encapsulating anti-RhoC (+) and scrambled (-) 
siRNA sequence was evaluated using paired t test where * denotes p ≤ 0.05, ** denotes p ≤ 0.01 




“smart” anti-RhoC particles (+) and the scrambled control (-). These results show the specificity 
of “smart” anti-RhoC particles and confirm that the observed changes in cell invasion, migration, 
and motility are a direct result of RhoC knockdown. Further, this is an additional indication of the 
biocompatibility of the β-CD-g-P(HMA79-co-DMAEMA33-co-TMAEMA48)4.8 polymer. 
 
3.3.4 Effect of RhoC knockdown on cell invasion 
We evaluated the effect of RhoC knockdown using “smart” anti-RhoC particles (+) on the 
invasion of SUM149 and MDA-MB-231 cells through matrigel basement membrane using the 
Boyden chamber invasion assay (Figure 3.7 A). Results show statistically significant (p≤0.01) 
reduction in the invasion of SUM149 cells transfected with “smart” anti-RhoC particles loaded 
with 100nM of siRNA by 40 ± 0.4% compared to their scrambled controls (-) (Figure 3.7 B). 
Similarly, invasion of MDA-MB-231 cells transfected with “smart” anti-RhoC particles loaded 
with 100nM of siRNA is reduced by 47 ± 0.2% compared to scramble particles (-) (Figure 3.7 B). 
                                 A               B 
  
Figure 3.6: Effect of siPORT amine-based complexes and “smart” particles prepared by 
complexing the respective polymers with anti-RhoC siRNA (+) or scrambled siRNA (-) on (A) 
RhoA mRNA and (B) protein level in SUM149 cells after 48 h. Results are the average + the 
standard error of the mean of five replicates. Statistical difference between particles encapsulating 
anti-RhoC siRNA (+) and scrambled siRNA sequence (-) was evaluated using paired t test where * 
denotes p ≤ 0.05, ** denotes p ≤ 0.01 and, *** denotes p ≤ 0.005. 
 





Treatment of SUM149 and MDA-MB-231 cells with “smart” particles loaded with the scrambled 
siRNA sequence (-) did not cause a statistically significant change in cell invasion through the 
matrigel matrix compared to untreated cells (control group) (Figure 3.7 B). These results are in 
agreement with previous reports showing that double transfection of MDA-MB-231 cells with 







Figure 3.7 (A): SUM149 and MDA-MB-231 cells were plated on Matrigel invasion chambers 
and treated with “smart” particles prepared by complexing β-CD-g-P(HMA79-co-DMAEMA33-
co-TMAEMA48)4.8 polymer with 1.14μg of anti-RhoC siRNA (+) or scrambled siRNA (-). 





3.3.5 Effect of RhoC knockdown on cell motility 
We started by quantifying the effect of RhoC knockdown on the phagokinetic motility of 
SUM149 and MDA-MB-231 cells using Cellomics Random Motility Assay Kit where we 
measured the area of the phagokinetic tracks of each migrating cell using ImageJ software (NIH, 
Bethesda, MD).  
 
 
Figure 3.7 (B): The 1% crystal violet used to stain the invaded SUM149 and MDA-MB-231 
cells on the lower membrane was dissolved in 10% acetic acid and its absorbance was measured 
at 560 nm. Absorbance of cells treated with “smart” anti-RhoC (+) and the scrambled (-) 
particles was normalized to that of untreated cells (control group). Plotted results are the average 
+ the standard error of the mean of five replicates. Statistical difference between “smart” anti-
RhoC (+) and scrambled (-) particles was evaluated using paired t test where * denotes p ≤ 0.05, 




We normalized the area of the phagokinetic tracks of cells treated with “smart” anti-RhoC 
particles (+) and those loaded with the scrambled siRNA sequence (-) to the area of the 
phagokinetic tracks of untreated cells (control group) to calculate the % reduction in cell motility. 
Results show 60 ± 8.7% inhibition in the migration of SUM149 cells treated with “smart” anti-
RhoC particles (+) compared to those treated with the scramble particles (-) (Figure 3.8). 
Similarly, migration of MDA-MB-231 cells treated with “smart” anti-RhoC particles (+) was 
reduced by 57 ± 1.1% compared to the cells treated with the negative scramble control (-) (Figure 
3.8). These results show a statistically significant (p≤0.001) reduction in the migration of SUM149 
and MDA-MB-231 cells treated with “smart” anti-RhoC particles compared to the cells transfected 
with the scrambled siRNA sequence (-). In addition, there was no change in the migration of 
SUM149 and MDA-MB-231 cells transfected with the scrambled siRNA sequence (-) compared 
to untreated cells (control group) indicating the lack of non-specific effect of the polymeric carrier 
on cell survival or migration (Figure 3.8). 
We also used the wound-healing assay to investigate the change in cell migration in 
response to different treatments following established protocols42, 43. Images show that SUM149 
(Figure 3. 9 A) and MDA-MB-231 cells (Figure 3.9 B) treated with “smart” particles loaded with 
the scrambled siRNA sequence retained their migration capacity indicated by complete “healing” 
of the scratch after 36 h similar to untreated cells (control group). In comparison, SUM149 and 
MDA-MB-231 cells treated with “smart” anti-RhoC particles (+) exhibited reduced migration 
indicated by the incomplete healing of the scratched area. Using Green’s theorem to calculate the 
unoccupied area of the scratch after 36 h and normalizing it to the initially scratched surface (at t 
= 0 h), results show coverage of only 33 ± 5.4% of the scratched surface by SUM149 cells treated 
with “smart” anti-RhoC particles, which is statistically (p≤0.01) less than the 94.2 ± 4.4% wound 
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coverage observed for the cells transfected with the scrambled siRNA sequence (-) (Figure 3.9 
C). Similarly, MDA-MB-231 cells treated with “smart” anti-RhoC particles (+) occupied only 33.1 
± 20.4% of the wound area, which is statistically (p≤0.05) less than the 106.1 ± 24.4% wound 
coverage observed for the cells transfected with the scrambled siRNA sequence (-) (Figure 3.9 
C). These results clearly show that knockdown of RhoC expression inhibits the migration of 










Figure 3.8: Effect of “smart” anti-RhoC (+) and the scrambled (-) particles on the 
phagokinetic motility of SUM149 and MDA-MB-231 cells. The phagokinetic cell 
tracks were quantified using ImageJ software and the average track area per cell 
transfected with “smart” anti-RhoC (+) and the scrambled (-) particles were 
normalized to that of untreated cells. Statistical difference between “smart” anti-
RhoC (+) and scrambled (-) particles was evaluated using paired t test where * 








Figure 3.9: Representative images (10X magnification) showing the effect of “smart” anti-RhoC 







Figure 3.9 (C): The percentage of wound coverage by SUM149 and MDA-MB-231 cells 36 hours 
after treatment with “smart” anti-RhoC (+) and scrambled (-) particles normalized to the initial 
wound (t = 0 h). Plotted results are the average + the standard error of the mean of three replicates. 
Statistical difference between “smart” anti-RhoC (+) and scrambled (-) particles was evaluated 
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Presentation of EPPT1 Peptide for Binding of Underglycosylated MUC1 and 
Cytoplasmic Delivery of Anti-RhoC Silencing RNA by “Smart” Particles 




The American Cancer Society estimated that 231,840 women were diagnosed with 
invasive breast cancer in 2015 in the United States of America 1 and ~25% of these cases would 
succumb to their disease due to the progression and development of distant metastases in the bone, 
brain, liver, and lungs 1, 2. Metastasis of aggressive breast cancer cells require a well-orchestrated 
sequence of cellular events that include the disruption of cell-cell and cell-matrix adhesion, loss of 
cell polarity, acquisition of invasive and migratory phenotype(s), cell extravasation into the 
systemic and lymphatic circulations, and dissemination to secondary sites 3, 4, 5. The increase in 
cancer cell motility and invasion has been closely linked to the onset of cancer metastasis, poor 
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patient prognosis, and increased patient mortality 6; therefore, motivating the search for potential 
therapeutic targets to suppress the metastatic spread of aggressive cancer cells.  
RhoC protein belongs to the Ras superfamily of small guanosine triphosphatases 
(GTPases)7, which has been implicated in the progression of metastasis in several cancers 8. Unlike 
other Ras family proteins9, RhoC expression has been shown to progressively increase as primary 
tumors become aggressively metastatic10, 11. Overexpression of RhoC GTPases is observed in most 
metastatic breast cancers and 90% of inflammatory breast cancers (IBC)12. Down-regulation of 
RhoC expression using silencing RNA (siRNA) has greatly inhibited stress fiber formation and 
subsequently reduced the invasive spread of metastatic breast cancer cells in vitro 13 as well as  
significantly decreased the formation of metastatic lung foci in vivo 14. These results collectively 
indicate the potential of pursuing RhoC as a therapeutic target to suppress metastases of aggressive 
breast cancer cells. Therefore, we reported the use of degradable, pH-sensitive, membrane-
destabilizing polymers composed of a -cyclodextrin (-CD) core with amphiphilic polymers 
grafted from the secondary face via acid-labile hydrazone linkers to complex anti-RhoC siRNA 
into “smart” nanoparticles15. The “smart” nanoparticles proved effective in shuttling anti-RhoC 
siRNA cargo past the endosomal membrane and into the cytoplasm of MDA-MB-231 and 
SUM149 breast cancer cells resulting in the knockdown of RhoC expression at the mRNA and 
protein levels by 90% and 100%, respectively 15. The knockdown in RhoC expression; however, 
resulted in a 50% and 70% suppression of invasion and migration in both aggressive MDA-MB-
231 and SUM149 breast cancer cells, respectively 15. This partial reduction in invasive and 
migratory phenotypes, despite the complete knockdown of RhoC protein expression, suggests the 




Mucins belong to a family of large, heavily glycosylated transmembrane proteins, that 
constitute the protective mucous layer of epithelial surfaces and play an important role in signal 
transduction 16. Mucin-1 (MUC1), a membrane-tethered mucin, has been extensively studied due 
to its widespread implication in cancer progression through increased cell invasion, growth, and 
metastasis 17, 18. MUC1 comprises of a characteristic extracellular domain (ECD) with up to 120 
tandem peptide repeats (TR) and a short preserved cytoplasmic tail 19. In normal epithelial cells, 
the TR region of the ECD remains protected via extensively glycosylated oligosaccharide chains 
20. However, in greater than 90% of human breast carcinomas, the once heavily glycosylated and 
protected peptide backbone becomes exposed due to the underglycosylation of MUC1 (uMUC1) 
with fewer and shorter glycans 21 (Figure 4.1). Furthermore, underglycosylation of the peptide 
core has been linked with poor prognosis and an increased risk for breast cancer metastasis 22. 
Earlier studies using uMUC1 knockout mice showed a delay in tumor growth and a reduction in 
the number of metastatic foci formed compared to transgenic mice overexpressing uMUC1 
antigens 23; therefore, linking uMUC1 overexpression to the development of invasive breast 
cancer. Prior work showed that uMUC1 receptors recruit β-catenin to the cytoplasmic domain 
upon binding to galectin-3 (a galactoside-binding protein) 24. This interaction disrupts β-catenin-
mediated adheren junction formation that results in the loss of cell-cell adhesion and enables cancer 
cell invasion of the surrounding tissue 24, 25. Furthermore, uMUC1 has the ability to firmly adhere 
to ICAM-1 present on the vascular endothelium that results in the downstream activation of non-
receptor kinase Src 26. Src activation has been implicated in the promotion of metastasis of cancer 
cells through downstream interaction with focal adhesion kinase (FAK) and the subsequent 
activation of the CrkL signaling pathways 27. CrkL, a known activator of Rho GTPases like Cdc42 
and Rac1, plays a key part in actin cytoskeletal reorganization and migration; thereby, making 
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uMUC1 receptors a potential molecular target to further suppress cancer cell invasion and 
migration27. 
Moreover, the exposed ECD peptides of uMUC1 antigens have been previously exploited 
for the development of targeted immunotherapeutic vaccines such as anti-mucin-1 antibodies as 
well as for targeted tumor imaging28–30. To date, while most anti-MUC1 monoclonal antibodies 
(mAbs) successfully target the exposed TR domains – their long plasma half-life and poor 
pharmacokinetic properties often elicits detrimental immunogenic responses – halting their clinical 
development31 ,32. To address the limitations of mAbs, researchers developed a shorter synthetic 
peptide sequence namely EPPT1 (YCAREPPTRTFAYWG) derived from the third heavy-chain 
complementarity-determining region (CDR-3VH) of the antitumor ASM2 mAb
33. The EPPT1 
peptide selectively binds uMUC1 receptors with a high binding affinity (Kd = 20 μM)
30, 34, 35. This 
prompted its use as a targeting ligand to achieve selective homing of super magnetic iron oxide 
nanoparticles to uMUC1-expressing breast cancer cells in vivo 35. Further, the EPPT1 peptide 
allowed selective binding and uptake of cationic polyacrylamide nanoparticles into uMUC1 
expressing malignant colorectal cancer cells34. We, therefore predict that the binding of EPPT1–
targeted nanoparticles to uMUC1 receptors could potentially exhibit dual functionality of 
uMUC1–specific targeting for selective intracellular delivery of therapeutic targets via receptor-
mediated internalization as well as prevent downstream signal transduction and the subsequent 
inactivation of molecular targets involved in cell invasion and migration pathways. 
In this study, we expand on our previous work by asymmetrically functionalizing the -
CD core to display a “brush” of hydrophilic polyethylene glycol (PEG) chains on the primary face 
and amphiphilic cationic/hydrophobic grafts on the secondary face, which complex the siRNA 
cargo forming “smart” pH-sensitive nanoparticles. The free tips of the PEG chains are 
91 
 
functionalized to display the EPPT1 targeting ligands to achieve selective recognition and 
internalization of the nanoparticles by uMUC1 receptors present on the surface of aggressive breast 
cancer cells (Figure 4.1). We investigate the effects of nanoparticle PEGylation by evaluating 
their ability to complex siRNA molecules as well as their interaction with red blood cells (RBCs) 
and serum proteins (e.g., FBS). We then evaluate the ability of EPPT1-targeted nanoparticles to 
achieve functional delivery of anti-RhoC siRNA into both MDA-MB-231 and SUM149 cancer 
cells compared to their non-targeted counterparts based on the associated suppression of RhoC 
protein expression. Finally, we explore if combining EPPT1 peptides and anti-RhoC siRNA 
molecules on the same nanoparticle can elicit a synergistic reduction in cell invasion and 
migration. We evaluate the synergistic effect by quantifying the suppression of cell invasion and 
migration achieved by: i) the cytoplasmic delivery of anti-RhoC siRNA, ii) the presentation of 
EPPT1 targeting ligands, and iii) the combination of cytoplasmic delivery of anti-RhoC siRNA 





Figure 4.1: The illustration represents the hypothesized mode of action of (EPPT1)6 – (5kDa-PEG)6.5 – β – 
CD – P(HMA-co-DMAEMA-co-TMAEMA)5.9 polymers complexing therapeutic anti-RhoC siRNA in 
aggressive breast cancer cells. We propose that the preferential binding of EPPT1 peptides to the EC 
domain of uMUC1 receptors expressed on the surface of inflammatory breast cancer cells would result in 
selective receptor-mediated endocytosis of our targeted “smart” nanoparticles. Once inside the endosome, 
the acidic microenvironment will facilitate hydrolysis of the acid-labile hydrazone linkers to release the 
P(HMA-co-DMAEMA-co-TMAEMA) grafts. The hydrophobic (HMA) and pH-sensitive (DMAEMA) 
monomers of the P(HMA-co-DMAEMA-co-TMAEMA) graft will further trigger the rupture of the 
endosomal membrane and release the loaded anti-RhoC siRNA cargo into the cytoplasm 
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4.2 Materials and methods 
 
4.2.1. Materials 
Poly (ethylene glycol) methyl ether with Mn 2 kDa and 5 KDa (Sigma-Aldrich, St. Louis, 
MO, US), α-NHS-ω-Alkyne PEG with Mn 5000 Da (Rapp polymere, Tübingen, Germany) were 
purchased and used as delivered. Iodine (I2), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
HCl (EDC.HCl), hydroxybenzotriazole (HOBt), 4-pentynoic acid, 4-dimethylaminopyridine 
(DMAP), anisole anhydrous, iodomethane, p-toluenesulfonyl hydrazide, propargyl alcohol, oxalyl 
chloride were procured from Sigma-Aldrich (St. Louis, MO, US, > 98% purity). 2-
bromoisobutyryl bromide (Fluka, >97%), triphenylphosphine (P(Ph)3, Acros chemicals, NJ, US), 
sodium azide (NaN3, Acros chemicals, NJ, US), N, N-diisopropylethylamine (DIPEA, Alfa Aesar, 
Haverhill, MA, US), N, N'-dicyclohexylcarbodiimide (DCC, TCI chemicals, Portland, OR, US), 
8-bromo-1-octanol (Alfa Aesar, Haverhill, MA, US, 95%). EPPT1-NH2 
(YCAREPPTRTFAYWG, proteomics & peptide synthesis core facility, University of Michigan, 
Ann Arbor, MI, US) was used as received. All chemicals used for the secondary face modification 
of the -CD core were obtained as previously reported36. All solvents were procured from Sigma 
Aldrich (St. Louis, MO, US, > 97% purity). All reagents involved in the sub-culturing of both 
SUM149 and MDA-MB-231 breast cancer cells were obtained and cultured as previously 
described 15. DMEM/F12 medium, horse serum, epidermal growth factor (EGF), hydrocortisone, 
cholera toxin, and insulin were obtained from Invitrogen (Carlsbad, CA, US). All experimental 
reagents used to characterize and validate the efficacy of our -CD nanoparticles were procured 
as previously outlined15. All anti-rabbit mAb were purchased from Cell Signaling Technologies 
(Danvers, MA, US). The anti-β-actin rabbit antibody and goat anti-rabbit IgG-HRP antibodies 
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were procured from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, US). The Pico Green assay 
was purchased from Molecular probes (Eugene, OR, US).  
 
4.2.2. Synthesis of asymmetric, PEGylated, and EPPT1-targeted pH-sensitive β-CD 
carriers 
We previously reported selective grafting of the amphiphilic P(HMA79-co-DMAEMA33-
co-TMAEMA48)4.8 polymers from the hydroxyl (OH) groups of the secondary face of the β-CD 
core via acid-labile hydrazine linkages forming (OH)7-β-CD-g-P(HMA79-co-DMAEMA33-co-
TMAEMA48)4.8 as the first star-shaped pH-sensitive carrier
36. We report grafting of P(HMA-co-
DMAEMA) polymers onto the secondary face of the β-CD core via “click” coupling while 
maintaining the hydrazine linkages and the associated sensitivity to acidic pH values (Figure 4.2). 
We capitalized on the difference in reactivity between the primary and secondary OH groups to 
covalently attach 2 kDa or 5 kDa PEG chains to the primary face of the β-CD core to prepare (2 
kDa-PEG)7-β-CD-P(HMA-co-DMAEMA-co-TMAEMA)6.1 and (5 kDa-PEG)7-β-CD-P(HMA-
co-DMAEMA-co-TMAEMA)6.4 carriers, respectively (Figure 4.3). The free ends of the 5 kDa 
PEG brushes were further modified to present the EPPT1 peptides forming the (EPPT1)6-(5 kDa-
PEG)6.5-β-CD-P(HMA-co-DMAEMA-co-TMAEMA)5.9 carriers (Figure 4.4). The following 
sections summarize the details of the synthesis process. 
 
4.2.2.1. Synthesis of (OH)7 - β-CD-P(HMA-co-DMAEMA-co-TMAEMA)4.8 polymers  
Synthesis of amphiphilic β-CD-based carriers started with protecting the primary OH 
groups of the β-CD core (1) by reacting it with tert-butyldimethylsilyl chloride (TBDMSCl) in 
pyridine to obtain (TBDMS)7-β-CD (2) (Figure 4.2). Protecting the highly reactive primary OH 
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groups was imperative to facilitate the selective modification of secondary OH groups in 
subsequent reactions. Compound 2 was then reacted with phenyl bromoacetate in the presence of 
NaH in DMF to obtain (TBDMS)7-β-CD-(phenylacetate)8.4 (3). The acid-labile hydrazone linkers 
were introduced by reacting compound 3 with (E)-N'-(8-azidooctylidene)-4-methyl-
benzenesulfonohydrazide (compound A) in the presence of NaH in DMF to obtain (TBDMS)7-β-
CD-O-(E)-N'-[(8-azidooctylidene) acetohydrazide]8.4 (4). Synthesis of compound A is described 
in the supplementary data (Scheme S5). The alkyne-P(HMA-co-DMAEMA) copolymers (B) were 
synthesized using atom transfer radical polymerization (ATRP) techniques following published 
protocols 36. Compound 4 and alkyne-P(HMA-co-DMAEMA) copolymers (B) were reacted 
together in the presence of Cu(I)Br and PMDETA in DMF to obtain (TBDMS)7-β-CD-P(HMA-
co-DMAEMA)5 polymers (5). The primary OH groups were deprotected by treating compound 5 
with TBAF in THF to yield (OH)7-β-CD-P(HMA-co-DMAEMA)4.8 (6) before quaternizing 50% 











4.2.2.2. Synthesis of (PEG)7-β-CD-P(HMA-co-DMAEMA-co-TMAEMA)n polymer 
We capitalized on the high reactivity of primary OH groups to transform them into iodo 
groups by reacting the β-CD core (1) with I2 and P(Ph)3 to obtain (6-Iodo)7-β–CD (8) (Figure 4.3). 
Compound 8 was reacted with NaN3 in DMF at high temperature to obtain (6-Azido)7-β-CD (9), 
which will allow “click” coupling with PEG-alkyne. Subsequently, we focused on modifying the 
secondary OH groups of compound 9 by reacting with phenyl bromoacetate to obtain (6-Azido)7-
β-CD-(phenylacetate)8.3 (10). To prepare non-targeted carriers, we “clicked” alkyne-PEG-OMe (2 
kDa or 5 kDa; C or D) polymers to the primary face of compound 10 in presence of CuBr and 
PMDETA in DMF to obtain (2 kDa-PEG)7-β-CD-(Phenylacetate)8.3 (11) or (5 kDa-PEG)7-β-CD-
(Phenylacetate)8.3 (12), respectively. Following PEGylation of the primary face, compounds 11 
and 12 were reacted with (E)-N'-(8-azidooctylidene)-4-methylbenzenesulfonohydrazide (A) to 
produce compound 13 and 14, respectively. The alkyne-P(HMA-co-DMAEMA) copolymers were 
grafted to the secondary face of compounds 13 and 14 via “click” coupling in the presence of 
Cu(I)Br and PMDETA in DMF to obtain (2 kDa-PEG)7-β-CD-P(HMA-co-DMAEMA)6.1 (15) and 
(5 kDa-PEG)7-β-CD-P(HMA-co-DMAEMA)6.4 (16), respectively. Approximately 50% of 
DMAEMA monomers in polymers 15 and 16 were quaternized to obtain (2 kDa-PEG)7-β-CD-
P(HMA-co-DMAEMA-co-TMAEMA)6.1 (17) and (5 kDa-PEG)7-β-CD-P(HMA-co-DMAEMA-




Figure 4.3: Chemical illustration representing the synthesis of (PEG)7–β–CD–P(HMA-co-
DMAEMA-co-TMAEMA)n polymers of varying PEG lengths (i.e., 2 kDa, and 5 kDa), respectively 
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4.2.2.3.Synthesis of (EPPT1)6-(5kDa-PEG)6.5-β-CD-P(HMA-co-DMAEMA-co-TMAEMA)5.9 
polymer 
We followed the synthesis scheme outlined in Figure 4.3 to obtain (6-Azido)7-β-CD-
(phenylacetate)8.3 (10). Subsequently, compound 10 was reacted with alkyne-PEG-NHS (MW 5 
kDa, E) in the presence of Cu(I)Br and PMDETA in DMF to obtain (NHS-PEG)6.5-β-CD-
(Phenylacetate)8.3 (19) (Figure 4.4). The phenyl bromoacetate of compound 19 was reacted with 
(E)-N'-(8-azidooctylidene)-4-methyl-benzenesulfonohydrazide (A) in presence of NaH in DMF to 
obtain (NHS-PEG)6.5-β-CD-[(E)-N`-(8-azodooctylidene)-acetohydrazide]7.2 (20). Compound 20 
was then reacted with EPPT1-NH2 in the presence of EDC, HOBt, DIPEA in DMF to obtain 
(EPPT1)6-(PEG)6.5-β-CD-[(E)-N`-(8-azodooctylidene) acetohydrazide]7.2 (21). Finally, 
compound 21 was “clicked” to alkyne-P(HMA-co-DMAEMA-co-TMAEMA) (F) in presence of 
Cu(I)Br and PMDETA in DMF at 40oC to obtain the final product (EPPT1)6-(PEG)6.5-β-CD-
P(HMA-co-DMAEMA-co-TMAEMA)5.9 (22). It is important to note that the identity, purity, and 
exact composition of all the synthesized compounds, reagents, intermediates, and polymers were 




4.2.3.  Formulation and characterization of “smart” anti-RhoC particles 
Stock polymer solution was prepared by dissolving 1 mg of the lyophilized (OH)7-β-CD-
P(HMA-co-DMAEMA-co-TMAEMA)4.8 polymer in 5% DMSO in PBS (pH 7.4) whereas 




PEGylated β-CD carriers were dissolved in 0.2% DMSO in PBS (pH 7.4). We evaluated the ability 
of all polymer compositions to complex FAM-labeled scrambled siRNA molecules (0.75 g) after 
simple mixing and allowing the solution mixture to stand at room temperature for 20 min before 
loading onto a 1% w/v agarose gel containing 0.5 g/ml ethidium bromide (EtBr) dye. The ability 
of PEGylated and non-PEGylated -CD polymers to complex siRNA molecules was investigated 
at different nitrogen/phosphate (N/P, +/-) ratios of 1.5/1, 2.5/1 and 4/1. Free FAM-labeled siRNA 
(0.75 g) and free polymer solutions were loaded onto the agarose gel as positive and negative 
controls, respectively. The gels were immersed in Tris-Acetate-EDTA (TAE) buffer and exposed 
to 60V for 60 min before visualizing the gels under UV light. We used ImageJ software (NIH, 
Bethesda, MD) to quantify the amount of free siRNA observed with different polymers at different 
N/P ratios and normalized the observed fluorescence to that of the free siRNA loaded on the gel 
as a positive control to determine the optimum N/P ratio for full complexation of the loaded siRNA 
cargo. We prepared four anti-RhoC particles by complexing 1.42 g (2 l of a 50 M stock 
solution) of anti-GAPDH siRNA with (OH)7-β-CD-P(HMA-co-DMAEMA-co-TMAEMA)4.8, (2 
kDa-PEG)7-β-CD-P(HMA-co-DMAEMA-co-TMAEMA)6.1, (5 kDa-PEG)7-β-CD-P(HMA-co-
DMAEMA-co-TMAEMA)6.4, and (EPPT1)6-(5 kDa-PEG)6.5-β-CD-P(HMA-co-DMAEMA-co-
TMAEMA)5.9 polymers as a function of varying N/P ratios of 1.5/1, 2.5/1, and 4/1 to obtain P0, 
P1, P2, and P3, respectively. We measured the size and zeta potential of P0-P3 particles prepared 
at different N/P (+/-) ratios using 90Plus particle size analyzer with ZetaPALS capability 
(Brookhaven Instruments Corporation, Holtsville, NY). 
 
4.2.4.  Assessment of hemolytic activity 
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We assessed the effect of PEGylation as well as the length of PEG chains (2 kDa vs. 5 
kDa) on the hemo-compatibility of P1 and P2 compared to non-PEGylated P0 as a function of 
polymer concentration following established protocols 36. Briefly, whole human blood was 
collected from volunteers following an approved IRB protocol in accordance with the University 
of Michigan and NIH guidelines. The collected blood was centrifuged at 13,500  g for 5 min to 
separate the red blood cells (RBCs) fraction, which was washed three times with 0.15 M saline 
solution before diluting it 10-fold (1:10 v/v) with 0.1 M phosphate buffer solution (PBS) at pH 7.4 
to obtain a final RBC concentration of 108 RBC’s per 200 μl solution. Stock solutions of P0, P1, 
and P2 “smart” anti-RhoC particles were prepared in PBS (pH 7.4) as previously described. The 
appropriate volume of each stock solution was mixed with 800 μl of PBS (pH 7.4) and 200 μl of 
diluted RBC’s to reach the desired polymer concentration (i.e., 0.5, 1, 1.5, 2, 2.5, 5 μg/ml) followed 
by gentle mixing and incubating the solution at 37C for 60 min. RBC’s were mixed with PBS 
(pH 7.4) and water as negative and positive controls, respectively. At the end of the incubation 
period, the RBC solutions were centrifuged at 13,500  g for 5 min to pellet the intact RBC’s 
followed by measuring hemoglobin absorbance in the supernatant at its characteristic wavelength 
( = 541 nm). We measured % hemolysis of RBC’s in response to different concentrations of P0-
P2 using the following equation. 
% Hemolysis = 
Sample Absorbance−Absorbance of RBC′s incubated with PBS
Average Absorbance of RBC′sincubated with distilled water
 
 
4.2.5. Nanoparticles stability in serum  
We investigated the ability of P0-P3 anti-RhoC particles to retain their siRNA cargo upon 
incubating with different concentrations of FBS to determine the ability of PEG to shield the 
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siRNA cargo. Briefly, P0-P3 nanoparticles were prepared by mixing the appropriate -CD 
polymer with 1.42 g (2 l of a 50 M stock solution) of anti-GAPDH siRNA in PBS (pH 7.4) at 
N/P ratio of 2.5/1. Particle solutions were mixed with different volumes of FBS to adjust FBS 
content to 0%, 10% or 25% (v/v) before incubating at 37C for 6 h. We added the Pico Green dye 
to different particle solutions to allow complexation of released siRNA molecules, which would 
result in a detectable increase in solution fluorescence (ex
 
= 485 nm & em
 
= 518 nm) measured 
using a Fluoroskan microplate reader (Thermo Fisher Scientific Inc., Waltham, MA). We 
normalized the fluorescence signal of each solution to that observed upon mixing the Pico Green 
dye with 1.42 g anti-GAPDH siRNA incubated with FBS (0%, 10%, 25% v/v) under the same 
conditions to determine the fraction of siRNA cargo released from each particle upon incubation 
with serum. 
 
4.2.6. Cell culture 
SUM149, MDA-MB-231, and MCF10A breast cancer cells were generously provided by 
Dr. Sofia D. Merajver (University of Michigan, School of Medicine). While SUM149 and MDA-
MB-231 cells were cultured following established protocols as previously described15. MCF10A 
cells were cultured in DMEM/F12 medium supplemented with 5% horse serum, EGF (20 ng/ml), 
hydrocortisone (0.5 mg/ml), cholera toxin (100 ng/ml), and insulin (10 μg/ml). MCF10A cells 
were incubated at 37C and 5% CO2.  
 




We investigated the ability of EPPT1-targeted (P3) and non-targeted (P2) particles to 
discriminate between SUM149, MDA-MB-231, and MCF10A cells expressing varying levels of 
underglycosylated MUC1 (uMUC1) surface receptors based on particle’s uptake into each cell 
line. Briefly, cells were seeded at a density of 50,000 cells per well in 24-well plates and allowed 
to adhere for 16 h at 37C before incubating with different concentrations of P2 and P3 particles 
loaded with FAM-labeled scrambled siRNA prepared at a N/P ratio of 2.5/1 as previously 
described. After 6 h of incubation, the cells were washed with PBS, treated with 0.05% 
Trypsin/EDTA for 5 min, harvested, pelleted, and re-suspended in the appropriate culture medium 
before being analyzed using Biosciences FACSCalibur Flow Cytometer (Becton Dickinson, 
Franklin Lakes, NJ) to determine the % of fluorescently-labeled cells. All cells were gated by 
forward/side scatter and 10,000 gated events were collected per sample to discriminate between 
live and dead cells to account only for live cells. 
 
4.2.8. “Smart” particles effect on RhoC expression 
We investigated the ability of EPPT1-targeted (P3) and non-targeted (P2) particles to 
achieve functional delivery of the anti-RhoC siRNA cargo into the cytoplasm of SUM149 and 
MDA-MB-231 breast cancer cells by quantifying the changes in expression of RhoC protein 
following published protocols 15. Briefly, SUM149 and MDA-MB-231 cells were seeded at a 
density of 2.5 × 105 cells per well in 6-well plates and allowed to adhere for 18 h. “Smart” P2 and 
P3 particles loaded with anti-RhoC (+) or scrambled siRNA (-) molecules were prepared in OPTI-
MEM solution at a N/P ratio of 2.5/1. P2 and P3 particles were incubated with SUM149 and MDA-
MB-231 cells at a final siRNA concentration of 25 or 50 nM for 6 h before adding fresh culture 
medium (1 ml) and incubating for a total of 48 or 72 h. We investigated the effect of double 
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transfection (i.e. incubating the cells with a given treatment at t = 0 and 24 h) on RhoC expression 
as a function of siRNA concentration (25 and 50 nM) while keeping total incubation time at 48 h 
or 72 h. 
At the end of the transfection cycle, we washed the cells twice with cold PBS, incubated 
them with RIPA lysis buffer for 5 min on ice, and centrifuged the solution at 14,000 rpm for 15 
min to isolate the supernatant containing the protein fraction. We measured the total protein 
concentration in isolated cell lysates using the BCA kit (Pierce Biotechnology, Rockford, IL) 
following manufacturer’s protocol. Equal amount of protein (10 μg/ml) isolated from different 
treatments were resolved on 12.5% Criterion Tris-HCl gels (Bio-Rad, Hercules, CA) and 
transferred onto a polyvinylidene fluoride (PVDF) membrane using a semidry apparatus (Bio-Rad, 
Hercules, CA). Membranes were blocked with 5% milk solution for 1 h and probed overnight at 
4°C with either anti-β-actin rabbit antibody (Santa Cruz, CA) and primary anti-RhoC rabbit mAb 
(Cell Signaling Technologies, MA) at a 1:1000 dilution. Bound primary antibodies were visualized 
using enhanced chemiluminescence (Pierce, Rockford, IL) after incubating with secondary 
horseradish peroxidase-coupled anti-rabbit antibody (Santa Cruz, CA) at a 1:5000 dilution for 1 h 
at room temperature. The knockdown of RhoC proteins in response to different particles and 
treatment conditions was quantified using the ImageJ image analysis software (NIH, Bethesda, 
MD) and normalized to the endogenous β-actin control and untreated SUM149 and MDA-MB-
231 cells. 
 
4.2.9. Boyden chamber invasion assay  
We evaluated the ability of our EPPT1–targeted (P3) and non-targeted (P2) particles to 
suppress RhoC-associated cell invasion in aggressive breast cancer cells. BD matrigel invasion 
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assay chambers (BD Biosciences, Bedford, MA) were used to quantify cell invasion in both 
SUM149 and MDA-MB-231 cells as per manufacturer’s instructions. Briefly, SUM149 and 
MDA-MB-231 cell lines were plated in 6-well plates at a seeding density of 2.5 × 105 cells per 
well and allowed to adhere for 18 h, respectively. The adhered cells were then treated with “smart” 
P2 and P3 particles loaded with anti-RhoC (+) or scrambled siRNA (-) molecules at a final 
concentration of 25 or 50 nM for 6 h in serum-free OPTI-MEM, followed by the addition of 
respective growth media and incubated for a total of 72 h. At 24 h, the treated MDA-MB-231 cells 
were subjected to dual particle transfection for a total incubation period of 72 h. After 72 h, both 
cell lines were washed with PBS, trypsinized using 0.05% Trypin/EDTA, and centrifuged to 
collect the cell pellets before suspending them in serum-free culture medium at a density of 50,000 
cells per ml. The cells were added to the upper chamber and allowed to invade the matrigel 
membrane for 20 h at 37C in a CO2 incubator. The lower chamber contained growth media with 
varying serum concentrations (i.e., 5 or 10% v/v). Non migrating cells were removed from the 
upper chamber with a cotton swab. The remaining cells on the lower surface of each insert were 
fixed, stained with staining buffer (1% (w/v) crystal violent in 20% (v/v) methanol) for 1 h at room 
temperature, and measured at 595 nm after extraction with 10% acetic acid for 10 min. Results 
were normalized to the untreated SUM149 and MDA-MB-231 cells and reported as the average 
of three independent experiments + SEM.  
 
4.2.10. Scratch assay 
We evaluated the effect of “smart” P2 and P3 anti-RhoC siRNA (+) particles prepared at a 
N/P ratio of 2.5/1 on the migratory activity of SUM149 and MDA-MB-231 cells compared to their 
scrambled siRNA (-) counterpart using scratch assay. SUM149 and MDA-MB-231 cells were 
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plated in 24-well plates at a seeding density of 50,000 cells per well and allowed to grow under 
normal culture conditions to 95% confluence. The cell monolayer was scratched with a sterile 200 
µl pipette tip to create a “wound” across the center of each well. Each well was washed with PBS 
to remove the detached cells and the wound was imaged (t = 0 h) at a 10X magnification using a 
Nikon Eclipse Ti inverted microscope equipped with a camera to capture phase contrast images of 
the wound. Subsequently, the SUM149 and MDA-MB-231 cell monolayers were treated with 
“smart” P2 and P3 anti-RhoC siRNA (+) or scrambled siRNA (-) particles prepared at an N/P ratio 
of 2.5/1 following the same treatment conditions as described in the Boyden chamber invasion 
assay. After 72 h, the wounds were imaged using the same microscope setup. The acquired images 
were processed using ImageJ image analysis software to calculate the wound area at t = 0 h and 
72 h. The wound area after 72 h was normalized to the initial area (t = 0 h) to quantify the change 
in cell migration in response to different particle compositions. 
 
4.2.11. Coefficient of drug interaction 
The coefficient of drug interaction (CDI) was used to analyze the synergistic effect of 
EPPT1–targeting peptides and anti-RhoC siRNA on the suppression of cancer cell invasion and 
migration.
 
CDI was calculated as follows: CDI=AB/(A×B). AB is the ratio of the 2-treatment 
combination group (i.e., (+) P3) to the control group, and A or B is the ratio of the single treatment 
group (i.e., (-) P3 or (+) P2) to the control group. In the Boyden chamber invasion assay, the CDI 
values were calculated as a function of the number of cells invading the matrigel following 
different treatment conditions to the untreated controls of the respective cell lines. While in the 
scratch assay, the ratio was evaluated as a function of the unoccupied wound area after different 
treatment conditions to the untreated controls, respectively. Furthermore, CDI <1 indicates 
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synergism, CDI <0.7 indicates a significantly synergistic effect, CDI =1 indicates an additive 
effect, and CDI >1 indicates antagonism.  
 
4.2.12. Effect of targeted (EPPT1)6-(5 kDa-PEG)6.5-β-CD-P(HMA-co-DMAEMA-co-
TMAEMA)5.9 polymers on phosphorylated Src and FAK protein expression 
Activated P-Src (Y419) and P-FAK (Y576/577) protein expression levels in SUM149 cells 
upon treatment with different particle compositions were quantified using previously described 
western blot techniques. Briefly, SUM149 cells were plated in 6 well plates at a seeding density 
of 2.5 x 105 cells/well. The cells were allowed to adhere overnight and treated with either “smart” 
non-targeted P2 and EPPT1–targeted P3 particles complexing scrambled siRNA (-) at a N/P ratio 
of 2.5/1 at a final siRNA concentration of 50 nM for a total incubation time of 48 or 72 h, 
respectively. The treated cells were harvested and total protein lysates of respective treatments 
collected and quantified using BCA protein assay. Equal amounts of total protein extracts (60 
μg/μl) obtained from different particle treatments and incubation time points were resolved on 4-
15% Criterion Tris-HCl gel (Bio-Rad, Hercules, CA) and transferred onto polyvinylidene fluoride 
(PVDF) membranes using the iBlot apparatus (Thermo Scientific, Waltham, MA). Membranes 
were blocked with 5% milk solution for 1 h and probed overnight at 4°C with β-actin goat antibody 
(Santa Cruz, CA), Phospho-Src (Tyr419) rabbit mAb, Phospho-Fak (Tyr567/577) rabbit mAb, Src 
(Tyr419) rabbit mAb, and Fak (Tyr567/577) rabbit mAb (Cell Signaling Technologies, MA) at a 
1:1000 dilution. Bound primary antibodies were visualized using enhanced chemiluminescence 
(Pierce, Rockford, IL) after incubating with secondary horseradish peroxidase-coupled anti-rabbit 
antibody (Santa Cruz, CA) at a 1:5000 dilution for 1 h at room temperature. The activated P-Src 
(Y419) and P-FAK (Y576/577) protein levels in response to different particle formulations and 
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treatment conditions were quantified using ImageJ software (NIH, Bethesda, MD) and normalized 
to the endogenous β-actin control as well as their respective total Src and total Fak protein 
expression levels, respectively. Four replicates were used for each condition and particle 
formulation and the results show the average + the standard error of the mean (SEM). 
 
4.2.13. Statistical analysis 
Results are presented as the mean  standard error of the mean (SEM). Comparisons of 
various “smart” particle parameters in all experiments were analyzed using one-way ANOVA with 
Tukey’s post hoc analysis.  
 
4.3. Results and Discussion 
  
4.3.1. Synthesis of (OH)7 - β-CD-P(HMA-co-DMAEMA-co-TMAEMA)4.8 polymers 
The highly reactive primary OH groups of the -CD core were successfully protected with 
TBDMS groups (Figure 4.2, compound 2), followed by the successful modification of the 
secondary OH’s with phenylacetate groups (Figure 4.2, compound 3). The identity and purity of 
compound (2) and (3) were determined by 1H NMR spectra, respectively. The 1H NMR spectra 
showed successful capping of all 7 primary OH groups with TBDMS groups, while approximately 
8.4 units of secondary OH groups were modified with phenylacetate determined by quantifying 
the aromatic protons observed between 6.66 – 7.35ppm compared to sugar protons. The 
incomplete conversion of secondary OH groups can be attributed to the steric hindrance of the 
bulky phenylacetate groups. However, the incorporation of 8.4 phenylactetate units on the 
secondary face is in accordance with our previously reported scheme for the synthesis of 
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amphiphilic “smart” nanoparticles36. Compound 4 in Figure 4.2 showed a 100% conversion of 
secondary face aromatic groups into acid labile hydrozone aliphatic linkers. The identity and purity 
of compound 4 was verified by 1H NMR spectrum that confirmed the successful coupling of 8.4 
aliphatic chains on the secondary face based on the aliphatic protons observed between 0.90 – 
1.85ppm relative to sugar protons. We modified our previously reported synthesis strategy36 by 
using compound A (Figure 4.2) to form acid-labile hydrozone linkages at the secondary face due 
their ability to facilitate kinetically favorable forward reactions between their self-eliminating tosyl 
group and phenylacetate in the presence of a base. Moreover, the 8 carbon atom aliphatic chain 
terminating in an azide (N3) group of compound 8 allowed “click” coupling of bulky polymeric 
grafts (Figure 4.2, compound B) with minimum steric hindrance and maximum coupling 
efficiency. Compound B was synthesized using atom transfer radical polymerization reactions 
(ATRP) to control the molecular weight (25 kDa) and the molar feed ratio of HMA and DMAEMA 
(50/50) monomers per graft. The graft composition and purity was characterized using 1H NMR 
techniques. Using the 1H NMR spectra, the number of HMA/DMAEMA monomers present per 
graft was determined by quantifying the ratio of HMA protons (3.92ppm) relative to DMAEMA 
protons (2.26, 2.54, and 4.04ppm). Further, the “click” coupling reaction between the alkyne group 
of compound B and  the terminal N3 of compound 4 resulted in the successful grafting of 4.8 
copolymers from the secondary face as seen in compound 5 (Figure 4.2). The identity and purity 
of compound 5 was determined by 1H NMR spectra. The number of polymeric grafts attached to 
the secondary face was quantified by comparing the ratios between the sugar and 
HMA/DMAEMA protons. Prior to the partial conversion of DMAEMA monomers into cationic 
TMAEMA units, the primary OH groups were successfully deprotected (Figure 4.2, compound 
6) and characterized via 1H NMR techniques. Compound 7 (Figure 4.2) revealed that 54% of 
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DMAEMA monomers were converted into TMAEMA units and confirmed via 1H NMR. The final 
(OH)7 - β-CD-P(HMA-co-DMAEMA-co-TMAEMA)4.8 (P0) polymer (compound 7) exhibited 
approximately 4.8 polymer grafts coupled to the secondary face (comprising of 86 units of HMA, 
39 units of DMAEMA, and 47 units of TMAEMA per graft) with a molecular weight of 155597.6 
g/mol, and a yield of 580 mg. Every step involved in the synthesis of compound 7 was further 
characterized by 13C NMR and MADLI-TOF techniques. The presence of N3 groups was 
confirmed using FT-IR techniques. 
 
4.3.2. Synthesis of (PEG)7-β-CD-P(HMA-co-DMAEMA-co-TMAEMA)n polymer 
The highly reactive primary OH groups were successfully substituted with I2 groups 
(Figure 4.3, compound 8), followed by the nucleophilic substitution of all seven primary I2 with 
N3 groups (Figure 4.3, compound 9). The identity and purity of compounds 8 and 9 were 
determined using standard 1H NMR techniques. Furthermore, the successful nucleophilic 
substitution of the primary face with N3 groups was confirmed by the characteristic FT-IR peak 
observed at 2113.6 and MALDI-TOF that suggested a 100% conversion from I2 (MWcalc 1926.7 
g/mol) to N3 groups (MWcalc 1332.4 g/mol). The primary OH was modified prior to secondary face 
modifications due to their ease of accessibility as well as higher susceptibility to nucleophilic 
substitution reactions. Following primary face nucleophilic substitution reactions, the secondary 
face OH’s were modified and characterized to exhibit approximately 8.3 phenylacetate groups as 
described in the section 4.3.1. The primary N3 groups on compound 10 (Figure 4.3) were “click” 
coupled with either compound C or D to produce compound 11 and 12 (Figure 4.3), respectively. 
The identity and purity of compound 11 and 12 were determined using 1H NMR spectra, 
respectively. The 100% “click” coupling efficiency was quantified by calculating the number of 
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protons appearing between 2.70-3.80 ppm as well as validated via MALDI-TOF techniques. 
Following the primary face modification with either 2 or 5 kDa PEG molecules, the secondary 
face phenylacetate groups were successfully reacted with compound A to exhibit acid labile 
hydrazone linkers, namely compound 13 & 14, respectively. The 1H NMR spectra of compounds 
13 & 14 revealed the coupling of approximately 6.4 and 7 units of hydrazone linkers on the 
secondary face. The “click” coupling of compound B to the secondary face resulted in 
approximately 6.1 & 6.4 amphiphilic grafts per β-CD core of compounds 15 & 16 (Figure 4.2), 
respectively. The number of amphiphilic grafts were quantified using 1H NMR spectrum to 
compare the ratios between sugar and HMA/DMAEMA protons. The higher polymer graft 
coupling efficiency observed in compounds 15 & 16 compared to compound 5 can be attributed 
to improved solubility in DMF due to the presence of primary PEG brushes. Finally, 1H NMR was 
used to calculate the % of DMAEMA quaternization into TMAEMA monomers in compounds 17 
& 18 (Figure 4.3), respectively. The ratios between the number of methyl protons of DMAEMA 
monomers at 2.26 ppm and TMAEMA methyl protons at 3.16 ppm indicated 54% and 47% degree 
of quaternization in compounds 17 & 18, respectively. (2 kDa-PEG)7-β-CD-P(HMA-co-
DMAEMA-co-TMAEMA)6.1 (P1) polymers exhibited an amphiphilic graft polymer composition 
of 75 units of HMA, 34 units of DMAEMA, and 38 units of TMAEMA monomers with a 
molecular weight of 201387 g/mol and a yield of 32 mg. The (5 kDa-PEG)7-β-CD-P(HMA-co-
DMAEMA-co-TMAEMA)6.4 (P2) comprised of an amphiphilic graft composition of 77 units of 
HMA, 41 units of DMAEMA, and 36 units of TMAEMA with a molecular weight of 221539 
g/mol and a yield of 21 mg. All steps involved in the synthesis of compounds 17 & 18 was further 
characterized by 13C NMR and MADLI-TOF techniques. The presence of N3 groups were 




4.3.3. Synthesis of (EPPT1)6-(5 kDa-PEG)6.5-β-CD-P(HMA-co-DMAEMA-co-
TMAEMA)5.9 polymer 
The primary N3 groups of compound 10 (Figure 4.3) were “click” coupled to compound 
E (Figure 4.4) to obtain compound 19 (Figure 4.4). The successful coupling of all 7 primary N3 
groups with compound E was confirmed using 1H NMR by quantifying the number of CH2 protons 
on compound E relative to the number of sugar protons. The secondary face phenylacetate groups 
of compound 19 were modified and characterized as previously reported in section 4.3.1. 
Approximately 6.5 units of EPPT1 targeting peptide was successfully attached in situ to the NHS 
groups present on compound E to obtain compound 21. The EPPT1 peptide density per β-CD 
molecule (i.e., 6.5 units/β-CD) was chosen based on previously published work 37 that showed 
significant homing of nanoparticles that exhibited nearly 7.8 EPPT1-targeting peptides into 
uMUC1 expressing tumors. Unlike the above synthesis schemes (Figure 4.2 and 4.3), the 
amphiphilic polymer grafts (Figure 4.4, compound F) were partially quaternized prior to “click” 
coupling to the secondary face N3 groups of compound 21. 
1H NMR spectrum indicated the 
coupling of approximately 5.9 amphiphilic grafts per β-CD molecule. The reason for partially 
quaternizing the amphiphilic grafts prior to coupling was to prevent an undesired quaternization 
of amine groups present in the amino acid residues of EPPT1 peptides. The final (EPPT1)6-(5 kDa-
PEG)6.5-β-CD-P(HMA-co-DMAEMA-co-TMAEMA)5.9  polymer (P3) comprised of an 
amphiphilic graft composition of 76 units of HMA, 43 units of DMAEMA, and 34 units of 
TMAEMA with a molecular weight of 228416 g/mol and a yield of 118 mg (92% yield). All steps 





4.3.4. Formulation and characterization of “smart” anti-RhoC particles 
Polymer P0 was soluble in physiological media containing 5% DMSO, while the 
PEGylated polymer series (P1-3) showed improved solubility by dissolving in physiological media 
containing 0.2% DMSO. The incorporation of amphiphilic PEG molecules (either 2 or 5 kDa) on 
the primary face of the β-CD core further improved their solubility profile in physiological media 
at room temperature compared to their non-PEGylated counterparts. All polymers (P0-3) showed 
complete complexation of 0.75 g of FAM-labeled scrambled siRNA molecules at all N/P ratios 
(i.e., 1.5/1, 2.5/1, and 4/1) compared to free siRNA molecules as seen in Figure 4.5 A & B. 
Therefore, suggesting that both 2 or 5 kDa PEG molecules present on the non-targeted particles 
P1-2 and EPPT1-targeted particles P3 do not interfere with siRNA complexation. The 
incorporation of PEG molecules with increasing molecular weight resulted in a modest increase in 
size distribution for all “smart” particles (P1-3) prepared at N/P ratios of 1.5/1, 2.5/1, and 4/1 
(Figure 4.5 C). With the average “smart” particle size at the desired N/P ratio of 2.5/1 increasing 
from 104 ± 1.4 nm for P1 and 110 ± 5.6% for P2 to 191 ± 8.2% for P3. However, all nanoparticles 
were within the acceptable 200 nm tumor size cut-off range. All “smart” particle compositions 
(P1-3) exhibited a net positive zeta potential at all N/P ratios (+/-) (Figure 4.5 D). At the desired 
N/P ratio of 2.5/1, “smart” particle P1 exhibited a positive charge density of 32 ± 0.6%, while P2 
showed a lower charge of 19.4 ± 0.1% suggesting that the 5 kDa PEG molecules of P2 
demonstrated significantly better cationic shielding capability compared to P1’s 2 kDa PEG 
molecules. On the other hand, P3 particles had a charge of 28 ± 0.6% that could be attributed to 




4.3.5. Biocompatibility study of our “smart” particles 
The effect of PEG length on the systemic biocompatibility of our asymmetric -CD 
polymers were evaluated in vitro based on their stability in varying serum concentrations and their 
hemocompatibility profiles in RBC solutions under physiological conditions.  
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Figure 4.5:  Characterization of asymmetric “smart” nanoparticles. The degree of siRNA complexation 
achieved by our “smart” polymers as a function of different N/P (+/-) ratios (i.e., 1.5/1, 2.5/1, and 4/1) 
was determined using a 1% w/v agarose gel and quantified using ImageJ software (NIH, Bethesda) 
relative to free siRNA molecules. (A) Illustrates the ability of (OH)7–β–CD–P(HMA-co-DMAEMA-
co-TMAEMA)5 (P0), (2kDa-PEG)7–β–CD–P(HMA-co-DMAEMA-co-TMAEMA)6.1 (P1), (5KDa-
PEG)7––CD–P(HMA-co-DMAEMA-co-TMAEMA)5.9 (P2), and (EPPT1)6 - (5kDa-PEG)6.5–β–CD–
P(HMA-co-DMAEMA-co-TMAEMA)5.9 polymer (P3) (B) to complex siRNA molecules as a function 
of varying N/P (+/-) ratios. The size (C) and zeta potential (D) of particles P0-3 prepared by 
complexation of  “smart” polymers (P0-3) with 0.57 g of anti-GAPDH siRNA were determined as a 
function of different N/P (+/-) ratios of 1.5/1, 2.5/, and 4/1, respectively. The plotted results are the 
average + the standard error of the mean of two independent experiments each carried out in triplicates.  
 






































4.3.5.1. Hemolytic activity of “smart” particles 
The determination of hemolytic properties is one of the most common preclinical tests 
performed to understand nanoparticle interaction with blood components namely RBC’s. The -
CD polymers (P0-2) effect on RBC’s were determined by measuring the amount of hemoglobin 
pigment present in the supernatant using spectrophotometry ( = 541 nm) after 1 h and normalized 
to the positive water control. The % RBC hemolysis observed by -CD polymers (P0-2) was 
plotted in Figure 4.6 as a function of varying polymer and siRNA concentration. From the results, 
we observe that polymers P0 and P1 exhibit relatively high hemolysis profiles (20 – 50%) at low 
polymer concentrations of 0.5, 1, 1.5 g/ml compared to P2 (< 15%). We can, therefore infer that 
while the 2 kDa PEG molecules (P1) are not significantly better in preventing hemolysis compared 
to non-PEGylated P0 particles - the 5 kDa PEG brushes show statistically significant improvement 
in minimizing RBC disruption compared to P0 and P1. At polymer concentrations of 2 – 2.5 g/ml 
(i.e., polymer concentrations used in the subsequent study), P2 continued to show significantly 
low hemolysis profiles (i.e., < 20%), while both P0 and P1 showed a significantly higher degree 
of RBC hemolysis. We can thus conclude that 5 kDa PEG molecules present of polymer P2 
significantly improved the biocompatibility profile of our -CD polymers by reducing RBC 
hemolysis compared to their 2 kDa counterparts; therefore, were used to conjugate EPPT1 






4.3.5.2. Nanoparticles stability in serum 
The % of siRNA released from each particle composition (P0-3) was determined by 
normalizing the PicoGreen dye signal obtained from each particle condition to the free siRNA 
signal using a Fluoroskan microplate reader at ex
 
= 485 nm and em
 
= 518 nm. The results plotted 
 
Figure 4.6: The biocompatibility profile of our “smart” nanoparticles (P0-2) was determined by 
evaluating their effect on eliciting RBC membrane hemolysis at physiological pH as a function of 
varying polymer concentrations. The observed hemolytic activity for each polymer formulation was 
normalized to that of the positive control (DI water).  Results are the average + the standard error of 
the mean of three independent experiments each carried out in triplicates. Statistical difference 
between “smart” nanoparticle (P0-2) means at a given polymer concentration were evaluated using 
one-way ANOVA test with Tukey’s post hoc. Statistical difference between group population means 
was significant at the 0.05 level where * denotes p ≤ 0.05, ** denotes p ≤ 0.01, *** denotes p ≤ 
0.005, and **** denotes p ≤ 0.001 





































in Figure 4.7 represent the % of unshielded siRNA observed as a function of varying nanoparticle 
composition and serum concentrations. Results show that “smart” particles (P0 – 3) retained 90 – 
92% of the loaded siRNA cargo in serum-free medium after 6 h. The incubation of nanoparticles 
(P0 – 2) with 10 – 25% of FBS resulted in partial siRNA decomplexation with a modest reduction 
in the amount of shielded siRNA molecules to nearly 75% of the loaded sample. This siRNA 
decomplexation pattern was observed across -CD polymer compositions (P0-2) irrespective of 
their PEG lengths suggesting that neither 2 kDa nor 5 kDa PEG MW brushes significantly altered 
the serum stability of our nanoparticles. Thereby, suggesting that neither 2 kDa nor 5 kDa PEG 
brushes are sufficiently long enough to completely shield the cationic amphiphilic grafts 
complexing siRNA molecules on the secondary face. Moreover, prior studies have shown no 
considerable decrease in serum adsorption by PEG MW brushes > 5 kDa 38. Despite the partial 
release of 25% of the loaded siRNA molecules, these particles retained and shielded the bulk of 
the loaded siRNA dose at a low N/P ratio (i.e., 2.5/1) and over a relatively long incubation time (6 
h). On the other hand, particle P3 displayed a partially improved siRNA shielding capacity of 80 
– 90% at all serum concentrations (Figure 4.7). The serum stability of polymeric nanoparticles 
plays a critical role upon introduction into systemic circulation as the dilution effect often 




4.3.6. Nanoparticles uptake into breast cancer cells 
We evaluated if our EPPT1 targeted approach for the selective recognition of dysregulated 
uMUC1 target biomarkers showed significantly improved cellular internalization compared to our 
non-targeted -CD particles. We used three different cell lines exhibiting varying degrees of 
uMUC1 receptor expression, namely a normal mammary epithelial cell line MCF10A (devoid of 
 
Figure 4.7: Percentage of siRNA molecules shielded by “smart” polymers complexing anti-
GAPDH siRNA (i.e., P0, P1, P2, and P3) upon incubation with varying concentrations of FBS (i.e., 
10% and 25% v/v) for 6 h at 37C compared to “smart” nanoparticles incubated in serum-free 
medium (0% v/v). PicoGreen dye was used to determine the amount of unshielded siRNA molecules 
present in solution that were released from each particle formulation incubated in different FBS 
concentrations. The RFU values obtained for each particle formulation were normalized to RFU 
values obtained for the total encapsulated siRNA dose (0.75 g) to determine % of shielded siRNA 
in each particle under different conditions. All particles were prepared at N/P ratio of 2.5/1. The 
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uMUC1 receptors), a TNBC cell line MDA-MB-231 (basal uMUC1 expression, +), and IBC cell 
line SUM149 cells (high uMUC1 expression, +++). The % cell uptake was determined by 
measuring the relative fluorescence intensity of each cell line incubated for 6 h with either non-
targeted P2 or EPPT1-targeted P3 particles complexing FAM-labeled siRNA molecules (N/P of 
2.5/1) at varying siRNA concentrations using flow cytometry. In Figure 4.8, panel A, B, and C 
we observe that non-targeted particle P2 showed no significant labeling of all three cell lines at 
lower siRNA concentration (i.e., 5, 7.5, 10, 15 nM) compared to their respective untreated cells. 
While at higher siRNA concentration (50 nM), particle P2 showed a 64.8  1.7% uptake into 
MCF10A cells, and a significantly higher uptake of 89.5  0.2% and 95.7  0.8% into MDA-MB-
231 and SUM149 cells, respectively. These findings indicate that there is no selective 
internalization of particle P2 into the three cell lines at all siRNA concentrations suggesting that 
at lower siRNA concentrations (i.e., < 15 nM) the 5 kDa PEG molecules on the primary face hinder 
cell uptake, while at higher siRNA concentrations the higher uptake profiles can be contributed to 
absorptive endocytosis due to an increase in the number of polymeric amphiphilic grafts present 
in solution. On the other hand, EPPT1-labeled P3 particles showed a significantly higher uptake 
of 55.2  5.0% in SUM149 (Figure 4.8 C) cells compared to 1.8  0.2% and 7.5  1.7% in 
MCF10A (Figure 4.8 A) and MDA-MB-231 (Figure 4.8 B) cells, respectively at the lowest 
siRNA concentration of 5 nM. At 15 nM siRNA concentration, P3 particles showed maximum 
uptake of 92.4  0.5% in SUM149 cells and significantly higher uptake of 81.7  0.2% in MDA-
MB-231 cells compared to a 4.5  0.3% uptake in MCF10A cells. The results indicate that the 
significantly higher uptake (> 90%) of EPPT1-peptide coupled particles (P3) in uMUC1 
expressing SUM149 cells at siRNA concentrations  25nM compared to non-targeted particle P2 
that showed < 25% uptake is due to improved particle selectivity and receptor-mediated 
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endocytosis. The significant difference in P3 uptake profiles at a given concentration in the three 
cell lines can be attributed to varying uMUC1 receptor expression levels, thus further 
corroborating the ability of our EPPT1-coupled particles to distinguish between the normal and 
cancer epithelial cells and reduce particle-associated cytotoxicity. Furthermore, our P3 particles 
exhibit increased cell specificity and higher uMUC1 sensitivity at lower polymer concentrations 
















Figure 4.8: The plot represents the % of fluorescently-labeled (A) MCF10A, (B) MDA-MB-231, and (C) 
SUM149 cells after incubating for 6 h in a serum-free culture medium with “smart” nanoparticles (P2-3) 
prepared by complexing these “smart” polymers with 1.14 μg of FAM–labeled anti-GAPDH siRNA at N/P 
ratio of 2.5/1 as a function of different siRNA molecule concentrations (i.e., 5, 7.5, 10, 25, 50 nM). Cells 
treated with free siRNA were used as a negative control. Statistical difference between the nanoparticles’ 
means were evaluated using one-way ANOVA test with Tukey’s post hoc. Statistical difference between 
group population means was significant at the 0.05 level where * denotes p ≤ 0.05, ** denotes p ≤ 0.01, 
and *** denotes p ≤ 0.005. 
 
































































4.3.7. Effect of “smart” particles on RhoC expression 
We evaluated the ability of our “smart” particles, P2 and P3, to functionally deliver anti-
RhoC siRNA molecules (+) at a N/P ratio of 2.5/1 into the cytoplasm of MDA-MB-231 and 
SUM149 cells by quantifying their ability to suppress RhoC protein expression using western blots 
compared to their scrambled siRNA (-) counterparts, respectively. The results illustrated in Figure 
4.9 represent % RhoC protein suppression in both cell lines as a function of varying particle 
composition (i.e., P2 or P3 in panel A), siRNA concentration (i.e., 25 nM and 50 nM in panel B, 
C), and particle incubation time (i.e., 48 and 72 h in panel B, C) and frequency (i.e., 1x and 2x in 
panel B). The % knockdown of RhoC proteins in response to different treatment conditions were 
quantified using ImageJ software and normalized to the endogenous β-actin control and untreated 
SUM149 and MDA-MB-231 cells, respectively.  
Figure 4.9 (A) compares the transfection efficacy of particle P2 and P3 complexing anti-
RhoC siRNA molecules (+) (50nM) in both cell lines after a single transfection for 48 h. The 
results indicate that the (+) P2 particles showed no suppression and 56  3.5% knockdown of RhoC 
protein expression in MDA-MB-231 and SUM149 cells, respectively compared to their scrambled 
control (-) P2. While (+) P3 showed 47  3.5% and 66  1.4% RhoC protein expression in MDA-
MB-231 and SUM149 cells, respectively. In both cell lines, (+) P2 showed a significantly lower 
RhoC protein reduction compared to (+) P3 that could be attributed to their 5 kDa PEG brushes 
affecting endosomal escape and therefore, the subsequent release of anti-RhoC siRNA molecules. 
Also, the significantly higher RhoC protein knockdown using (+) P3 in SUM149 cells compared 
to MDA-MB-231 cells could be due to improved particle internalization as a result of higher 
uMUC1 receptor expression in SUM149 cells.  
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Figure 4.9 (B) outlines the RhoC protein expression levels in MDA-MB-231 cells treated 
with P3 encapsulating varying concentrations of anti-RhoC siRNA molecules (i.e., 25 or 50 nM) 
following either a single or double transfection cycles for different incubation lengths (i.e., 48 or 
72 h). The results suggest that the double transfection cycle (i.e., at t = 0 h, and t = 24 h) shows 
significantly higher RhoC protein knockdown in MDA-MB-231 cells compared to single 
transfection at all anti-RhoC siRNA concentrations and incubation times. These observations are 
in compliance with the findings reported by Pille et. al. demonstrating significant improvement in 
RhoC knockdown upon the second and third transfection cycles. Furthermore, the results also 
suggest that on increasing the P3 complexed anti-RhoC siRNA concentration from 25 nM to 50 
nM, the RhoC protein knockdown significantly increased from 59  0.13% to 88  2.2% in MDA-
MB-231 cells upon double transfection for a 48 h incubation period suggesting a dose-dependent 
effect. Increasing particle incubation periods from 48 h to 72 h, however, did not significantly 
reduce RhoC protein expression, thereby suggesting a sustained RhoC suppression effect over 
time. 
Figure 4.9 (C) exhibits the ability of P3 encapsulating different concentrations of anti-
RhoC siRNA molecules (i.e., 25 or 50 nM) on suppressing RhoC protein expression in SUM149 
cells following single transfection for different incubation times (i.e., 48 h or 72 h). The results 
indicate a time-dependent increase in RhoC protein knockdown at both anti-RhoC siRNA 
concentrations. The highest RhoC knockdown in SUM149 cells was observed (91  2.4%) after a 
72 h incubation with P3 encapsulating 50 nM anti-RhoC siRNA molecules. At all treatment 
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Figure 4.9: Effect of “smart” -CD 
polymers complexing anti-RhoC 
siRNA (+) or scrambled siRNA (-) 
at an N/P ratio of 2.5/1 on RhoC 
protein levels in SUM149 and 
MDA-MB-231 cells were 
evaluated using western blot 
experiments. The RhoC protein 
expression levels (A), (B), (C) 
using both particles P2 and P3 were 
evaluated as a function of varying 
siRNA concentrations (i.e., 25, and 
50 nM), varying transfection 
frequency (i.e., 1x, and 2x), and 
varying transfection duration (i.e., 
48, and 72h). RhoC protein levels 
at each condition was quantified 
using ImageJ software (NIH, 
Bethesda, MD) and normalized to 
the levels of β-actin at similar time 
points. Results are the average + 




4.3.8 Boyden chamber invasion assay 
We evaluated both the individual and combinatorial effect of reducing RhoC expression 
via anti-RhoC siRNA and inhibiting uMUC1 receptor activity via the EPPT1 binding on 
suppressing the invasive phenotypes of both breast cancer cells using the Boyden invasion 
chamber. The results of both individual and combinatorial treatment effects in both cell lines have 
been shown in Figure 4.10, panel A-G. The individual contribution of anti–RhoC siRNA 
molecules and EPPT1-targeted peptides in suppressing cell invasion illustrated in Figure 4.10 (G) 
was determined by quantifying the number of invading cancer cells upon treatment with either (+) 
P2 and (-) P3 complexing 50 nM siRNA, respectively. In Figure 4.10 (G), we observe a 44  1.0% 
and 43%  6.4% significant reduction in the number of invading MDA-MB-231 cells, while a 37 
 4.1% and 41  6.0% statistical reduction in invading SUM149 cells compared to the untreated 
control upon treatment with (+) P2 and (-) P3 particles, respectively. The combinatorial effect of 
anti-RhoC siRNA molecules and EPPT1-targeted peptides on cell invasion shown in Figure 4.10 
(G) treated with (+) P3 complexing 50 nM siRNA concentration demonstrated a significant 
reduction of 86  4.6% and 75  1.4% in invading MDA-MB-231 and SUM149 cells, respectively. 
The negative scrambled control (-) P2 showed no particle associated cytotoxicity compared to the 
untreated controls in both cell lines. The combinatorial interaction of both therapeutic components 
determined using CDI analysis suggested a synergistic inhibition (CDI < 1) of invasive phenotypes 
in both cell line. We previously reported a 50% reduction in invasive phenotypes in SUM149 
and MDA-MB-231 cells on silencing RhoC expression using our non-PEGylated “smart” 
nanoparticle complexing anti-RhoC siRNA molecules. Using (+) P2 nanoparticles, we 
demonstrated similar reduction in invasive phenotypes (44%) upon knocking down RhoC 
expression in the above mentioned cell types. These results suggest that RhoC expression is 
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responsible for only a portion of the invasive machinery of metastatic breast cancer cells and 
further lead us to investigate the effect of uMUC1 inhibition on suppressing cell invasion. The 
40% reduction in invasive phenotypes observed in both cell lines upon treatment with (-) P3 
compared to negative control (-) P2 and untreated controls, respectively indicates the potential role 
of EPPT1-peptides binding in inhibiting uMUC1 activity. We hypothesize that the observed results 
could be due to the high binding affinity of EPPT1 peptides for the PDTR region of the ECD 
uMUC1 receptors that prevents the binding of other factors like galectin-3 to these sites may inhibit 
the uMUC1 cytoplasmic signal transduction by preventing β-catenin recruitment through the 
activation of non-receptor kinase src, thereby suppressing adheren junction disruption and 
reduction of loss of cell adhesion.  
Now on combining the individual therapeutic agents (i.e., anti-RhoC siRNA and EPPT1 
peptides) into the same “smart” nanoparticle (i.e., (+) P3), we observed a synergistic reduction in 
invasion (80%) in both SUM149 and MDA-MB-231 cells. We believe that this synergistic 
inhibition observed maybe due to the suppression of the Rho-GTPase subfamily, namely RhoC, 
Cdc42 and Rac1 proteins in both cell lines that have been implicated in the reorganization of actin 
cytoskeleton and the assembly of focal adhesion points involved in cell invasion. By preventing 
the activity of non-receptor kinase scr through EPPT1-uMUC binding could suppress activation 
of downstream signaling pathways like FAK and CrkL that are known regulators of Rho-GTPases 
like Cdc42 and Rac1. It is important to note that all experiments were performed as per pre-
optimized treatment conditions identified during the western blot experiments. We observed a 
similar reduction in the number of cells invading the matrigel on treatment with P3 complexing a 
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Figure 4.10: SUM149 and MDA-MB-231 cells were plated on Matrigel invasion chambers 
and treated with “smart” β-CD polymers P2 and P3 complexing 1.14μg of anti-RhoC siRNA 
(+) or scrambled siRNA (-). (A), (B), and (C) represent images of MDA-MB-231 cells 
invading the lower matrigel membrane as a function of varying siRNA concentrations (i.e., 
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Figure 4.10: SUM149 and MDA-MB-231 cells were plated on Matrigel invasion chambers 
and treated with “smart” β-CD polymers P2 and P3 complexing 1.14μg of anti-RhoC siRNA 
(+) or scrambled siRNA (-). (D), (E), and (F) represent images of SUM149 cells invading 







4.3.9 Scratch assay 
The effect of anti-RhoC siRNA molecules and EPPT1-targeted peptides on suppressing 
cancer cell migration was evaluated using standard wound healing assay. The results obtained are 
shown in Figure 4.11, panel A-C. As described in the previous section, the individual contribution 
of each therapeutic entity on suppressing cell migration was evaluated by treating each cell line 
                   G 
 
Figure 4.10: The % of MDA-MB-231 and SUM149 cells invading the lower matrigel 
following their treatment with different polymer compositions after 72 h. G represents the 
% of cells treated with “smart” polymer (P2) complexing 50 nM anti-RhoC siRNA (+) and 
EPPT1-targeted polymer (P3) complexing 50 nM anti-RhoC siRNA (+) or scrambled 
siRNA (-). Plotted results are the average + the SEM of five replicates. Statistical difference 
between the nanoparticles’ means were evaluated using one-way ANOVA test with Tukey’s 
post hoc. Statistical difference between group population means was significant at the 0.05 
level where * denotes p ≤ 0.05, ** denotes p ≤ 0.01, and *** denotes p ≤ 0.005. 
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with either (+) P2 to determine the migratory effect of knocking down RhoC expression and (-) P3 
to evaluate the effect of uMUC1 inhibition. Figure 4.11 (C) shows a 0% and 39%  2.5% reduction 
in migration in MDA-MB-231 cells, while a 62  2.2% and 31  2.5% suppression in migration 
in SUM149 cells compared to the untreated controls upon treatment with (+) P2 and (-) P3 
particles, respectively. The combinatorial effect of antiRhoC siRNA molecules and 
EPPT1targeted peptides on cell migration (Figure 4.11 C) was evaluated with (+) P3 complexing 
50 nM siRNA concentration that demonstrated a significant reduction in migration by 72  6.5% 
and 80  2.4% in MDA-MB-231 and SUM149 cells, respectively. The negative scrambled control 
(-) P2 showed no particle associated cytotoxicity compared to the untreated controls in both cell 
lines. The combinatorial interaction of both therapeutic components determined using CDI 
analysis suggested a synergistic inhibition (CDI < 1) of migratory phenotypes in both cell line. 
Prior work has demonstrated MUC1and-catenin co-localization with the actin-bundling protein 
fascin in membrane protrusions of migrating cells - suggesting this complex plays a role in cell 
migration. The role of fascin in membrane reorganization involves tight packing of actin filaments 
into membrane protrusions such as lamellipodia, microspikes, and membrane ruffles resulting in 
invasion and migration. We believe that the EPPT1-peptide binding to uMUC1 inhibits the co-










Figure 4.11: Representative images (10X magnification) showing the effect of “smart” anti-
RhoC (+) and scrambled (-) particles P2 and P3 on the migration of (A) SUM149 and (B) MDA-
MB-231 cells. (C) The percentage of wound coverage by SUM149 and MDA-MB-231 cells (48 
h) after treatment with “smart” anti-RhoC (+) and scrambled (-) particles normalized to the initial 
wound (t = 0 h). Statistical difference between “smart” anti-RhoC (+) and scrambled (-) particles 
was evaluated using paired t test where * denotes p ≤ 0.05, ** denotes p ≤ 0.01 and, *** denotes 
p ≤ 0.005 
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4.3.10 Effect of targeted (EPPT1)6-(5 kDa-PEG)6.5-β-CD-P(HMA-co-DMAEMA-co-
TMAEMA)5.9 polymers on phosphorylated Src and FAK protein expression 
We further investigated the potential drivers of the observed synergistic reduction in both 
invasive and migratory phenotypes in SUM149 breast cancer cells treated with EPPT1-targeted 
(P3) particles encapsulating anti-RhoC siRNA molecules (i.e., 50 nM) at a N/P ratio of 2.5/1. We 
determined the downstream effect of EPPT1 peptide binding to uMUC1 receptors by evaluating 
the activation of P-Src (Y419) and P-FAK (Y576/577) protein expression in SUM149 cells 
following treatment with EPPT1-targeted (P3) and non-targeted (P2) particles complexing 
scrambled siRNA (-) for 48 and 72 h. The amount of activated P-Src (Y419) and P-FAK 
(Y576/577) protein expressed in SUM149 cells were quantified as a function of total Src and FAK 
protein expression under different treatment conditions and time points (i.e., 48 and 72 h) in Figure 
4.12. The results show a 25% and 35% reduction in activated P-Src (Y419), while a 26% and 21% 
reduction in P-FAK (Y576/577) expression levels after a 48 h treatment with (-) P2 and (-) P3 
particles compared to the untreated control, respectively. However, a significant reduction of 75% 
in P-Src (Y419) and 87% in P-FAK (Y576/577) was observed after a 72 h treatment of SUM149 
cells with (-) P3 compared to the untreated controls. The P-Src (Y419) and P-FAK (Y576/577) 
levels of SUM149 cells treated with (-) P2 particles remained unchanged after the 72 h treatment. 
The results, therefore suggest that the binding of EPPT1 peptides to uMUC1 receptors affect the 
downstream activation of Src and FAK proteins. Previous studies have shown that the activation 
of uMUC1 receptors plays a significant role in the activation and phosphorylation of several SH2 
domain containing proteins including c-Src and activation of SH2 domain containing proteins like 
c-Src 27. Following activation by c-Src via phosphorylation at the active site, the activated Src 
directly phosphorylates its downstream effector molecule FAK resulting in increased metastasis 
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and invasion (Figure 4.13). These findings suggest a temporal overlap in activity of both the 
EPPT1 targeting peptides and the anti-RhoC siRNA molecules delivered into the cytoplasm of 
SUM149 cells following a 72 h treatment; thereby, resulting in a synergistic reduction of cell 




           
 
Figure 4.12: Determine the downstream effect elicited by EPPT1 - targeting peptides upon 
binding to uMUC1 receptors overexpressed on the surface of SUM149 cells after 48 h and 72 h. 
SUM149 cells were treated with (-) P2 and (-) P3 particles encapsulating 50nM scrambled siRNA, 
respectively. The western blot illustrates the effect of (-) P3 particles on the activation of Src and 
FAK compared to their negative controls suggesting that the synergistic reduction in invasion and 
migration can be attributed to the inactivation of P-Src(Y419) and P-FAK(Y576/577) upon 
EPPT1 binding to uMUC1 receptors. Statistical difference (-) P2 and (-) P3 particles was 












Figure 4.13: Illustrates the suggested mechanism of action following the binding of EPPT1 
peptides displayed on P3 particles to uMUC1 receptors (panel B). Panel A represents the 
signal transduction pathway upregulated following the binding of specific growth factors to 
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In vivo evaluation of active and passive targeted nanoparticle strategies for the 
enhanced delivery of therapeutic siRNA to breast cancer tumors 
  
5.1 Introduction  
Since the discovery of endogenous RNA interference (RNAi) in mammalian cells1, there 
has been a drive toward developing this pathway for the treatment of several diseases2, 3. However, 
RNAi-based drugs, like silencing RNA (siRNA), often suffer from poor tissue penetration and low 
serum stability in vivo that results in reduced therapeutic efficacy. To achieve the clinical potential 
of RNAi-based drugs, delivery vechicles that incorporate siRNA are required to efficiently 
transport the therapeutic payload into the cytoplasm of target cells4. In general, these delivery 
vechicles are designed to facilitate efficient uptake into the target tissue of interest and when used 
for systemic delivery, protect siRNA payloads and inhibit non-specific distribution5.  
To design efficient siRNA-based delivery systems for systemic applications, we previously 
reported the development of a series of biocompatible, pH-sensitive, membrane-destabilizing β-
cyclodextrin (β-CD) polymers6, A. These β-CD-based polymers can successfully complex a large 
dose of therapeutic anti-RhoC siRNA at low N/P ratios (e.g., 2.5/1) to form stable nanoparticles 
and can functionally deliver their therapeutic cargo into the cytoplasm of aggressive breast cancer 
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cell lines, namely SUM149 and MDA-MB-231 cells7, A. This was done by utilizing the varying 
reactivity of the primary and secondary hydroxyl (OH) groups exhibited by the β-CD core. The 
secondary OH groups were coupled to cationic amphiphilic copolymers coupled via acid-labile 
hydrazone linkages, while the primary OH groups were attached to hydrophilic PEG grafts 
comprising peptide-based targeting ligands (e.g. EPPT1 peptide sequence)A to produce 
asymmetric polymer configurations. 
In the simplified in vitro setting, the positive charge of the secondary face amphiphilic 
copolymer graft facilitates both formation of stable nanocomplexes with polyanionic anti-RhoC 
siRNA molecules and promotes cell uptake by associating with the negatively charged cellular 
membrane8. In complex in vivo models, however, the positively charged nanocomplexes tend to 
bind the negatively charged serum proteins in the bloodstream, thereby, making them ineffective9. 
To mitigate this problem, we coupled seven PEG molecules to the primary face of the β-CD core 
via click chemistry. In addition, by varying the lengths of the primary face PEG chains (e.g., MW 
= 2 kDa & 5 kDa), we were able to modulate the hemolytic and serum stability profile of the β-
CD-based nanoparticles in vitroA. We identified that the 5 kDa PEG chains exhibit negligible 
hemolytic degradation as a function of increasing nanoparticle concentration compared to 2 kDa 
PEG chainsA. The β-CD-based polymer design can be further optimized by building upon the 5 
kDa PEG graft composition through the incorporation of active-targeting ligands for tissue specific 
distribution11. 
We addressed the issue of non-specific tissue distribution of siRNA-based delivery systems 
to the organs of the RES system, namely the liver, lungs, spleen, and kidneys, by conjugating 
EPPT1-peptide ligands to the free ends of the seven primary face 5 kDa PEG chains. The EPPT1-
peptide has a significant affinity (Kd = 20 µM) for underglycosylated mucin-1 (uMUC1) 
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receptors10. The reduced glycosylation of MUC-1 antigens is an early hallmark of tumorigenesis 
and is overexpressed and underglycosylated on almost all human epithelial cell adenocarcinomas 
(e.g., in > 90% breast carcinomas)10. To determine the tumor specificity and biodistribution profile 
of the asymmetric β-CD nanoparticles, we conjugated a near-infrared dye, IRDye 680RD (λex = 
675nm, λem = 720nm), to a single 5 kDa PEG molecule of both non-targeted (IRDye 680RD-P2) 
and EPPT1-targeted (IRDye 680RD-P3) polymers, respectively. Following the intraperitoneal 
(IP) injection of both the IRDye 680RD-labeled β-CD nanoparticles in immune-suppressant 
SUM149 tumor-bearing female mice, we were able to determine their distribution and 
accumulation profiles in uMUC-1 expressing SUM149 tumors as well as in the organs of the RES 
system. 
Most synthetic RNAi-based delivery systems demonstrate effective gene silencing in vitro, 
but this effect often does not translate into the desired therapeutic effect in vivo11. We previously 
demonstrated that our non-targeted (P2) and EPPT1-targeted (P3) β-CD polymers complexing 
anti-RhoC siRNA at an N/P ratio of 2.5/1 suppressed RhoC protein expression in SUM149 cells 
by approximately 90% after 72 h, respectivelyA. We extended our study to identify the dosing 
regimen of our anti-RhoC siRNA β-CD polymers, namely (+) P2 and (+) P3, that would exhibit a 
comparable RhoC protein suppression following their intratumoral administration in SUM149 
tumor-bearing female mice.  
The objective of our study is twofold, one: to evaluate if our EPPT1-targeted, degradable 
β-CD nanoparticle strategy can facilitate improved tumor-specific accumulation in SUM149 
tumor-bearing mice compared to their non-targeted counterparts upon IP administration. And two: 
to evaluate the therapeutic efficacy of our nanoparticles in suppressing RhoC expression in 
SUM149 cells upon direct administration into the tumor site. This will provide us with the 
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necessary information regarding the siRNA dose and dosing frequency of our anti-RhoC siRNA 
nanoparticles to obtain the desired knockdown of RhoC protein expression. 
 
5.2 Materials and methods 
 
5.2.1 Materials 
β-Cyclodextrin (β-CD, Aldrich, 98%) was freeze-dried before using. 2-
(dimethylamino)ethyl methacrylate (DMAEMA, Aldrich, 98%), and hexyl methacrylate (HMA, 
Aldrich, 98%) were purified in a basic alumina column to remove the inhibitor. 1,1,4,7,10,10-
Hexamethyltriethylenetetramine (HMTETA, Aldrich, 97%), N,N,N′,N′,N′′-pentamethyl-
diethylenetriamine (PMDETA, Aldrich, 99%) were distilled before use. Sodium hydride (NaH, 
Aldrich, 60% dispersion in mineral oil, washed with hexane, dried before use). Poly(ethylene 
glycol) methyl ether (Mn 5000 from Fluka); α-NHS-ω-Alkyne PEG (Mn 5000 from Rapp 
polymere, Germany). Copper (I) bromide (CuBr, Aldrich, 99.9%), bromophenyl acetate (Aldrich, 
98%), iodine (I2, Aldrich), triphenylphosphine (Pph3, Acros chemicals), sodium azide (NaN3, 
Acros chemicals), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide HCl (EDC.HCl, Aldrich), 
hydroxybenzotriazole (HOBt, Aldrich), N,N-diisopropylethylamine (DIPEA, Alfa Aesar), 4-
dimethylaminopyridine (DMAP, Aldrich, 99%), triethylamine (TEA, Aldrich), 2-bromoisobutyryl 
bromide (Fluka, >97%), iodomethane (Aldrich, 99%), 8-bromo-1-octanol (Alfa Aesar, 95%), 
Oxalyl chloride (Aldrich, 99%), p-Toluenesulfonyl hydrazide (Aldrich, 97%), propargyl alcohol 
(Aldrich, 99%), tetrahydrofuran anhydrous (THF, Aldrich, >99.9 %), dichloromethane anhydrous 
(DCM, Aldrich, >99.9 %), N-N-dimethylformamide anhydrous (DMF, Aldrich, >99.9 %), IRDye 
680 NHS ester (LI-COR biosciences), EPPT1-NH2 (Proteomics & peptide synthesis core facility, 
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University of Michigan) were used as received. All cell lines and reagents used in cell culture work 
were procured and used as previously described.  
 
5.2.2 Synthesis of near-infrared labeled polymers 
We previously reported the synthesis of asymmetric, degradable, pH-sensitive β-CD-based 
polymers where we modified the primary face of the β-CD core to exhibit either active EPPT1-
targeted peptides attached to the free ends of PEG brushes (P3) or passive non-targeted PEG 
brushes (P2). We previously optimized the EPPT1-peptide density (approximately 6.5 peptides/ 
β-CD) and PEG molecular weight (i.e., 2 kDa or 5 kDa) to identify nanoparticle compositions that 
exhibited selective accumulation in uMUC1-receptor overexpressing aggressive breast cancer 
cells, while improving overall nanoparticle biocompatibility in vitro. The secondary face of both 
asymmetric polymer compositions displayed similar modifications. Briefly, amphiphilic P(HMA-
co-DMAEMA-co-TMAEMA) copolymer grafts were characterized to exhibit a molecular weight 
of 25 kDa, a 50/50 molar feed ratio of HMA/DMAEMA monomers, and 50% quaternization of 
DMAEMA monomers to cationic TMAEMA monomers6. The amphiphilic graft composition was 
based on previously reported in vitro results that demonstrated effective functional delivery of the 
therapeutic cargo into the cytoplasm of target cells7. In this study, we synthesized two near-infrared 
(NIR)-labeled, degradable, pH-sensitive, asymmetric β-CD-based polymers that exhibited the 
same primary and secondary face modifications as polymers P2 and P3, with the exception of a 
single IRDye-680RD dye coupled to the free end of a primary face PEG molecule. Detailed 
description of the experimental procedures for the synthesis and characterization of these polymers 




5.2.3 Characterization of near-infrared labeled polymers  
The near-infrared labeled polymer compositions, namely IRDye 680RD-P2 and IRDye 
680RD-P3, were formulated in aqueous PBS (1X, pH 7.4) and 1% (v/v) dimethyl sulfoxide 
(DMSO) solution for both in vitro and in vivo experiments. Briefly, for in vitro experiments – a 
stock solution of either near-infrared labeled nanopolymer was prepared by dissolving 1 mg of the 
respective nanopolymers in 0.5 ml of aqueous PBS (1X, pH 7.4) and 1% DMSO solution for gel 
retardation and size and zeta potential experiments, while the same amount of the respective 
polymers were dissolved in 3 ml of Opti-MEM and 1% DMSO for cell uptake studies. The in vivo 
stock formulation involves dissolving 1 mg of the respective nanopolymers in 100 µl of aqueous 
PBS (1X, pH 7.4) and 1% DMSO solution. Gel retardation assay. We evaluated the ability of 
our near-infrared labeled polymer compositions to complex FAM-labeled scrambled siRNA 
molecules (0.75 g) was investigated at different nitrogen/phosphate (N/P, +/-) ratios of 1.5/1, 
2.5/1 and 4/1 and compared to free siRNA (0.75 g) and free polymer solutions. Following the 
simple mixing, the solution mixture was allowed to stand at room temperature for 20 min before 
loading onto a 1% w/v agarose gel containing 0.5 g/ml ethidium bromide (EtBr) dye. The gels 
were immersed in Tris-Acetate-EDTA (TAE) buffer and exposed to 60 V for 60 min before 
visualizing the gels under UV light. We used ImageJ software (NIH, Bethesda, MD) to quantify 
the amount of free siRNA observed with different polymers at different N/P ratios and normalized 
the observed fluorescence to that of the free siRNA loaded on the gel as a positive control to 
determine the optimum N/P ratio for full complexation of the loaded siRNA cargo. Size and zeta 
potential. We prepared our near-infrared labeled nanoparticles, IRDye 680RD-P2 and IRDye 
680RD-P3, by complexing the respective polymer compositions with 1.42 g (2 l of a 50 M 
stock solution) of anti-GAPDH siRNA at an N/P ratios of 2.5/1 to obtain the respective 
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nanoparticles. We measured the size and zeta potential the near-infrared labeled nanoparticles 
using 90Plus particle size analyzer with ZetaPALS capability (Brookhaven Instruments 
Corporation, Holtsville, NY). 
 
5.2.4 Cell culture 
SUM149, an inflammatory breast cancer cell line, was generously provided by the 
Merajver lab (University of Michigan, Ann Arbor, MI). SUM149 was grown in Ham’s F-12 
medium (Gibco, Carlsbad, CA, USA) supplemented with 5% fetal bovine serum (FBS, Hyclone, 
South Logan, Utah, USA), insulin (5µg/ml), and hydrocortisone (HC, 1µg/ml) (Sigma-Aldrich, 
St. Louis, MO). The cell line was maintained in a humidified incubator with 10% CO2 atmosphere 
at 37ºC. HepG2 cells was acquired from the American Type Culture Collection (ATCC, Manassas, 
VA, USA). HepG2 cells was cultured in MEM medium (Gibco, Carlsbad, CA, USA) 
supplemented with 10% FBS, and 1% penicillin/streptomycin/amphotericin, sodium pyruvate, and 
non-essential amino acids. HepG2 cells were incubated at 37ºC, 5% CO2 and 95% relative 
humidity. 
  
5.2.5 Cell uptake study 
We investigated the ability of our near-infrared labeled nanoparticles, IRDye 680RD-P2 
and IRDye 680RD-P3, to be taken up by SUM149 cells as a function of varying siRNA 
concentration (i.e., 15 nM, 25 nM, and 50nM). Briefly, cells were seeded at a density of 50,000 
cells per well in 24-well plates and allowed to adhere for 16 h at 37C before incubating with 
different polymer compositions, namely IRDye 680RD-P2 and IRDye 680RD-P3, loaded with 
different concentrations of FAM-labeled scrambled siRNA prepared at a N/P ratio of 2.5/1 as 
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previously described. After 6 h of incubation, the cells were washed with PBS, treated with 0.05% 
Trypsin/EDTA for 5 min, harvested, pelleted, and re-suspended in the appropriate culture medium 
and analyzed using Biosciences FACSCalibur Flow Cytometer (Becton Dickinson, Franklin 
Lakes, NJ) to determine the % of fluorescently-labeled cells. All cells were gated by forward/side 
scatter and 10,000 gated events were collected per sample to discriminate between live and dead 
cells to account only for live cells. 
 
5.2.6 Tumor model 
All animal housing and experimental conditions were in compliance with the protocol 
approved by the Institutional Animal Care and Use Committee at the University of Michigan. 
SUM149 and HepG2 cells were suspended in HBSS solution and diluted 1:1 with Matrigel (BD 
Biosciences). Orthotopic SUM149 tumors were established in female NOD/SCID/gamma (NSG) 
mice (8-10 weeks old, 20 – 25g). Briefly, the animals were anesthetized, the mammary fat pad was 
exposed, and the mice were injected with 100µl of 1 x 105 SUM149 cells directly into the fourth 
mammary gland. HepG2 tumors were prepared by inoculating a suspension of 1 x 106 HepG2 cells 
into the subcutaneous dorsa of in male NSG mice (8-10 weeks old, 25 – 30g). Tumors were 
monitored weekly and tumor volume(s) measured using calipers. The tumor size was calculated 
as a x b2/2, where a is the largest and b is the smallest diameter. All experiments were initiated 
when the tumors measured approximately 100 mm3. The mice were euthanized once tumor volume 
approached 2 cm3 or mice showed signs of morbidity.  
 
5.2.7 Whole-body in vivo biodistribution 
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To evaluate the biodistribution of EPPT1-targeted and non-targeted β-CD nanoparticles in 
tumor-bearing mice, both β-CD nanoparticles were labeled with IRDye 680RD (Licor 
Biosciences, Lincoln, NE), a near-infrared fluorophore. SUM149 tumor-bearing mice were 
randomized into four groups (n=4) once the tumors were palpable. Each group was given either 
IRDye 680RD-labeled EPPT1-targeted or IRDye 680RD-labeled non-targeted β-CD nanoparticles 
complexing either 2.5 mg/kg or 5 mg/kg scrambled siRNA molecules at an N/P (+/-) ratio of 2.5/1 
via the intraperitoneal (IP) route of administration, respectively. The volume of administration was 
0.15 ml/mouse. All groups were subjected to non-invasive fluorescent imaging performed at 
various time points (e.g., 10min, 4h, 24h, and 48h) up to 2 days after injection using the IVIS 
Spectrum (PerkinElmer). The mice were sedated and imaged for 1-2 s at a λex = 675 nm and λem = 
720 nm. The data was analyzed with the IVIS software (Living Image Program (v.4.0)). HepG2 
tumor-bearing mice (n=4) were given a single IP injection of IRDye 680RD-labeled EPPT1-
targeted β-CD nanoparticles complexing 5 mg/kg of scrambled siRNA molecules at the above 
mentioned volume and N/P (+/-) ratio. The animals were imaged and the data analyzed via IVIS 
Spectrum as previously described. 
 
5.2.8 Ex vivo biodistribution 
To evaluate the tissue-specific distribution of the various IRDye 680RD-labeled β-CD 
nanoparticle compositions in tumor-bearing mice after 48 h, NSG mice in all groups were 
euthanized and organs (liver, lungs, kidney, spleen, heart, and stomach) and tumors were 
harvested. The organs and tumors were washed with 1X PBS prior to near-infrared fluorescence 
imaging and analysis using IVIS Spectrum (PerkinElmer) as previously outlined. The fluorescence 
148 
 
signal obtained from each organ and tumor for all groups was measured as a function of radiant 
efficiency. 
 
5.2.9 In vivo effect of anti-RhoC siRNA nanoparticles 
The ability of anti-RhoC siRNA complexing β-CD nanoparticles to efficaciously deliver 
the therapeutic cargo in SUM149 tumor-bearing mice was evaluated by quantifying RhoC 
expression levels in the tumor mass using western blot techniques. Female NSG mice inoculated 
with SUM149 cells were randomized into various treatment groups (n=3) upon exhibiting tumors 
that measured approximately 100 mm3 in size. Briefly, non-targeted (P2) and EPPT1-targeted (P3) 
β-CD nanoparticles were prepared by dissolving the respective polymers in 1X PBS solution 
containing 2.5 mg/kg of either anti-RhoC siRNA (+) or scrambled siRNA (-) molecules at an N/P 
ratio of 2.5/1. The volume of administration was 0.15 ml/mouse. The control group received 1X 
PBS solution, and the treatment groups received (+) P2, (-) P2, (+) P3, or (-) P3 solutions, 
respectively. Mice were treated everyday by intratumoral injections, for up to 3 days. The animals 
were euthanized on day 4 and their tumors excised to determine RhoC expression levels. Briefly, 
the excised tumors from all groups were homogenized in tissue lysis buffer and the total protein 
lysate collected following centrifugation at the maximum speed for 30 min at 4ºC. Total protein 
concentration was quantified using BCA assay. 60 µg/ml of protein was loaded and separated on 
a 12.5% Tris-HCl gel (Bio-Rad, Hercules, CA) and transferred onto NC membrane using a dry 
blotting system (Thermo Scientific, Waltham, MA). Membranes were blocked for 1 h in 5% milk 
solution and hybridized in 5% BSA solution containing 1X TBS and 0.1% Tween-20 with RhoC 
mAb (1:1000, CST) and β-actin (1:5000, Santa Cruz) at 4°C with gentle shaking, overnight. 
Membranes were subjected to secondary detection using 1:5000 dilution of HRP-conjugated anti-
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rabbit or anti-goat antibody (Santa Cruz). The membranes were stained with a chemiluminescence 
substrate and the RhoC and β-actin proteins were quantified using ImageJ software (NIH, 




5.3.1 Synthesis of near-infrared labeled polymers 
We utilized the asymmetric distribution and reactivity of primary and secondary OH 
groups to exhibit seven PEG brushes on the primary face and approximately six amphiphilic 
poly(hexyl methacrylate-co-(2-(dimethylamino)ethyl methacrylate) (P(HMA-co-DMAEMA) 
copolymer grafts via click coupling onto the secondary face. Here, we used previously reported 
strategies to successfully synthesize NIR-labeled non-targeted β-CD (IRDye 680RD-P2) and 
EPPT1-targeted β-CD polymers (IRDye 680RD-P3). 
 
5.3.1.1 Synthesis of EPPT1-targeted IRDye 680RD-P3 polymers 
The synthesis of EPPT1-targeted IRDye 680RD-P3 polymers is outlined Figure 5.1 
 
5.3.1.1.1 Primary face modification  
Briefly, alkyne-PEG-NHLicor (2) and alkyne-PEG-NHS (3) were allowed to react with the 
primary azide groups on compound 1 (Figure 5.1) in the presence of Cu(I)Br and PMDETA in 
DMF to obtain (NHS-PEG)5.5-(PEG-Licor)1-β-CD-(Phenylacetate)8.3 (4). All compounds were 




5.3.1.1.2 Secondary face modification 
Compound 4 on reacting with compound A in the presence of NaH resulted in (NHS-
PEG)5.5-(PEG-Licor)1-β-CD-[(E)-N`-(8-azodooctylidene)-acetohydrazide]7.2 (5). Compound A 
was synthesized as previously reported.[R] Compound 5 was then reacted with EPPT1-NH2 in the 
presence of EDC, HOBt, DIPEA in DMF to give (EPPT1-PEG)5.5-(PEG-Licor)1-β-CD-[(E)-N`-
(8-azodooctylidene) acetohydrazide]7.2 (6). We used 
1H NMR to analyze the number of EPPT1 
peptides attached by comparing PEG protons to aromatic protons of the EPPT1 peptide. Alkyne-
P(HMA-co-DMAEMA-co-TMAEMA) (C) grafts were click coupled to compound 6 in the 
presence of Cu(I)Br and PMDETA in DMF at 40oC to give the final polymer product (EPPT1-
PEG)5.5-(PEG-Licor)1-β-CD-P(HMA-co-DMAEMA-co-TMAEMA)5.5 (7). We used 
1H NMR to 
quantify the number of amphiphilic grafts coupled to the secondary face of the β-CD by comparing 
the ratios between PEG and HMA protons in the polymer grafts. Finally, the grafts were 
quaternized by reacting alkyne-P(HMA-co-DMAEMA) (compound B) with methyl iodide in THF 
(Supplementary information).  The methyl protons of DMAEMA monomers at 2.24 ppm and 
the TMAEMA monomers at 3.61 ppm were used to calculate the % of DMAEMA quaternized 







Figure 5.1: Schematic of (EPPT1-PEG)5.5-(Licor-PEG)1-β-CD-[(hydrazone)-p(HMA-co-
DMAEMA-co-TMAEMA)5.5 targeted star polymer (IRDye 680RD-P3) 
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5.3.1.2 Synthesis of non-targeted IRDye 680RD-P2 polymers 
The synthesis of non-targeted IRDye 680RD-P2 polymers is outlined Figure 5.2 
 
5.3.1.2.1 Primary face modification  
Briefly, alkyne-PEG-NHLicor (2) and alkyne-PEG-OMe (8) were allowed to react with 
the primary azide groups on compound 1 in the presence of Cu(I)Br and PMDETA in DMF to 
obtain (OMe-PEG)5.5-(PEG-Licor)1-β-CD-(Phenylacetate)8.3 (9). (Figure 5.2).  Compound 8 was 
synthesized as previously described[R]. 
 
5.3.1.2.2. Secondary face modification  
Compound 9 was then reacted with compound A in the presence of NaH to produce (OMe-
PEG)5.5-(PEG-Licor)1-β-CD-[(E)-N`-(8-azodooctylidene)-acetohydrazide]7.2 (10). The click 
coupling between compound 10 and compound B in the presence of Cu(I)Br and PMDETA in 
DMF resulted in (OMe-PEG)5.5-(PEG-Licor)1- β -CD-P(HMA-co-DMAEMA)5.5 (11). We 
quantified the number of amphiphilic grafts coupled to the secondary face by 1H NMR spectrum. 
By comparing the ratios between sugar and HMA/DMAEMA protons (supporting information). 
Alkyne-P(HMA-co-DMAEMA) (B) was synthesized using ATRP polymerization in the presence 
of Cu(I)Br, HMTETA in THF[A]. We partially quaternized the DMAEMA monomers into 
TMAEMA monomers using methyl iodide to obtain the final polymer (OMe-PEG)5.5-(PEG-
Licor)1-β-CD-P(HMA-co-DMAEMA-co-TMAEMA)5.5 (12). We used 
1H NMR spectrum to 













All polymer compositions were completely soluble in aqueous PBS (1X, pH 7.4) and 1% 
DMSO solution. Figure 5.3 (A) shows the degree of complexation between different polymer 
compositions and FAM-labeled scrambled siRNA molecules as a function of varying N/P (+/-) 
ratios. The gel indicates that both near-infrared (NIR) polymer compositions can completely 
complex siRNA molecules at all N/P ratios (i.e., 1.5/1, 2.5/1, and 4/1) when compared to the 
positive control (free siRNA). Table 5.1 contains the information regarding the nanoparticle 
composition loaded in each well of the 1% (w/v) agarose gel. Figure 5.3 (B) represents the plot of 
the size (in nm) of the respective near-infrared labeled nanoparticle compositions at an N/P ratio 
of 2.5/1. The non-targeted IRDye 680RD-P2 particles were 213 ± 4.7 nm and EPPT1-targeted 
IRDye 680RD-P3 particles were 189 ± 5.4 nm in size. The incorporation of a single, hydrophobic 
NIR unit to polymer P2 and P3 did not significantly alter their size profile or result in particle 
aggregation compared to the parent polymer P2 and P3 at the same N/P ratio. The zeta potential 
measurements of both nanoparticles, namely IRDye 680RD-P2 and IRDye 680RD-P3, exhibited 






























Figure 5.3: (A) The image indicates the degree of complexation of NIR-labeled 
polymers complexing FAM-labeled scrambled siRNA molecules at varying N/P ratios 
(i.e., 1.5/1, 2.5/1, and 4/1). The different polymer compositions were loaded on a 1% 
(w/v) agarose gel stained with 0.5 g/ml EtBr and subjected to electrolysis at 60 V for 1 
h. The degree of complexation at each condition was compared to the free siRNA (0.71 
g) molecules loaded in lane 10. (B) Represents the size data of NIR-labeled polymers 
complexing scrambled siRNA at an N/P ratio of 2.5/1 




5.3.3 Cell uptake study 
We evaluated the in vitro uptake of non-targeted IRDye 680RD-P2 and EPPT1-targeted 
IRDye 680RD-P3 polymers complexing FAM-labeled scrambled siRNA at an N/P ratio of 2.5/1 
by uMUC1 receptor expressing SUM149 cells. Figure 5.4 represents the % labeled SUM149 cells 
by the respective FAM-labeled siRNA complexing nanoparticles as a function of varying siRNA 
concentrations (i.e., 15 nM, 25 nM, and 50 nM). At the siRNA concentration, namely 25 nM and 
50 nM, previously reported to exhibit therapeutic suppression of RhoC protein expression in 
SUM149 cells using anti-RhoC siRNA complexing P2 and P3 nanoparticles, we observed > 85% 
labeling of SUM149 cells compared to the untreated control and free siRNA molecules (not shown 
in Figure 5.4). At 25 nM siRNA concentration, IRDye 680RD-P2 nanoparticles labeled cells by 
87 ± 0.7%, while IRDye 680RD-P3 nanoparticles labeled 93 ± 0.2% cells. At 50 nM siRNA 
Lane no. Sample information 














9 Free polymer 
10 Free siRNA (0.71 μg) 
11 DNA ladder (100 kbp) 
Table 5.1: Represents the sample composition loaded in each lane of the 1% (w/v) 





concentration, IRDye 680RD-P2 nanoparticles labeled 93 ± 0.8% cells, while IRDye 680RD-P3 
nanoparticles labeled 94 ± 1.1% cells. At 25 nM siRNA concentration, the EPPT1 targeted IRDye 
680RD-P3 nanoparticles showed significant labeling of SUM149 cells compared to their non-
targeted counterparts. However, at 50 nM siRNA concentration there was no statistical difference 
in the % SUM149 cells labeled by the respective NIR-labeled nanoparticles. The % labeling of 
SUM149 cells by NIR-labeled nanoparticles at the above reported siRNA concentrations were 
comparable to the results previously reported for nanoparticles P2 and P3 complexing FAM-













5.3.4 Whole body in vivo biodistribution 
We evaluated the biodistribution of EPPT1-targeted IRDye 680RD-P3 nanoparticles in 
SUM149 tumor-bearing female NSG mice compared to their non-targeted counterparts. Briefly, 
 
Figure 5.4: The plot represents the % labeled SUM149 cells after incubating for 6 h 
in a serum-free culture medium with NIR-labeled nanoparticles complexing varying 
concentrations of FAM-labeled scrambled siRNA at an N/P ratio of 2.5/1. The 
experiment was performed in triplicates and the results represent the mean + SEM.  
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we initiated the IP administration of the NIR-labeled nanoparticles on the SUM149 tumors raised 
in the mammary fat pads of female NSG mice attaining approximately 100 mm3 in size. The 
SUM149 tumor-bearing mice were grouped at random into three treatment groups (n = 4). Each 
group received either IRDye 680RD-P3 polymers complexing 2.5 mg/kg or 5mg/kg of scrambled 
siRNA molecules or IRDye 680RD-P2 polymers complexing 5 mg/kg of scrambled siRNA, 
respectively. The treated groups were then imaged using IVIS Spectrum (λex = 675nm, λem = 
720nm) at different time points (i.e., t = 10 min, 24 h, and 48 h). Figure 5.5 (A) represents the 
biodistribution profile (measured in radiant efficiency) of EPPT1-targeted IRDye 680RD-P3 
nanoparticles in SUM149 tumor bearing mice as function of time and siRNA concentration. In 
Figure 5.5 (A), the upper panel represents the ventral side, while the lower panel indicates the 
dorsal side of SUM149 tumor-bearing mice administered with varying concentrations of EPPT1-
targeted IRDye 680RD-P3 nanoparticles. The observed biodistribution profile for IRDye 680RD-
P3 nanoparticles shows a strong signal in the intraperitoneal space at all time points and siRNA 
concentrations. The dorsal images of SUM149 tumor-bearing mice in Figure 5.5 (A) shows two 
distinct regions of high signal intensity labeled A and B contributed by the NIR dye coupled to 
EPPT1-targeted P3 nanoparticles. Region A in Figure 5.5 (A) represent the stomach and 
gastrointestinal (GI) region of the animal. Thereby, suggesting that the IRDye 680RD-P3 
nanoparticles predominately distribute and is potentially cleared out by the GI tract. The second 
region of interest (B) in Figure 5.5 (A) represents the mammary fat pad tumors suggesting the 
potential accumulation of EPPT1-targeted nanoparticles (IRDye 680RD-P3) in SUM149 tumors. 
IRDye 680RD-P3 nanoparticles appear to accumulate in region B at the ealiest time point (i.e., t = 
10 min) when administered at 5 mg/kg siRNA concentration and the signal persists over the 48 h 
time period. While a distinct signal is observed in region B only at t = 48 h for the IRDye 680RD-
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P3 polymers complexing 2.5 mg/kg suggesting a dose-dependent accumulation of EPPT1-targeted 
nanoparticles in region B.  Figure 5.5 (B) represents the biodistribution profile measured in radiant 
efficiency of non-targeted IRDye 680RD-P2 polymers complexing 5 mg/kg scrambled siRNA in 
SUM149 tumor-bearing mice as function of time. Similar biodistribution profiles were observed 
for IRDye 680RD-P2 nanoparticles in SUM149 tumor-bearing mice. However, the dorsal side in 
Figure 5.5 (B) indicates a strong signal in region A, while no signal was observed in the previously 
defined (in Figure 5.5 (A)) region B. Therefore, suggesting that the non-targeted IRDye 680RD-
P2 nanoparticles predominantly distribute to the stomach and gut of the animal with little or no 








Figure 5.5: Represents the biodistribution profile of NIR-labeled nanoparticles, namely IRDye 
680RD-P3 (A) and IRDye 680RD-P2 (B) upon IP administration into SUM149 tumor –bearing 
mice measured at different time-points (i.e., t = 10 min, 24 h, 48 h). The SUM149 tumor-
bearing mice were imaged using IVIS Spectrum (λex = 675nm, λem = 720nm) and the signal 
intensity measured in units of radiant efficiency. The dosal sections of Figure 5.5 (A) & (B) 
indicate two distinct regions of high signal intensity, namely A and B, respectively 
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5.3.5 Ex-vivo biodistribution 
We harvested the organs of the RES system and the tumors of all the animals in every 
treatment group after 48 h. The excised organs and tumors were imaged using the IVIS Spectrum 
(λex = 675nm, λem = 720nm) as illustrated in Figure 5.6 (A), (B), and (C). Figure 5.6 (A) and (B) 
represents the distribution profile of IRDye 680RD-P3 polymers complexing either 2.5 mg/kg or 
5 mg/kg of scrambled siRNA at an N/P ratio of 2.5/1 in different organs and tumors, respectively. 
Figure 5.6 (C) represents the organ-distribution profile of IRDye 680RD-P2 polymers complexing 
5 mg/kg of scrambled siRNA at an N/P ratio of 2.5/1. The total NIR dye signal was measured in 
units of radiant efficiency ((p/s)/(µW/cm2)). Figure 5.6 (D) depicts a plot of the total radiant 
efficiency measured in the RES organs and SUM149 tumors following treatment with IRDye 
680RD-P3 nanoparticles as a function of varying siRNA concentration. Figure 5.6 (E) illustrates 
the total radiant efficiency measured in the RES organs and SUM149 tumors following treatment 
with IRDye 680RD-P2 polymers complexing 2.5 mg/kg of scrambled siRNA molecules. The 
results obtained from ex-vivo organ imaging experiments suggests that IRDye 680RD-P3 
nanoparticles show a dose-dependent accumulation of EPPT1-targeted nanoparticles in SUM149 
tumors after 48 h. Figure 5.6 (D) indicates a significantly higher labeling of SUM149 tumors when 
subjected to 5 mg/kg siRNA nanoparticle concentration (4.4 x 108 ± 1.2 x 108 (p/s)/(µW/cm2)) 
compared to 2.5 mg/kg siRNA nanoparticle concentration (1.4 x 108 ± 6.8 x 107 (p/s)/(µW/cm2)). 
There was no significant accumulation in the liver at either 5 mg/kg siRNA nanoparticle 
concentration (6.1 x 107 ± 3.4 x 107 (p/s)/(µW/cm2)) or 2.5 mg/kg siRNA nanoparticle 
concentration (6.7 x 107 ± 4.6 x 107 (p/s)/(µW/cm2)) as seen in Figure 5.6 (D). After 48 h, a 
significantly higher signal (approximately 1010 (p/s)/(µW/cm2)) was detected in the stomach and 
GI tract of all animals in either treatment groups. This strong signal detected in the stomach and 
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GI tract correlates with the biodistribution profile previously observed at both 5 mg/kg siRNA and 
2.5 mg/kg siRNA IRDye 680RD-P3 polymer concentrations during whole-body imaging of the 
animals. The higher tumor accumulation of EPPT1-targeted IRDye 680RD-P3 nanoparticles at 5 
mg/kg prompted us explore the biodistribution profile of non-targeted IRDye 680RD-P2 
nanoparticles at this concentration Figure 5.6 (E). The plot indicates negligible accumulation in 
SUM149 tumors and the organs of the RES system (in the order of 107 (p/s)/(µW/cm2)). The large 
error bars can be attributed to the lack of a signal detected in all tissues of three out of the four 
mice. While a significantly strong signal was detected in the stomach and GI tract of mice 
subjected to IRDye 680RD-P2 nanoparticles. HepG2 subcutaneous tumors raised in male NSG 
mice (n = 4) were subjected to IP administration of IRDye 680RD-P3 polymers complexing 5 
mg/kg scrambled siRNA at an N/P ratio of 2.5/1. The RES organs and tumors harvested after 48 
h showed no signal, while a strong signal was detected in the stomach and GI tract of the all animals 





5.3.6 In vivo effect of anti-RhoC siRNA nanoparticles 
 
   D                             E 
    
Figure 5.6: Ex-vivo distribution of NIR-labeled nanoparticles upon IP administration. The images 
represent the biodistribution profile of EPPT1-targeted IRDye 680RD-P3 polymers complexing 2.5 
mg/kg (A) and 5 mg/kg (B) of scrambled siRNA molecules at an N/P ratio of 2.5/1. (C) represents 
the biodistribution profile of non-targeted IRDye 680RD-P2 polymers complexing 5 mg/kg of 
scrambled siRNA molecules at an N/P ratio of 2.5/1. Figure 5.6 (D) and (E) represents the NIR 
signal measured in total radiant efficiency ((p/s)/(µW/cm2)) from SUM149 tumors and the RES 
organs excised from SUM149 tumor-bearing mice treated with EPPT1-targeted IRDye 680RD-P3 
nanoparticles and non-targeted IRDye 680RD-P2 nanoparticles, respectively.  
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We evaluated the ability of our non-targeted P2 and EPPT1-targeted P3 polymers 
complexing 2.5 mg/kg of therapeutic anti-RhoC siRNA molecules at an N/P ratio of 2.5/1 to 
suppress RhoC protein expression in SUM149 tumor-bearing mice upon intratumoral 
administration. When the SUM149 tumors raised in the fourth mammary fat pad of female NSG 
mice attained approximately 100 mm3 in size, the mice were randomly divided into five treatment 
groups (n = 3). The negative control group received 100 µl of saline solution once every day for 
three days (i.e., t = 0 h, 24 h, 48 h) intratumorally. The remaining four treatment groups received 
100 µl of one of the following polymer compositions: non-targeted P2 polymers complexing either 
2.5 mg/kg of anti-RhoC siRNA (+ P2) or scrambled sequence siRNA (- P2) or EPPT1-targeted P3 
polymers complexing either 2.5 mg/kg of anti-RhoC siRNA (+ P3) or scrambled sequence siRNA 
(- P3). Each polymer composition was administered once daily for three days. After 72 h, animals 
in all groups were euthanized and their tumors harvested to quantify RhoC protein expression for 
different treatment conditions using western blot. The 72 h treatment regimen was chosen based 
on previously reported in vitro results that showed a 91 ± 2.4% reduction in RhoC protein 
expression in SUM149 cells following treatment with anti-RhoC siRNA complexing P3 
nanoparticles (at 50 nM siRNA concentration). Figure 5.7 shows the % reduction in RhoC protein 
expression in the excised SUM149 tumor mass as a function of different treatment conditions. The 
groups subjected to (+) P2 and (+) P3 nanoparticle treatment conditions exhibited 87.7 ± 5.8% and 
84.6 ± 1.7% reduction in RhoC protein expression compared to their scrambled counterparts, 
respectively. The groups treated with scrambled siRNA (-) complexing P2 and P3 nanoparticles 
showed comparable RhoC protein expression compared to the negative saline control groups, 
respectively. The endogenous β-actin control showed unaltered expression levels in all treatment 






The key criterion for the development of effective nanotherapeutics include (i) overcoming 
biological barriers, (ii) specific accumulation of the therapeutic at the target site (i.e, targeting), 
and (iii) preventing rapid clearance from the body. To achieve the characteristics of an “ideal” 
nanoparticle, we previously reported the use of versatile β-cyclodextrin (β-CD) as the core 
molecule to develop assymetric, biocompatible β-CD-based polymers that can successfully 
complex and can functionally deliver a therapeutic dose of anti-RhoC siRNA molecules into the 
cytoplasm of aggressive breast cancer cells in vitro. Briefly, we incorporated seven PEG brushes 
(MW = 5 kDa) containing EPPT1-peptide targeting moieties on to the primary face to ensure 
improved circulation time and prevent rapid clearance from the body as well as achieve selective 
accumulation in uMUC1-overexpressing SUM149 cells. While the secondary face was modified 
to exhibit six cationic amphiphilic copolymer grafts attached via acid-labile hydrazone linkages. 
The cationic amphiphilic grafts facilitated the electrostatic complexation of the desired dose of 
therapeutic siRNA molecules, while the pH-sensitive DMAEMA and hydrophobic HMA 
 
Figure 5.7: In vivo therapeutic effect of non-targeted P2 and EPPT1-targeted P3 polymers 
complexing 2.5 mg/kg of anti-RhoC siRNA (+) at an N/P ratio of 2.5/1 in suppressing RhoC 
protein expression compared to their scrambled siRNA complexing counterparts. RhoC 
protein levels at each condition was quantified using ImageJ software (NIH, Bethesda, MD) 




monomers enabled endosomal escape of particle fragments upon hydrolysis of the acid-labile 
hydrazone linkages in acidic endosomal pH. In order to translate these β-CD based polymers into 
suitable in vivo nanotherapeutics, it is crucial to primarily understand the pharmacokinetics and 
tissue distribution profile of nanoparticles as they have been shown to profoundly dictate the 
therapeutic effect and potential toxicity profiles11, 12 . Based on this fact, the goal of our study 
was to investigate the pharmacokinetics of our targeted drug delivery system and explore the 
effects of active targeting compared to passive targeting strategies on nanoparticle 
biodistribution. To this end, we succefully developed and characterized near-infrared labeled 
active EPPT-1 peptide targeted nanoparticles (IRDye 680RD-P3) and passive targeted 
nanoparticles (IRDye 680RD-P2) using previously optimized synthesis schemes.  
Previous studies have demonstrated that nanoparticle size, surface charge, and mode of 
administration has a tremendous consequence on nanoparticle behavior in vivo13. Size 
dependent organ distribution has been previously investigated and nanoparticles with a 
hydrodynamic diameter less than 5.5 nm are known to be cleared through the kidneys. 
Nanoparticles between 50 and 100 nm primarily accumulated in the liver and spleen13. Both our 
active EPPT1-targeted IRDye 680RD-P3 and passive targeted IRDye 680RD-P2 nanoparticles 
measured 189 ± 5.4 nm and 213 ± 4.7 nm in size. Therefore, the lack of a signal in the RES organs, 
namely liver, kidney, spleen, (Figure 5.5 A, B, C) for both the NIR-labeled nanoparticles 
following imaging by IVIS Spectrum (λex = 675nm, λem = 720nm) can be attributed to their 
relatively large size profiles (> 100 nm). Moreover, both NIR-labeled nanoparticles exhibit a net 
positive charge due to the presence of cationic TMAEMA monomers in the amphiphilic graft 
composition and the complexation of a higher molar ratio of positively-charged polymer amine 
groups to the negatively charged siRNA phosphate groups (i.e., N/P =2.5/1) used to form serum 
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stable nanoparticles. Hirano et al. described that the charge of the liposomes is a predictive factor 
for the retention time14. For instance, when the liposomes have a negative charge they were rapidly 
absorbed from the peritoneal cavity, while positively charged liposomes had a slower absorption 
rate. This might be attributed to the electrostatic interaction between the positively charged 
liposomes and the negative surface of the peritoneal mesothelium, in combination with a low 
uptake of positive liposomes by peritoneal macrophages15. This explanation potentially holds true 
for both our NIR-labeled nanoparticles as we observed a strong signal in the peritoneal cavity 48 
h after IP administration of our nanoparticles, thereby suggesting that the net positive charge on 
our particles increases their retention time in the peritoneal space.  
Following IP injection, the nanoconjugate must cross the peritoneal barrier that protects 
the abdominal cavity before entering into the blood stream or accumulating in organs. The 
peritoneal membrane is a semi-permeable membrane composed of the parietal peritoneum that 
lines the abdominal wall and the visceral peritoneum that lines the abdominal viscera and 
internal organs16. Moreover, the peritoneal membranes are comprised of mucus secreting cells, 
which we hypothesized is a reason for low bioavailability and nanoconjugate accumulation at 
these sites following IP administration. Mucus is a complex, viscous biological material that 
typically serves as a lining, a protective barrier, as well as a lubricant17. The Hanes group 
demonstrated the use of low molecular weight PEG molecules to penetrate mucus17. We, 
therefore employed PEG in our nanoparticle design as a passive targeting moiety to reduce the 
adhesive interactions associated with the mucus in the peritoneum and to facilitate an improved 
uptake into the blood circulation.  
Our active targeted EPPT1-peptide nanoparticles (IRDye 680RD-P3) demonstrated a 
dose-dependent accumulation of NIR-labeled nanoparticles in uMUC1-expressing SUM149 
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tumors as seen in Figure 5.6 A and B. However, our passively targeted strategy (IRDye 680RD-
P2) failed to capitalize on the hyperpermeability of the “leaky” tumor vasculature and showed 
negligible accumulation at the tumor site (Figure 5.6 C). Both targeting strategies showed rapid 
clearance (i.e., t = 4 h) via the GI tract and accumulation in the stomach. Finally, we briefly 
looked into the therapeutic dosing strategy of both our active EPPT1-targeted nanopolymers 
(P3) and passive targeted nanopolymers (P3) encapsulating either therapeutic anti-RhoC siRNA 
(+) or scrambled sequence siRNA (-). Both nanotherapeutics showed comparable reduction in 
RhoC protein expression (> 80%) upon intratumoral administration.  
In summary, the active targeting strategy proved significantly more effective in 
accumulating at the tumor site compared to our passively targeted nanoparticles. While both 
nanoparticle strategies were rapidly cleared out by the GI tract, neither particles showed 
accumulation in the RES organ system. The therapeutic efficacy observed by both our 
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6.1.1 “Smart” nanoparticles enhance the cytoplasmic delivery of anti-RhoC silencing 
RNA and inhibit the migration and invasion of aggressive breast cancer cells 
Degradable, pH-sensitive, star-shaped β-CD-g-P(HMA79-co-DMAEMA33-co-
TMAEMA48)4.8 polymers were developed as a siRNA-based delivery platform to complex and 
efficaciously delivery the therapeutic payload into the cytoplasm of target cells. Briefly, the star 
polymers utilized β-CD, a cone-shaped oligosaccharide composed of seven glucose units, as the 
core for the development of the “smart” vectors. The seven primary OH groups on the primary 
face of the β-CD core and the fourteen secondary OH groups on the secondary face have different 
chemical reactivity; therefore, allowing us to graft amphiphilic membrane-destabilizing polymers 
from the secondary face of the β-CD core via acid-labile hydarzone linkages while leaving the 




The “ideal” graft composition of the amphiphilic membrane-destabilizing polymer was 
previously identified from a library of star-shaped polymers that exhibited different graft 
compositions (i.e, varying molecular weight of 25 kDa and 40 kDa, hydrophobic/hydrophilic ratio 
of 50/50 and 75/25, and degree of quaternization of 50% and 100%)1. The star-shaped polymers 
that exhibited secondary face amphiphilic grafts with a polymer composition of 25 kDa and molar 
hydrophobic/hydrophilic feed ratio of 50/50 with partial (50%) conversion of the hydrophilic pH-
sensitive methacrylate monomers to cationic methacrylate monomers exhibited the most desirable 
physicochemical properties as well as the highest suppression of specific mRNA in target cells. 
To validate the therapeutic efficacy of this amphiphilic graft composition in aggressive breast 
cancer cells, we were interested in complexing the star-shaped β-CD-g-P(HMA79-co-
DMAEMA33-co-TMAEMA48)4.8 polymers with a therapeutic dose of anti-RhoC siRNA at low N/P 
ratios (i.e., 2.5/1) and evaluate the functional delivery of their cargo past the endosomal membrane 
and into the cytoplasm of SUM149 and MDA-MB-231 cells, respectively.  
We chose RhoC-GTPase protein as our molecular target of interest as they are known to 
be overexpressed and linked to the metastatic progression observed in inflammatory breast cancer 
(IBC) and triple-negative breast cancer (TNBC). The role of RhoC in promoting cancer cell 
migration and invasion has been confirmed by multiple in vitro and in vivo studies. In our study, 
we demonstrated that our “smart” anti-RhoC siRNA particles could successfully knockdown RhoC 
protein expression by 90-100% in both SUM149 and MDA-MB-231 cells, respectively. We, 
further demonstrated that this suppression of RhoC protein expression translated into a significant 
reduction in cell invasion, motility, and migration of both SUM149 and MDA-MB-231 cells by 
approximately 50%. In conclusion, the results from this study suggested that our “smart” anti-
RhoC nanoparticle composition was effective in suppressing the metastatic spread of aggressive 
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breast cancer cells. Therefore, validating the efficacy of our star-polymers’ amphiphilic graft 
composition to functionally deliver therapeutic anti-RhoC siRNA into the cytoplasm of aggressive 
breast cancer cells.  
 
6.1.2 Presentation of EPPT1 Peptide for Binding of Underglycosylated MUC1 and 
Cytoplasmic Delivery of Anti-RhoC Silencing RNA by “Smart” Particles 
Synergistically Inhibit the Migration and Invasion of Aggressive Breast Cancer 
Cells 
In our previous study, we demonstrated that our star-shaped β-CD-based polymers 
exhibiting the “ideal” secondary face amphiphilic copolymer graft composition demonstrated 
effective suppression of target RhoC expression in aggressive breast cancer cells with no particle-
associated cytotoxicity in vitro. Here, we were interested in developing in vivo based delivery 
solutions by utilizing the seven primary face OH groups of our star-shaped β-CD polymers to 
conjugate either passive-targeted PEG moieties or active-targeted EPPT1-peptides. We 
successfully designed and synthesized a series of asymmetric multimodal PEGylated and EPPT1-
targeted -CD polymers that can complex the desired dose of anti-RhoC siRNA to form stable 
“smart” particles. We showed that 5 kDa PEG particles exhibited significantly improved 
biocompatibility profiles in vitro compared to their 2 kDa PEG counterparts; therefore, prompting 
their future use in developing our in vivo nanoparticle strategy. We, therefore developed our 
EPPT1-targeting strategy using 5 kDa PEG particles that specifically targeted uMUC1 expressing 
breast cancer cells (like SUM149 cells) and showed efficient internalization via receptor-mediated 
endocytosis. We demonstrated significantly higher uptake of EPPT1-targeted particles into 
SUM149 and MDA-MB-231 cells at low siRNA concentrations (i.e., 15 nM) compared to their 
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non-targeted counterparts. Upon receptor-mediated internalization, the EPPT1-targeted--CD 
particles showed a sustained release of anti-RhoC siRNA molecules and a subsequent knockdown 
of RhoC protein expression in SUM149 and MDA-MB-231 cells after 72 h compared to the 
previously reported 48 h study using non-targeted--CD nanoparticles. The successful 
incorporation of EPPT1-targeted peptides and encapsulation of anti-RhoC siRNA molecules on 
the same nanoparticle also exhibited a synergistic suppression in cell invasion and migration in 
aggressive breast cancer cells. Further investigation of the effect of EPPT1-targeted particles in 
suppressing breast cancer cell invasion and migration showed that the EPPT1-peptide binding to 
uMUC1 receptors resulted in the downstream inactivation of p-Src and p-FAK proteins that are 
known to play a vital role in cell invasion and migration. The successful characterization of our in 
vivo based nanoparticles in vitro warranted their evaluation in SUM149 tumor-bearing animal 
models. 
 
6.1.3 In vivo evaluation of active and passive-targeted nanoparticle strategies for the 
efficient delivery of therapeutic siRNA for treatment of aggressive breast cancer 
Nanoparticles show their promise for improving the efficacy of drugs with a narrow 
therapeutic window or low bioavailability, such as anticancer and nucleic acid-based drugs. The 
pharmacokinetics (PK) and tissue distribution of nanoparticles largely define their therapeutic 
effect and toxicity. Chemical and physical properties of the nanoparticles, including size, surface 
charge, and surface chemistry, are important factors that determine their PK and biodistribution. 
In this study, we evaluated the in vivo behavior of our asymmetric active EPPT1-peptide targeted 
and passive PEG-targeted -CD nanoparticles upon administration in SUM149 tumor-bearing 
mice. Briefly, we synthesized near-infrared labeled EPPT1-peptide targeted and non-targeted 
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PEGylated -CD polymers based on similar strategies outlined in supplementary information of 
Chapter 4. The labeling of nanoparticles with a near-infrared dye (IRDye 680RD, λex = 675 nm 
and λem = 720 nm) enables real-time imaging (using IVIS Spectrum, PerkinElmer Inc.) of the 
animals at pre-defined time-points (i.e, 10 min, 24 h, 48 h) and mitigates the issue of tissue auto 
fluorescence. The whole-body and ex-vivo imaging of the mice demonstrated that both active 
EPPTI-targeted and passive PEG targeted nanoparticles were rapidly cleared from the body 
through the GI tract upon IP administration potentially due to their net positive charge. Moreover, 
the size of the nanoparticles (approximately 200 nm) hindered their accumulation or clearance by 
the organs of the RES system, namely liver, kidney, and spleen. While the passive PEG targeted 
nanoparticles failed to harness the enhanced retention and permeability (EPR) effect of the tumor 
vasculature to accumulate at the tumor site, the active EPPT1-targeted nanoparticles demonstrated 
a dose-dependent accumulation in the tumor mass upon ex-vivo tumor imaging at 48 h. Therefore, 
suggesting that our active EPPT1-targeted nanoparticles have improved tumor specificity 
compared to their passively targeted counterparts. We, also demonstrated the ability of both our 
polymer strategies complexing anti-RhoC siRNA to functionally deliver their therapeutic cargo 
into SUM149 tumors upon intratumoral administration. This study showed comparable therapeutic 
efficiency in suppressing RhoC protein expression (by 80%) on using either nanoparticle 
formulation. In conclusion, the results from the in vivo evaluation of our nanoparticles suggests 
that if deliver approximately 2.5 mg/kg of anti-RhoC siRNA at the tumor site upon IP 
administration of anti-RhoC siRNA complexing EPPT1-peptide targeted nanoparticles, we can 
potentially achieve therapeutic suppression of RhoC expression and subsequently inhibit tumor 




6.2 Future direction 
 
6.2.1 Understanding the mechanism of nanoparticle internalization and fate of EPPT1-
bound uMUC1 receptors 
MUC1, aberrantly overexpressed in various cancer cells, is known to serve as a physical 
barrier from the extracellular environment and as a receptor for various extracellular molecules10. 
The goal of this study is to understand the fate of MUC1 during and after the interaction with our 
EPPT1-peptide targeted -CD nanoparticles. In order to better understand the cellular trafficking 
of MUC1 antigens upon binding to EPPT1-peptides displayed on the primary face of -CD 
polymers, we have synthesized of a series of -CD polymers (positive control) that display EPPT1-
peptides on the primary face of the core molecule, but are void of any secondary face amphiphilic 
graft modifications (Figure 6.1). This is essential to delineate the effect attributed solely by the 
EPPT1-peptides binding to the MUC1 receptors and the potential interaction that may be elicited 
by the cationic amphiphilic grafts coupled to our EPPT1-peptide targeted -CD nanoparticles on 
MUC1 binding. We are interested in understanding the mechanism of internalization of our 
EPPT1-targeted asymmetric nanoparticles into SUM149 and other MUC1 expressing cell lines 
like MCF7, Panc-1, and HEK293 cells10. The internalization of a membrane protein has been 
shown to be mediated by the clathrin-dependent, raft/caveolin-dependent, or clathrin- and 
raft/caveolin-independent mechanism. Macropinocytosis, is another endocytotic mechanisms 
involving a raft/caveolin-dependent pathway to internalize extracellular fluid11, mycobacteria12, 




 In our proposed strategy to test the mechanism of entry, we intend on pretreating the 
respective MUC1-recepetor expressing cells with chlorpromazine, a clathrin-dependent 
endocytosis inhibitor15, methyl-β-cyclodextrin which inhibits a raft/caveolae-dependent 
endocytosis16, or amiloride and ethylisopropyl amiloride (EIPA), that selectively inhibit 
macropinosome formation compared with other endocytosis pathway17, respectively (Figure 6.2). 
This is followed by a time-dependent co-incubation of these pre-treated cells with the respective 
inhibitor and our near-infrared labeled EPPT1-targeted -CD nanoparticles and positive control 
nanoparticles, respectively. The near-infrared fluorescence signal from each treatment group can 
be visualized by confocal laser microscopy to determine our nanoparticles’ mechanism of entry. 
Furthermore, we can use GFP-labeled MUC1 receptors to track the internalization and trafficking 
mechanism of these receptors upon binding to our EPPT1-nanoparticles. Finally, we can examine 
whether the internalization of MUC1 is dependent on the presence of MUC1 on cell surface. By 
using MUC1-receptor variants with deleted MUC1-cytoplasmic tails. Previous studies showed that 
MUC1 internalization failed upon deletion of MUC1-cytoplasmic tail, but not by mutations at 
Y20, Y35, Y46, and Y60 of MUC1-cytoplasmic tail in transfected HEK cells10 which have been 









Figure 6.2: Antibody-induced internalization of MUC1 was mediated through 
macropinocytotic pathway. Panc-1 cells were pretreated without (A) or with chlorpromazine 
(5 μM, B), methyl-β-CyD (5 mM, C), amiloride (2 mM, D), EIPA (50 μM, E) for 30 min, 
followed by co-treatment with anti-MUC1 antibody and inhibitors at 37 °C for 1 h. After 
staining with TRITC-conjugated secondary antibody, fluorescence signals were visualized by 





6.2.2 In vivo evaluation of our asymmetric active and passive-targeted nanoparticles 
The preliminary in vivo testing of the behavior of our nanoparticle strategies in SUM149 
tumor-bearing mice (outlined in Chapter 5) set the stage for a more detailed and methodical 
evaluation of a) the effect of route of administration on nanoparticle biodistribution profiles in 
SUM149 tumor bearing mice, b) evaluating nanoparticle-associated toxicity profiles via MTD 
studies in both healthy and tumor-bearing mice, c) Determining the dosing regimen and therapeutic 
effect of anti-RhoC siRNA complexing nanoparticles upon IP or IV administration in SUM149 
tumor-bearing mice, and d) Establishing metastatic tumor models in mice and evaluating the effect 
of our anti-RhoC siRNA complexing nanoparticles on suppressing the metastatic spread of the 
disease. Evaluation of the therapeutic and toxicity effects of our nanoparticles in pre-clinical 
animal models can give us a better understanding of the potential steps required to translate this 
technology into a clinically-viable siRNA vector system.  
 
6.2.3 Synthesis of a library of MUC1-targeted nanoparticle therapies  
In many tumor types, MUC1 expression correlates with aggressive, metastatic disease, 
poor response to therapy and overall survival. While MUC1 expression is limited to the apical 
surface of most ductal epithelium, in metastatic disease, MUC1 is overexpressed and becomes 
localized throughout the cell2. This phenomenon has been most intensively studied in breast 
cancer, in which MUC1 expression has been evaluated clinically at the level of 
immunohistochemistry,3, 4 RNA,5 shed MUC1 in sera, expression on circulating tumor cells and 
biochemically6, and has correlated with poor disease-free and overall survival, as well as axillary 
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node metastases. Therefore, the role of MUC1 in both transformation and metastatic progression 
has led to extensive focus on this protein for the development of targeted therapies to treat 
metastatic disease (Figure 6.3).  A number of groups have developed vaccine-like therapies to 
target MUC1 and is listed in Table 6.1 
The incorporation of these MUC1 targeted peptides or antibodies (outlined in Table 6.1) 
on the primary face of our asymmetric -CD polymers can be developed to generate an arsenal of 
actively-targeted platform strategies. The advantage of these targeted strategies is twofold: one, it 
can potentially facilitate improved tumor accumulation of our MUC1 targeted nanoparticles, 
thereby improving the therapeutic efficiency and functional delivery of their siRNA cargo into the 
tumor space, and two, the MUC1 targeted moieties upon binding to the intended region of the 
MUC1 antigen can facilitate inhibition of MUC1 associated cell invasion and migration7, 8, 9.  In 
addition to the MUC1-targeting therapeutic strategy, these “smart” nanoparticles will be equipped 
to deliver a plethora of siRNA-based drugs to the target site (as described previously); thereby, 
establishing a platform delivery system that can elicit dual therapy through MUC1 targeted 








Figure 6.3: Targeted therapies directed against MUC1. MUC1 cDNA vaccine, M-FP vaccine 
and ImMucin vaccine induce immune response to MUC1 tumor antigen. 90Y-muHMGF1 
antibody binds glycosylated extracellular MUC1 and increases survival in human patients. 
HMFG2 and C595 antibodies bind the protein core of underglycosylated MUC1 and reduce 
tumor burden in mouse models of cancer. GP1.4 binds to MUC1 protein and decreases 
proliferation and invasion. GO-203 peptide binds to the juxtamembrane domain of MUC1 and 
blocks MUC1 homodimerization, preventing MUC1 activity and causing cell cycle arrest and 
apoptosis. PMIP decoy peptide inhibits MUC1-EGFR interaction and MUC1-β-catenin 
interaction, decreasing EGFR activity and inhibiting proliferation and invasion and inhibiting 
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